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1 Introduction 
 
 
1.1 Multidrug Resistance 
Multidrug resistance (MDR) is a major obstacle in the chemotherapeutic 
treatment of cancer (Gottesman, 1993).  An MDR tumor is characterized by the 
ability to simultaneously exhibit resistance towards a large number of structurally 
unrelated chemotherapeutic drugs.  Consequently, chemotherapeutic agents fail to 
target the MDR tumor, thus the cancer becomes untreatable by chemotherapy.  
MDR can be either intrinsic (de novo) or acquired by exposure of malignant cells to 
chemotherapeutic agents (Fojo, 1987; Dalton, 1989).   
In the clinical reality, MDR is a multifactoral and complex condition.  Various 
cellular and non-cellular mechanisms are involved in clinical MDR (Fojo, 2003).  
Although the focus of this thesis is on transporter-mediated MDR phenotypes, other 
cellular mechanisms of MDR will be introduced.  Cellular mechanisms can be further 
classified as non-classical and transporter-based MDR mechanisms.   
 
1.1.1 Cellular MDR mechanisms 
Cellular mechanisms of MDR arise in the tumor cell as a response to cytotoxic 
challenge.  In the course of chemotherapeutic treatment, some tumors can adapt to 
a toxic environment by altering the expression of key genes, which help the tumor 
cell to escape the toxic effects of the chemotherapeutic drug. 
 
1.1.1.1 Non-classical MDR mechanisms 
The term, “non-classical MDR mechanisms”, summarizes all non-transporter-
based MDR mechanisms.  These types of resistance include enzyme–mediated (e.g. 
   Introduction 
 
2 
Glutathione-S-transferase, topoisomerase) and apoptosis-derived mechanisms (e.g. 
tumor suppressor gene p53).   
 
Glutathione S-transferase enzyme system 
The Glutathione S-transferase (GST) enzyme system is involved in the 
biotransformation of drugs and xenobiotics (Lewis, 1989).  Furthermore, it protects 
cells from damage resulting from reactive epoxides (Kuzmich, 1991) and free 
radicals (Ketterer, 1990).  In many resistant tumor cell lines, the GST system has 
been found to be overexpressed (Lewis, 1989).  It is believed that the GST system, 
when expressed at a high level, can protect the cell from chemotherapeutic agents.  
For instance, when an isoform of GST gene was selectively transfected into yeast 
cells, an 8-fold increase in resistance towards the cytotoxic drug chlorambucil was 
obtained (Black, 1990).  However, the GST resistance mechanism appears to be 
specific only for some chemotherapeutic drugs.  There has been evidence that an 
induced GST activity is not a resistance mechanism for doxorubicin (Moscow, 1989).   
 
Topoisomerase enzymes 
Topoisomerase type I and II enzymes are involved in DNA replication 
processes.  Topoisomerase I assists to alter DNA topology via single strand breaks, 
whereas Topoisomerase II causes transient double strand breaks of the DNA 
molecule.  Some chemotherapeutic agents such as doxorubicin, etoposide or 
campothecin target topoisomerase enzymes by stabilizing the enzyme DNA complex 
and thus preventing the two DNA fragments from rejoining (Ross, 1984; Kunimoto, 
1978).  The resulting DNA strand breaks are thought to trigger apoptosis, which may 
lead to tumor death (Roy, 1992).  Tumor cells can develop resistance mechanisms 
against topoisomerase inhibitors by either downregulating the expression of the 
topoisomerase enzymes or by gene mutations within the topoisomerase gene 
(Drake, 1987).  Resistance against Topoisomerase II is often synchronized with the 
overexpression of P-glycoprotein (Kunikane, 1990).   
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Tumor suppressor gene p53  
In cases of DNA damage, incurred by stress stimuli like irradiation or hypoxia, 
the tumor suppressor gene p53 mediates a growth suppressive response through 
the activation of pathways involved in cell cycle arrest, DNA repair, apoptosis and 
angiogenesis (El-Deiry, 2003).  A loss of p53 function is often associated with the 
formation of aggressive tumors.  Some anticancer drugs are active against tumor 
cells by inducing DNA damage and triggering apoptosis via p53.  Therefore, 
downregulation or mutations of the p53 gene hinders chemotherapeutic agents from 
inducing apoptosis and protects the tumor cell against the treatment (Lowe, 1993a).  
Furthermore, p53 regulates the expression of a downstream gene, B-cell lymphoma-
2 (bcl-2) (Lowe, 1993b).  The anti-apoptotic protein bcl-2 inhibits the apoptosis 
pathway through a regulation of the mitochondrial pathway prior to caspase 
activation (Kaufmann, 2003).  Bcl-2 is involved in the cellular protection from cell 
death stimuli including gamma radiation, UV and tumor necrosis factor (Reed, 1995).  
Increased expression levels of bcl-2 have been associated with cellular resistance 
towards a number of cytotoxic agents including doxorubicin, taxol and mitoxantrone.   
 
1.1.1.2 Classical MDR mechanisms 
The term “classical MDR mechanisms” refers to transporter-based resistance 
mechanisms and describes the generally accepted primary mechanism of drug 
resistance.  The transporters involved in MDR mainly belong to the family of ATP-
binding cassette (ABC) transporters.  ABC transporters actively expel cytotoxic drugs 
out of the tumor cell and maintain an intracellular drug level below effective 
concentrations (Bodó, 2002).  This mechanism of resistance appears to be most 
relevant to drugs which enter cells by passive diffusion such as most natural 
chemotherapeutic agents including doxorubicin or paclitaxel.   
An important characteristic of MDR transporters is their wide substrate 
acceptance.  In contrasts to other mammalian transporters, the ABC-proteins are 
highly promiscuous transporters and recognize a wide range of structurally diverse 
substrates (Bodó, 2002).  This is of clinical importance: a tumor which develops an 
MDR transporter-based resistance mechanism as a result of treatment with one 
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cytotoxic drug will likely be resistant towards most other chemotherapeutic agents.  
Genes encoding for ABC transporters are often overexpressed in MDR tumors 
(Krishna, 2000).   
The family of ABC transporters and their most relevant members will be 
introduced in detail in chapter 1.2.   
 
1.1.2 Non-cellular MDR mechanisms  
Although less obvious, non-cellular mechanisms can contribute to an 
environment, in which the tumor protects itself from the chemotherapeutic drug.  
Non-cellular mechanisms of MDR arise during the formation of tumor tissue, and are 
associated with the physiological environment and the surrounding tissue of the 
tumor.  These mechanisms mainly occur in solid tumors and hinder anticancer drugs 
from accessing their sites of action.   
Several different mechanisms can lead to non-cellular-based resistance.  In 
some solid tumors, for example, the interstitial fluid pressure is increased. This can 
be due to either a higher vascular permeability or the absence of a functional 
lymphatic system (Jain, 1987).  As a consequence, the tissue is vascularized but 
poorly circulated and this prevents the chemotherapeutic drug from being 
transported into the tumor region.   
Tumor regions are often deficient in nutrition and oxygen.  This creates an 
environment of unfavorable physicochemical conditions for many chemotherapeutic 
drugs.  In these tumor areas, lactic acid generation and hypoxia lead to conditions, in 
which drugs can be protonated (Demant, 1990).  As many drugs are weak bases, 
protonation will introduce an ionic force, which might impair their ability to cross 
biological membranes and enter the tumor cell. 
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1.2 ABC-transporter family 
The family of ABC transporters is a large gene family of structurally related 
transmembrane proteins.  Close to 50 members of the ABC transporter family in 
humans have been discovered to date (Sarkadi, 2004).  All ABC transporters contain 
a distinct DNA signature which includes the ATP-binding domain (Klein, 1999).  ABC 
transporters are phylogenetically ancient and evolutionary conserved from bacteria 
to men.  Homologues of human ABC transporters were found in microorganisms 
such as bacteria and yeast where they were shown to be involved in conferring 
resistance to antibiotics (Van Veen, 1998b).  The human MDR1/Pgp transporter, for 
example, has a similar antineoplastic profile to, and can be substituted by, LmrA, the 
multidrug transporter from Lactococcis lactis (Van Veen, 1998a).   
In eukaryotic organisms, ABC transporters are ubiquitary present.  Human 
members of the ABC family are widely expressed throughout the body and take part 
in such diverse functions as transport across membranes or cell signaling (Holland, 
1999).  Functionally, ABC transporters move their substrates across biomembranes 
in an energy-dependent manner.  The ATPase activity necessary for this transport 
follows classical Michaelis-Menten kinetics (Ambudkar, 2003).   
The main physiological role of these transporters is the protection of the body 
against xenobiotics and toxic endogenous substrates.  Therefore, ABC transporters 
can be found in important pharmacological barriers or organs of excretion including 
the liver and the kidney.  ABC transporters are all characterized by a broad substrate 
acceptance which makes them clinically important as the majority of the current 
drugs on the market are substrates of the ABC-transporters (Beringer, 2005).  Thus, 
their ubiquitous expression and diverse affinity brings about many drug-to-drug 
interactions and pharmacokinetic alterations.   
In resistant tumor cells, ABC transporters are highly overexpressed and 
primarily involved in MDR mechanisms (see chapter 1.1.1.2).  Among the various 
ABC-transporters the following members have been recognized as the most 
significant for clinical MDR: P-glycoprotein (Pgp, ABCB1), the breast cancer 
resistance protein (BCRP, ABCG2) and the multidrug resistance associated proteins 
(MRPs, ABCC family) (Fojo, 2003; Tan, 2000; Bodó, 2002).  These transporters shall 
be described in the following chapters. 
   Introduction 
 
6 
1.2.1 P-glycoprotein (Pgp, ABCB1) 
Pgp was discovered and first characterized by Ling and co-workers (Ling, 
1974; Juliano, 1976) using multidrug resistant Chinese hamster ovary cells.  To date, 
Pgp, also termed ABCB1, is the most intensively studied and possibly the most 
prevalent of the ABC-transporters in cancer cells.  The 170 kDa protein is a 
membrane-bound, energy-dependent drug transporter (Ling, 1995).  By actively 
effluxing its substrates, Pgp reduces intracellular concentrations to subtherapeutic 
levels, thereby conferring resistance to a broad range of cytotoxic drugs.  These 
substrates are of such large structural diversity, that common features are difficult to 
discover.  Indeed the only common features for Pgp substrates appear to be 
hydrophobicity and a molecular mass of 300 – 2000 Da (Ford, 1990).  Anionic 
structures are not transported by Pgp.  Substrates for Pgp include many cytotoxic 
drugs used in cancer treatment such as the anthracyclines, Vinca alkaloids and 
taxanes as well as commonly prescribed drugs such as the calcium channel blockers 
and antiviral protease inhibitors.   
Pgp is encoded by the MDR1 gene in humans and by the mdr1a and mdr1b 
genes in rodents.  Together, mdr1a- and mdr1b-type Pgps fulfil the same function as 
the single human Pgp (Schinkel, 1997).  The human protein consists of 1280 amino 
acids and spans the biomembrane with 12 transmembrane domains (Figure 1.1).  
The protein is folded into two similar parts, each containing six transmembrane 
segments and one ATP binding domain.  The gene sequences of these two halves 
of the molecule share about 43 % of homology.  Pgp contains three glycosylation 
sites (see figure 1.2) on an extracytoplasmic domain (Chen, 1986).   
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Figure 1.1   Topological model of Pgp 
The organization of Pgp is depicted with two membrane spanning domains (MSD) and two intracellular ATP-
binding sites located between the MSD and at the C-terminus.   
 
 
Mechanisms of transport 
Different theories on the mechanism by which Pgp transports its substrates 
across biomembranes have been developed.  In the “Flippase” model, Higgins and 
Gottesman postulate that substrates congregate with Pgp at the inner leaflet of the 
plasma membrane.  There, Pgp flips the substrates into the outer leaflet, from which 
they diffuse into the extracellular area (Higgins, 1992).   
A second model by Gottesman and Pastan describes Pgp as a “hydrophobic 
vacuum cleaner” (Gottesman, 1993).  According to the model, substrates of Pgp 
passively diffuse into the inner layer of the plasma membrane.  There, Pgp 
recognizes the substrates and directly pumps them out.  In figure 1.2, the two 
postulated routes of transport are illustrated. 
 
 
 
 
 
NH2
ATP ATP
COOH
MSD1 MSD2
extracellular
cytoplasma
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Figure 1.2   Mechanisms of Pgp transport 
Two proposed routes of efflux (“Flippase model” and “Vacuum cleaner model”) are illustrated for doxorubicin. 
 
 
Multiple binding sites 
The binding parameters and putative binding sites on the molecule have been 
extensively characterized in the past using radio- or fluorescent-labeled probes.  
Evidence for a vinblastine binding site could be generated using the photoactive 
analogue of vinblastine, N-(p-azido-)-[3-125I]-salicyl)-N΄-ß-amino vindesine, in 
membrane vesicles obtained from MDR Chinese hamster lung cells.  As binding 
could be inhibited by the addition of vincristine and daunorubicin, competitive binding 
characteristics were concluded (Cornwell, 1986).   
The presence of multiple binding sites was proposed when additional Pgp 
substrates, including colchicine and actinomycin D, were discovered.  These 
substrates did not compete for the vinblastine binding site (Akiyama, 1988).  Studies 
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in models of purified and reconstituted Pgp in liposomes demonstrated a direct 
transport of the Pgp substrate Hoechst 33342 (Shapiro, 1995).  These investigations 
supported the “hydrophobic vacuum cleaner” transport model.  
Using fluorescent probes in a model of reconstituted Pgp in membrane 
vesicles, Shapiro and Ling could demonstrate the presence of at least two distinct 
binding sites, which they named the H site and the R site (R for rhodamine 123, H for 
Hoechst 33342).  According to their model, the two binding sites interact in a 
positively cooperative manner (Shapiro, 1997).  Further studies of the R and H site 
by Pajeva and coworkers revealed that both binding sites, the H and the R site, 
switch their orientation between two functional states characterized as nucleotide-
free and nucleotide-bound (Pajeva, 2004).  The described conformational change is 
thought to mediate the transport of the substrate from the membrane to the inner 
pore. 
By classifying drugs that interact with Pgp either as substrates or modulators, 
Martin and coworkers developed a model of Pgp’s transport mechanisms, in which 
they postulate a minimum of four drug binding sites.  These binding sites switch 
between high and low affinity binding and belong to two categories of either transport 
or regulatory function (Martin, 2000).   
The localization of drug-binding sites on the Pgp molecule was further 
investigated using photoaffinity analogues.  Results from these studies have been 
summarized by Ambudkar and coworkers (Ambudkar, 2003).  Ambudkar suggests 
that several transmembrane domains (TM) are involved in substrate binding and that 
different substrates possess multiple and potentially overlapping binding sites.   
Loo and Clarke have developed another model of substrate binding to Pgp 
(Loo, 2002).  This model is based on extensive investigations using cystein scanning 
mutagenesis and crosslinking experiments.  According to the authors, the protein 
contains one common binding site, folded like a pocket, involving eight different TM 
domains.  This ‘pocket’ allows diverse substrates to create their own binding sites in 
such a way that the substrates use a combination of residues from the different TM 
involved.  The binding pocket is thought to be mobile, however, when binding of the 
substrate occurs, the binding pocket stabilizes.   
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Very recently, Safa has developed a model of several binding sites on the Pgp 
molecule.  The model is based on data obtained from photoaffinity-labeled 
substrates and postulates seven different binding sites which account for distinct 
binding of vinblastine, taxol, Hoechst 33342, prazosin, bepridil, flupentixol and 
dihydropyridine calcium channel blockers (Safa, 2004).   
These reports exemplify the large number of sophisticated models, which 
have been developed to explain the enigma of Pgp’s broad function and efficacy.  
However, the exact mechanism of binding as well as structure activity relationships 
of substrates and modulators have not been entirely resolved to date.   
 
Physiological expression 
Pgp is widely expressed throughout the body with a concentration in excreting 
organs and physiological barriers.  In the intestine, liver and kidney, Pgp is localized 
in transporting tissues such as the brush border membrane of intestinal cells or the 
biliary canalicular membrane of the hepatocytes.  This indicates an involvement of 
Pgp in the transepithelial secretion of substrates into bile, urine or intestinal lumen.   
Pgp can also be found in barrier tissues such as the placenta or the testis.  In 
the brain, Pgp is expressed in endothelial cells of the brain capillaries and the 
choroid plexus, both major components of the blood-brain barrier (Borst, 2000; Rao, 
1999).  Hence, Pgp plays an important role in the excretion and the protection of 
various tissues against toxic xenobiotics (Borst, 1996; Smit, 1999).  Studies in MDR1 
knock out mouse models elegantly confirmed the physiological implications of Pgp 
(Schinkel, 1997).  Whereas the viability of mice lacking MDR1 transporters was not 
altered, these animals demonstrated a hypersensitivity to xenobiotics with altered 
excretion and distribution parameters.   
 
Involvement in MDR tumors 
Pgp is highly overexpressed in the majority of MDR tumor cells of leukemic 
and solid tumors (Ambudkar, 2003).  The MDR phenotype could be selected in vitro 
using natural product anticancer agents such as vinblastine, doxorubicin and 
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paclitaxel.  These tumor cells then displayed cross resistance to other structurally 
diverse compounds (Ling, 1995).   
In the clinical setting, Pgp has been associated with the development of MDR 
tumors.  Leith and coworkers have reported Pgp expression in 30 % of acute 
myelogenous leukemia patients at first diagnosis.  In patients with disease relapse, 
overexpression of Pgp was detected in over 50 % of the patients.  The degree of 
Pgp expression in tumors from these patients was comparable to the Pgp expression 
seen in MDR resistant tumor cells selected through in vitro assays (Leith, 1999).   
 
 
1.2.2 Breast Cancer Resistance Protein (BCRP, ABCG2) 
BCRP was first discovered and isolated from the doxorubicin resistant breast 
cancer cell line MCF7 AdVp3000, which did not possess detectable levels of Pgp or 
MRP1 (Doyle, 1998).  Doyle and coworkers named this new transport protein the 
breast cancer resistance protein (BCRP), as they derived it from a resistant breast 
cancer cell line.   
BCRP is a 72 kDa ABC-half transporter composed of 655 amino acids.  It is 
thought to function as a homodimer, thus requiring a second molecule for activity.  
The two halves are bridged by a disulfide bond (Doyle, 2003).  The BCRP peptide 
sequence reveals a single ATP binding domain and an ABC signature motif within 
the relatively hydrophobic amino terminal domain.  Furthermore, BCRP possesses 
six transmembrane domains and four potential N-glycosilation sites (Doyle, 1998).  
BCRP is similar to one half of the Pgp or MRP1 molecule with the exception that the 
ATP binding domain is located at the amino-terminus of the peptide and not at the 
carboxyl-terminus (Figure 1.3).  Of note, members of the ABCG subfamily are the 
only human ABC transporters discovered in which the ABC signature domain 
precedes the transmembrane region. 
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Figure 1.3   Topological model of BCRP  
The organization of BCRP is depicted with one membrane spanning domain (MSD1) and the intracellular ATP-
binding domain at the N-terminus.   
 
 
In humans, the BCRP gene is located on chromosome 4, a gene site where 
no other ABC transporter is located.  Analyses of the phylogenetic relationships 
showed that BCRP is only distantly related to Pgp.  However, Pgp is closely related 
to ABCG1, another member of the G subfamily of the ABC transporters (Chen, 1996) 
which regulates the macrophage cholesterol and phospholipid transport.   
Though different in structure and genetic background, Pgp and BCRP share 
many common substrates.  Both actively transport various structurally diverse 
substrates out of the cell.  Substrates of BCRP include the anticancer drugs 
mitoxantrone, camptothecin-based topoisomease I inhibitors, methotrexate and 
flavopiridol (Bates, 2001).  BCRP mutated at codon 482, can also transport 
anthracyclines (Doyle, 2003).  Most Pgp inhibitors including PSC 833 and LY335979 
do not inhibit BCRP.  Some other Pgp inhibitors have been reported to also interact 
with BCRP (Doyle, 2003), such as GF120918 (Maliepaard, 2001) and Cyclosporin A 
(Qadir, 2005).  Other selective inhibitors for BCRP include fumitremorgin C (Doyle, 
2003) and novobiocin (Shiozawa, 2004).  More recently a non-toxic, synthetic analog 
of fumitremorgin C, Ko143, has been identified as a potent and selective inhibitor of 
BCRP (Allen, 2002). 
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Physiological expression 
Immunohistochemical studies have confirmed the predominant localization of 
BCRP in the plasma membrane (Rocchi, 2000).  This is of importance, as almost all 
other known half-transporters are localized within the intracellular membranes of the 
mitochondria or the endoplasmatic reticulum.   
Similarly to Pgp, BCRP is widely expressed throughout the body, but with the 
highest concentration in the placenta.  These findings suggest that BCRP plays a 
protective role for the fetus preventing potentially harmful substances from entering 
the uterus (Jonker, 2000).  Moreover, BCRP expression is found in many other 
organs and tissues including the liver, ovaries, colon, kidneys and brain microvessels 
(Doyle, 2003).  Tissue distribution studies have demonstrated an extensive overlap 
between BCRP and Pgp, suggesting that BCRP plays a similar physiological role in 
providing protection from xenobiotics.  Indeed, BCRP regulates the distribution of 
xenobiotics to various tissues like the liver, intestine and placenta (Allen, 2002).   
Interestingly, BCRP has been found to be highly expressed in stem cell 
subpopulations, such as hematopoetic stem cells (CD-) (Zhou, 2001) or embryonic 
kidney cells (Scharenberg, 2002).  These findings imply that BCRP might be 
involved in the general regulation and protection of stem cells.   
 
Involvement in MDR tumors 
Immunohistochemical investigations of various tumors have revealed that 
BCRP is expressed in over 40 % of solid tumors (Diestra, 2002).  BCRP 
overexpression was detected in tumor specimens obtained from colon, 
endometrium, lung and melanoma.  Thus, BCRP has a substantial involvement in 
the development of MDR tumors.   
BCRP is believed to play a role in recurrent tumors.  High BCRP expression 
was found to be correlated with disease relapse and poor prognosis in acute myeloid 
leukemia.  Furthermore, BCRP expression was verified in premature stem cells of 
various different tissues.  These findings suggest that BCRP might be involved in the 
protection of cancer stem cell subpopulations where it is believed to offer survival 
advantages, particularly under hypoxic conditions (Sarkadi, 2004).   
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1.2.3 Multidrug Resistance Associated Proteins (MRP, ABCC) 
The multidrug resistance associated protein (MRP) family or ABCC family, is 
another distinct class of ABC drug efflux transporters with at least nine members.  
MRP proteins actively transport structurally diverse lipophilic anions across the 
biomembrane.  The members MRP1, MRP2 and MRP3 were found to play a role in 
the MDR phenotype of resistant tumors (Borst, 2000; Kruh, 2003).  In figure 1.4, the 
topological models of MRP1, MRP2 and MRP3 are compared.  As specified in the 
following, all three proteins are of almost equal size and organization.  They contain 
three membrane spanning domains, two intracellular loops and two nucleotide 
folding domains for ATP binding. 
 
 
 
 
 
 
 
 
 
Figure 1.4   Topology of MRP1, MRP2 and MRP3  
The organization of protein domains is schematically illustrated.  Regions are indicated as follows: Yellow, 
membrane-spanning domains; blue, cytoplasmic loops; orange, ATP binding domains. 
MSD: membrane spanning domain; L: intracellular loop; NBF: nucleotide-binding fold; C: C-terminus 
 
 
Multidrug Resistance associated Protein 1 
MRP1 is a 190 kDa basolateral efflux pump, which transports glutathione-S-
conjugates of anionic compounds directly or in cotransport with glutathione.  
Substrates of MRP1 include chemotherapeutic agents like mitoxantrone, 
anthracyclines and Vinca alkaloids.  Despite its partly overlapping resistance profile 
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with Pgp, the amino-acid sequence of MRP1 resembles Pgp to a small extent of only 
15 %.  The structure of MRP1 contains a central ‘core’ region and a third membrane 
spanning domain.  The additional domain (MSD0) contains five transmembrane 
helices, and an extracellular loop with the N-terminus located on the outside of the 
cell (Bakos, 1996).  Two membrane spanning domains as well as two ATP-binding 
domains are situated (see Figure 1.5) within the ‘core’ region.  
 
 
 
 
 
 
 
 
 
Figure 1.5   Topological model of MRP1  
The organization of MRP1 is depicted with three membrane spanning domains (MSD), the intracellular loops (L), 
two ATP-binding domains and an extracellular N-terminus.  This model resembles MRP2 and MRP3. 
 
 
MRP1 expression is found in the adrenal gland, breast, lung, kidney, heart, 
blood-brain barrier and endocrine tissue.  Studies in mrp1 -/- knockout mice have 
indicated that MRP1 is a transporter functioning as a resistance factor for some 
mucosal tissues and bone marrow.  Furthermore, MRP1 is involved in the 
physiological barrier for the protection of the testis and the choroids (Kruh, 2003).  In 
contrast to Pgp, MRP1 is expressed on the basolateral site of epithelial cells.  Thus, 
MRP1 transports its substrates away from the luminal surface (e.g. intestinal lumen, 
bile duct) into the tissue beneath it (Evers, 1996).   
Due to its strong affinity for glutathione and glucuronate conjugates, both 
products from the phase II cellular detoxification of hydrophobic compounds 
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(Ishikawa, 1992), MRP1 holds an important role in the physiological detoxification 
system.  MRP1 also transports unmodified lipophilic anions, such as many cytotoxic 
agents, in co-transport with glutathione.  Consequently, MRP1-based resistance 
mechanisms can be inhibited by agents, which block the synthesis of glutathione 
(Schneider, 1995).  Such an inhibitor is buthionine sulfoximine (BSO).  Other 
inhibitors of MRP1 include indomethacin and nifedipine (Draper, 1997; Cullen, 2001). 
 
Multidrug Resistance associated Protein 2 
MRP2 is another glutathione efflux pump for amphipathic anions.  The protein 
is composed of 1545 amino acids and its topological organization, as presented in 
figure 1.4 and 1.5, is closely related to MRP1.  Even though the substrate-specificity 
of MRP2 is very similar to that of MRP1, its physiological function is completely 
different.   
MRP2 has a distinct expression pattern and subcellular polarity.  In contrast to 
MRP1, MRP2 is expressed on the apical site of polarized cells.  In the liver, MRP2 is 
localized in canaliculi cells where it mediates the extrusion of lipophilic anions into 
the bile.  MRP2 is an important component in the biliary excretion of bilirudin 
glucuronates, which are conjugated end products of heme degradation (Jedlitschky, 
1997).  Families with hereditary deficiencies of MRP2 have an increased disposition 
for pathological liver conditions.  A lack of MRP2 is associated with defects in 
hepatobiliary excretion of anionic compounds, which leads to the Dubin-Johnson 
syndrome, a clinical manifestation of jaundice (Dubin, 1954).   
To a lesser extent, MRP2 is expressed in renal proximal tubules, enterocytes 
of the intestine and brain capillaries (Kruh, 2003).  The functional overlap with Pgp is 
evident as both transporters are involved in the excretion of cytotoxic compounds 
and the protection of tissue through barrier formation. 
With a similar resistance profile as MRP1, MRP2 confers resistance to a 
variety of natural chemotherapeutics such as anthracyclines, vinca alkaloids and 
epipodophyllotoxines.  Like MRP1, MRP2 needs glutathione for their transport.  The 
affinity to these substrates, however, is slightly weaker as in the case of MRP1.  
Importantly, MRP2 overexpression was detected in cisplatin resistant cell lines.  This 
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suggests that MRP2 might confer resistance to cisplatin, a substance that forms 
toxic glutathione-conjugates in the cell (Tanigutchi, 1996).  Of note, other ABC 
transporters such as Pgp or BCRP are not involved in resistance mechanisms 
against cisplatin. 
 
Multidrug Resistance associated Protein 3 
Among the MRP transporters, MRP3 is structurally most closely related to 
MRP1 with a homology of 58 %.  Likewise, MRP3 contains a third membrane 
spanning domain with an extracellular loop and the N-terminus on the extracellular 
side (see figure 1.4 and 1.5).  MRP3 functions as a transporter of glutathione and 
glucuronate-conjugated compounds.  Its affinity to these conjugates, however, is 
significantly lower than that of MRP1.  Contrary to MRP1 and MRP2, MRP3 does not 
require glutathione for transport of its substrates, thus, the MRP1 inhibitor BSO 
cannot attenuate MRP3-mediated transport (Zelcer, 2001).   
Although it was shown that MRP3 mediates resistance to some cytotoxic 
agents such as etoposide and teniposide (Kool, 1999), its involvement in MDR 
tumors appears to be much smaller compared to MRP1 or MRP2.  
MRP3 can be found in a variety of different tissues.  In the liver, MRP3 is 
expressed at the basolateral membrane of bile duct cells, where it extrudes 
monoanionic bile acids such as glycocholate and taurocholate.  During cholestatic 
liver conditions, MRP3 is highly upregulated and helps to detoxify the hepatocyte by 
transporting toxic bile acids into the blood (Hirohashi, 1998).  In addition to the liver, 
MRP3 is expressed in the intestine, kidney, pancreas and gall bladder (Belinsky, 
1998). 
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1.3 Modulation of Multidrug Resistance 
Conventional chemotherapy has succeeded in many different cancers and 
saved the lives of millions of patients.  At the same time, however, conventional 
chemotherapy has failed to cure cancer numerous times, unable to reverse the 
progress of the disease.  While some oncologists argue that the efficacy of 
conventional chemotherapy is limited; others state that resistance mechanisms 
hamper their potential (Fojo, 2003).  If the latter is true, resistance mechanisms, 
namely those outlined in chapter 1.1.1, could be inhibited and the chemotherapeutic 
activity restored.  Motivated by this argument, many researchers have investigated 
strategies to overcome MDR in untreatable tumors.  The strategies involving ABC 
transporters are introduced in the following chapters. 
 
1.3.1 P-glycoprotein inhibitors 
Development of chemosensitizing modulators which inhibit the function of Pgp 
thereby reversing MDR has been pursued extensively for the past 20 years.  In the 
early 1980s, the calcium channel blocker verapamil was discovered to reverse Pgp-
mediated MDR in vitro (Tsuruo, 1981).  Other first generation modulators of Pgp 
belonged to various therapeutic classes.  Among them are the class I antiarrythmic 
agent quinidine and the immunosuppressant cyclosporin A.  These agents are 
required at relatively high concentrations to effectively inhibit Pgp.  However, at 
these concentrations unacceptable in vivo toxicities and interactions with numerous 
physiological tissues and transporters occur.  Heart block with subsequent heart 
failure was observed, when verapamil was combined with doxorubicin (Ozols, 1987).  
Among the first generation modulators, the immunosuppressant cyclosporin A 
remains one of the most effective and best studied.   
Development of the second generation Pgp modulators was driven with the 
intension of improving the affinity to Pgp while reducing clinical toxicities.  These 
compounds were all derivatives of the first generation modulators, however, less 
toxic and without the main pharmacological effects of their templates.  The non-
immunosuppressive analog of cyclosporin A, PSC 833 (see figure 1.6), 
demonstrated a 10-fold more potent MDR reversal activity in vitro than cyclosporin A 
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(Krishna, 1997).  PSC 833 (Valspodar) has been used extensively in tumor 
xenografts and clinical trials (Oza, 2002; Fracasso, 2000).  As preclinical evidence 
suggested that serum protein binding would decrease the effectiveness of PSC 833 
(Lehnert, 1996), the compound was administered at doses, which in retrospect were 
much too high.  At these concentrations major pharmacokinetic interactions were 
reported.  In a clinical trial using PSC 833 and doxorubicin, a 10-fold increase in 
doxorubicin blood levels was detected, which substantially increased hematological 
toxicities (Giaccone, 1997).   
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Figure 1.6   Chemical structure of cyclosporin A and PSC 833 (Valspodar) 
Chemical structures of PSC 833 and Cyclosporin A are depicted; chemical variations of PSC 833 are indicated 
by a blue circle. 
 
 
Lessons learned from second generation Pgp inhibitors resulted in more 
sophisticated approaches with aims to develop specific inhibitors, which would not 
interact with other targets.  Pharmacophore models with efforts to explain Pgp’s 
broad substrate acceptance have been developed (Pajeva, 2002).  Furthermore, 
structure-activity relationships and combinatorial chemistry techniques have been 
elaborated and used to synthezise promising third generation Pgp modulators.  
These modulators demonstrated increased specificity for Pgp with an inhibition in the 
nanomolar range and reduced in vivo toxicities (Tan, 2000; Fojo, 2003).   
 
   Introduction 
 
20 
Some examples of third generation Pgp modulators are presented in figure 
1.7.  These compounds include XR9576 (Tariquidar: Dale, 1998), LY335979 
(Dantzig, 1996; Kemper, 2004), OC144-093 (Newman, 2000) and GF120918 (Hyafil, 
1993) and are currently referred to as the state of the art.   
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Figure 1.7   Chemical structures of selected third generation Pgp inhibitors 
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Various second- and third-generation modulators have been evaluated in 
clinical trials with partly encouraging, partly conflicting results (Tan, 2000).  Their 
drawbacks in clinical applications resulted from alterations in the pharmacokinetic 
profile of coadministered cytotoxic agents.  Additionally, clinical toxicities by and lack 
of efficacy of MDR inhibitors were observed.  These complications were  presumably 
caused by the existence of multiple and redundant cellular mechanisms of resistance 
(Fisher, 1996).  Despite tremendous efforts and many encouraging reports published 
in this field, no Pgp inhibitor has received a market authorization to date.   
 
1.3.2 Multi targeted MDR inhibitors 
The first generation Pgp inhibitor, cyclosporin A, has proven sufficient efficacy 
in clinical trials to reverse MDR in acute myelomic lymphoma (AML) (Smeets, 2001; 
List, 2001).  Interestingly, cyclosporin A was later found to inhibit not only Pgp but 
also BCRP, MRP1 and the lung resistance protein (LRP), another transporter 
involved in the transport of cytotoxic agents (Qadir, 2005).  Whereas third generation 
Pgp inhibitors are being developed to increase specificity for Pgp with means to 
prevent in vivo toxicities and pharmacokinetic interactions (Tan, 2000; Fojo, 2003), 
the concept of broad-spectrum MDR modulation has recently attracted much 
attention.  Most complicated MDR-protected tumors such as acute leukemia are 
protected by multiple and redundant cellular mechanisms of resistance (Ross, 2000; 
Urasaki, 1996).  Thus, modulation of more than one ABC-transporter-mediated 
mechanism appears to be a promising approach.   
Recently, some groups including Minderman and coworkers have developed 
MDR inhibitors targeted against more than one ABC transporter.  The synthetic 
taxane derivative BAY 59-8862 (Ortataxel) was found to simultaneously inhibit the 
function of Pgp, BCRP and MRP1 (Minderman, 2004) and is currently under 
investigation in Phase I clinical trials (Ramnath, 2004).  VX-710 (Biricodar), a 
pipecolinate derivative, is another multi targeted MDR inhibitor with modulating 
properties of Pgp, BCRP and MRP1 (Minderman, 2004), currently under 
investigation in Phase II clinical trails (see figure 1.8).   
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Figure 1.8   Chemical structure of VX-710 and BAY 59-8862 
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1.3.3 Antisense Therapy 
While modulation using small molecule inhibitors has been the main focus to 
circumvent MDR, other strategies including gene regulation approaches have been 
investigated.  Among them are synthetic DNA oligomers, the conventional antisense 
oligodeoxynucleotides (ODNs).  ODNs directed against the MDR1 gene can 
specifically inhibit the expression of Pgp.   
Antisense ODNs are powerful tools for the selective and sequence-specific 
regulation of gene expression (Benett, 1999; Galderisi, 1999).  The synthetic DNA 
molecules can be specifically designed for each target and are susceptible to 
degradation.  To produce oligonucleotides suitable for in vivo applications, chemical 
modifications of oligonucleotides have been described in efforts to increase their 
stability and specificity.  Most experience with in vivo application has been generated 
with phosphorothioate oligonucleotides (Eckstein, 2000) which contain a sulphur 
atom replacing a single oxygen atom at each phosphate group.  Phosphorothioation 
makes ODNs relatively nuclease resistant (Stein, 1988).  Although associated with 
non-specific binding and toxic side effects in vivo (Levin, 1999), a phosphorothioated 
antisense-based drug against CMV, VitraveneTM (De Smet, 1999), receive market 
authorization in 1998. 
Antisense molecules hybridize to their target mRNA in the cytosole, where 
they recruit the endonuclease RNAse H.  The enzyme destroys the target mRNA 
and releases the antisense molecule.  The released antisense molecule can 
hybridise to another target mRNA strand.  In this way, the degradation of target 
mRNA prevents the translation of the protein.  The mode of action is illustrated in 
figure 1.9.  
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Figure 1.9   Mechanism of protein-synthesis inhibition by antisense ODNs  
In the cyctoplasma, antisense ODNs hybridize to target mRNA.  This process recruits RNAse H enzyme, which 
degradates mRNA and releases the antisense strand.  Lack of mRNA, inhibits the translation of the protein. 
(Picture taken from Robinson, PLoS 2004;2:18-20) 
 
 
Antisense oligodeoxynucleotides directed against the MDR1 gene have been 
widely used to inhibit the translation of MDR1 mRNA and downregulate the 
expression of Pgp (Alahari, 1996; Dassow, 2000).  ODNs, designed mostly against 
the region of the initiation codon of MDR1, have been reported to inhibit the Pgp-
mediated multidrug resistant phenotype in vitro in cell culture (Alahari, 1998) and in 
vivo in human tumor xenografts (Ramachandran, 2003).  
Other antisense strategies used to downregulate Pgp include various 
chemically modified antisense oligonucleotides (e.g. locked nucleic acids), 
hammerhead ribozymes and siRNA (Kurreck, 2003). 
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1.4 Imaging of Multidrug Resistance  
Non-invasive methods to examine the multidrug resistant status of tumors 
before therapy are valuable tools to select the most effective combination of 
chemotherapy for treatment.  Detection of Pgp expression is commonly performed 
using immunohistochemical or immunofluorescence techniques (Beck, 1996).  
These techniques, however, may also detect altered or functionally impaired Pgp 
and are therefore of limited prediction.  Furthermore, their routine use in a clinical 
setting is laborious, expensive and rather complicated.   
Imaging of Pgp function with the cardioimaging tool 99mTc-Sestamibi (see 
chapter 3.3.6.1 and 3.3.7, methods) is a technique used to non-invasively evaluate 
Pgp activity in tumors (Piwnica-Worms, 1993).  The synthetic gamma-emitting 
organotechnetium complex, 99mTc-Sestamibi, is a Pgp substrate and has been 
approved by the Food and Drug Administration (FDA) for the use as a radiotracer.   
99mTc-Sestamibi accumulation is directly correlated to physiological Pgp 
expression; it is inversely proportional to the degree of Pgp expression.  Other ABC 
transporters do not interfere with 99mTc-Sestamibi transport.  MRP1 has a much 
lower affinity and the radiopharmaceutical does not interact with BCRP (Chen, 
2000).  Thus the detection of 99mTc-Sestamibi accumulation permits to selectively 
trace and map Pgp function.  Del Vecchio and coworkers have performed imaging 
studies in breast cancer patients using 99mTc-Sestamibi (Del Vecchio, 2004).  In Pgp 
overexpressing tumors, efflux of 99mTc-Sestamibi was increased over 2-fold 
compared to tumors with basal levels of Pgp expression.  Tumor response to 
chemotherapy has also been correlated with intratumoral 99mTc-Sestamibi 
accumulation.  In a study by Ciarmiello (Ciarmiello, 1998), the response rate of 
breast tumors to neoadjuvant chemotherapy was markedly decreased in tumors, 
which rapidly effluxed 99mTc-Sestamibi.  In human tumor xenograft models, 99mTc-
Sestamibi imaging has been successfully used to monitor the effectiveness of novel 
Pgp inhibitors (Marián, 2003; Hendrikse, 1999).  Through detectable changes in the 
distribution and accumulation of 99mTc-Sestamibi, the technique further permits to 
evaluate interaction of Pgp inhibitors with physiological Pgp expressed in various 
organs and barriers (Zhou, 2001). 
  
 
2 Rational  
 
 
2.1 Rational and hypothesis 
 Clinical MDR remains a major obstacle in the successful chemotherapeutic 
treatment of cancer.  In many recurring and untreatable tumors the machinery of 
MDR contributes to the fatal progress of the disease.  Over the past years, different 
therapeutic strategies, including those targeting Pgp by small molecule inhibitors or 
RNA inhibition, have been extensively investigated in cell culture, animal models and 
in cancer patients.  Yet a medication against the condition of “multidrug resistant 
cancer” could not be developed to a level of marketing authorization.   
 The disparity between research effort and outcome in the sense of a 
therapeutic strategy suggests that MDR is a phenomenon more multifaceted than 
originally thought.  Consequently, its resolution will likely be more involved.  A 
combinational treatment designed to target more than one MDR mechanism 
simultaneously might be a solution to master MDR in its complexity. 
Two hypotheses of combinational treatment strategies are being formulated:  
• Different mechanisms of MDR are targeted simultaneously  
• The same mechanism is targeted by more than one approach 
To address these hypotheses, I have investigated two different treatment strategies 
for their effectiveness and feasibility in reversing MDR in human tumors.  The two 
treatment strategies were studied both separately and in combination using in vitro 
and in vivo experimental techniques: 
I. Novel multi-targeted MDR inhibitors (Tetrahydroisoquinolin-ethyl-phenyl 
amine-based MDR inhibitors developed in Prof. Dr. M. Wiese’s laboratory at 
the University of Bonn)  
II. Transcriptional downregulation by MDR1 antisense ODNs (in 
combination with an MDR inhibitor) 
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Hypothesis 
 (I.) In line with recent discoveries that several ABC-transporters coexist in 
many tumors, multi-targeted MDR inhibitors are thought to reverse the ABC-
transporter-mediated multidrug resistant phenotype more effectively than selective 
inhibition of just one ABC-transporter (e.g. Pgp).  The novel tetrahydroisoquinolin-
ethyl-phenyl amine-based MDR inhibitors were characterized as potential multi-
targeted MDR inhibitors.   
 (II.) Moreover, a combination of transcriptional suppression and functional 
inhibition of the MDR1 gene and functional Pgp, respectively, is an interesting 
approach, which has not been investigated before.  The combined treatment using 
antisense ODNs together with a Pgp inhibitor is though to be more effective in 
comparison to the single treatments as it allows the simultaneous targeting of the 
function and formation of the protein.   
 
 
2.2 Aim and experimental outline  
 To address the two above-mentioned hypotheses, the two outlined treatment 
strategies (I. and II., see chapter 2.1) were implemented in a series of in vitro and in 
vivo studies using a tumor model of human ovarian cancer: 
 
In vitro 
• Novel MDR inhibitors were tested for their ability to inhibit transport function 
of relevant members of the ABC-transporter family, involved in MDR: Pgp, 
BCRP and MRP1-3.   
• Potential in vitro toxicities of novel MDR inhibitors and MDR1 antisense 
ODNs were investigated in several cell lines. 
• The potency and specificity of novel MDR inhibitors to reverse Pgp and 
BCRP-mediated resistance towards chemotherapeutic agents were studied 
in multidrug resistant cell lines.  
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• The effectiveness of MDR1 antisense ODNs to downregulate the surface 
expression of Pgp was studied in a Pgp overexpressing cell line.  
• The MDR-reversing properties of MDR1 antisense ODNs were investigated 
by studying inhibition of Pgp-mediated transport and resistance towards a 
chemotherapeutic drug.  
 
Among the novel MDR inhibitors, the most promising candidate, WK-X-34, was 
selected for further in vivo investigations. 
 
In vivo 
• Potential in vivo toxicity including hepatotoxicity of the selected MDR 
inhibitor, WK-X-34, was studied in mice.  
• The ability to reverse the MDR phenotype by WK-X-34 in vivo was studied in 
tumor xenograft models of resistant human ovarian cancer using 99mTc-
Sestamibi imaging techniques. 
• Potential interactions of WK-X-34 with physiological Pgp and 
pharmacokinetic alterations of the Pgp substrate 99mTc-Sestamibi were 
examined in nude mice. 
• The effectiveness of MDR1 antisense ODNs to downregulate MDR1/Pgp 
mRNA and protein expression were studied in tumor xenograft models of 
multidrug resistant human ovarian cancer. 
• The MDR-reversing ability of antisense treatments alone and in combination 
with the selected MDR inhibitor, WK-X-34, was investigated in a human 
MDR solid tumor xenograft models using 99mTc-Sestamibi imaging 
techniques. 
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2.3 Justification of experimental methods 
 
2.3.1 Choice of Pgp inhibitors  
The novel tetrahydroisoquinolin-ethyl-phenylamine-based MDR inhibitors WK-
X-34, WK-X-50 and WK-X-84 (Figure 3.1) were designed and synthesized by W. 
Klinkhammer in Prof. Dr. M. Wiese’s laboratory at the Pharmaceutical Institute, 
University of Bonn, Germany.  Based on initial functional in vitro assays, including 
the MTT assay and the Calcein AM and daunorubicin transport assays performed by 
H. Mueller and K. Breitbach, these compounds were selected as the most promising 
candidates for further in vitro and in vivo characterization.  Increased amounts of 
these compounds were synthesized by W. Klinkhammer and sent to the laboratory of 
Dr. Piquette-Miller at the University of Toronto.   
In vitro assays were conducted using verapamil and cyclosporin A as 
reference substances.  Verapamil is the oldest and most prominent amongst the Pgp 
inhibitors (Tsuruo, 1981).  To date, the first generation Pgp inhibitor cyclosporin A is 
the only inhibitor to perform convincingly in clinical applications.  Cyclosporin A 
demonstrated efficacy in clinical trials reversing MDR in acute myelomic lymphoma 
(AML) patients (Smeets, 2001; List, 2001).  One can argue, that the more effective 
and more potent third generation Pgp inhibitors such as GF120918 (Hyafil, 1993) or 
XR9576 (Mistry, 1999) are the current state of the art Pgp inhibitors.  Despite 
extensive research and clinical development, these compounds have not yet 
received market authorization.  As the successful clinical application is the main 
motivation for the development of MDR inhibitors, cyclosporin A was used as the 
reference compound.   
 
2.3.2 Cell model  
The multidrug resistant human ovarian cancer cell line A2780/Adr and its 
sensitive counterpart A2780/wt were used for the in vitro and in vivo investigations of 
Pgp.  These cell lines were initially isolated from a drug sensitive patient with ovary 
tumors.  Through selection with adriamycin, a multidrug resistant phenotype with 
cross resistance characteristics was obtained (Louie, 1986; Sasaki, 1991).  Over the 
Rational  
 
    
31
past decades, resistant A2780/Adr cells have proven to be a suitable model to study 
Pgp-mediated MDR in solid tumors. They have been widely used both in cell culture 
(e.g. Sasaki, 1991; Plumb, 1990; Mueller, 2004) and xenograft models (e.g. Caffrey, 
1998; De Cesare, 2001). Therefore, this well-established cell model was chosen and 
applied in this thesis.   
Resistant A2780/Adr cells tend to loose their phenotype over a span of 10-20 
passages by the development of two subpopulations, in which the sensitive fraction 
keeps increasing and the resistant fraction keeps decreasing.  To guarantee a high 
and constant expression of Pgp, adriamycin (10 µM) needed to be added to these 
cells every 10 passages.  To monitor and verify a constant Pgp expression, MDR1 
and Pgp expression was routinely examined by RT-PCR and protein staining 
techniques.   
 
2.3.3 MDR1 antisense ODN treatments  
I wanted to compare Pgp inhibition caused by small-molecule inhibitors to 
MDR1 antisense treatment, which downregulates the expression of functional Pgp.  
For this purpose, conventional phosphorothioated antisense ODNs directed against 
the start codon of the human MDR1 gene were used.  The ODN sequence was 
taken from reports by Alahari et al. (Alahari, 1998).  The anti-MDR activity of these 
sequences has been previously verified in vitro (Brigui, 2003) and in vivo 
(Ramachandran, 2003).  Among the DNA-based antisense tools, phosphorothioated 
antisense ODNs are the oldest and best characterized. Indeed VitraveneTM 
(Fomivirsen), a phosphorothioated antisense inhibitor of CMV replication (De Smet, 
1999; Naesens, 2001), developed by ISIS Pharmaceuticals is the only antisense-
based drug ever to get a marketing authorization.  As I was primarily interested in 
using a basic antisense tool, rather than optimizing antisense-targeted therapy in 
MDR cancer, I decided to utilize conventional phosphorothioated antisense ODNs.  
Moreover, I evaluated in vitro, whether the inhibitory effects were due to antisense 
effects and not simple toxic effects.  FITC-labeled MDR1 antisense ODNs were used 
to investigate the uptake path of antisense ODNs.  Fluorescent microscopy permitted 
to study whether antisense MDR1 ODNs actually accumulated in the nucleus.  
Interestingly, these studies demonstrated that the delivery of antisense molecule is 
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increased when formulated as a double-stranded antisense and sense duplex.  
These results have been published (Jekerle, 2005), however, they are only partly 
contained in this PhD thesis.   
For in vivo antisense treatments, I also used conventional phosphorothioated 
antisense ODNs for the same reasons: 1) much experience has been generated with 
in vivo applications using phosphorothioated antisense ODNs; 2) the rational of my 
thesis asked for a functional comparison of antisense strategy to Pgp modulation, 
rather than the optimization of different in vivo applications.  I designed the treatment 
regiments according to previously published antisense applications (Kuss, 2002).  
The in vivo experiments were conducted as proof of principle approaches.  
Therefore, the most direct route of application was chosen, an intra tumoral injection.  
By using this route of application, additional in vivo effects and complications 
resulting from unequal in vivo stability, distribution and delivery to the site of action 
could be minimized.   
 
2.3.4 Choice of in vitro functional assays for Pgp 
To evaluate in vitro inhibition of Pgp, a combination of chemosensitivity 
assays and transport assays were utilized.  Chemosensitivity assays investigate the 
effects of inhibition on the Pgp-mediated MDR phenotype.  The increased sensitivity 
of the multidrug resistant tumor cell towards chemotherapeutic agents such as the 
anthracyclines (e.g. daunorubicin) can be directly measured.  EC50 values allow the 
quantification and comparison of inhibitory effects by different modulators.   
A series of transport assays investigating both increases in intracellular 
accumulation and decreases in the efflux rate of Pgp substrates were utilized.  Three 
different Pgp transport assays were chosen for these studies: 1) 99mTc-Sestamibi 
accumulation assay; 2) Daunorubicin accumulation assay; and 3) Daunorubicin 
efflux assay.  This combination of transport assays included two different Pgp 
substrates and two different transport parameters (basic accumulation and efflux).  
Studies comparing the usefulness of the substrates 99mTc-Sestamibi and 
daunorubicin in Pgp transport assays have also indicated differences between these 
two assays.  Muzzammil and coworkers stated that sufficient sensitivity to distinguish 
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wild-type from resistant cell variants was given for both substrates (Muzzammil, 
2001).  A greater sensitivity with more reliable conclusions, however, was detected 
for 99mTc-Sestamibi-based transport assays.  These differences were explained by 
additional MDR factors (see chapter 1.1, introduction) unequally affecting 99mTc-
Sestamibi and anthracyclines.  Hence, combined results from both assays allow a 
more predictive and reliable evaluation of Pgp inhibition.   
 
2.3.5 Choice of in vitro functional assays for BCRP and MRPs  
To examine potential interactions with the MRP proteins, a conventional 5-
CFDA efflux assay was used.  The MRP family of ABC transporters has currently up 
to seven members and is constantly growing.  As outlined in the introduction, solely 
MRP1, MRP2 and MRP3 were found to be implicated in the MDR phenotype of 
resistant tumors (Borst, 2000; Kruh, 2003).  Therefore, I decided to examine 
potential effects of novel MDR inhibitors on these three MRP transporters.  
Selectively transfected cell lines were used for these studies.  In selectively 
transfected cell lines, the actual human protein of a defined sequence has been 
artificially engineered into the cell.  This has an advantage over selected resistant 
cell lines which might contain different mutants of a protein together with other 
resistance mechanisms.  Every cell line expresses basal levels of other ABC 
transporters.  The protein of interest, however, is relatively overexpressed in 
selectively transfected cell lines.  Results obtained from these cell lines can thus 
provide fairly accurate information about the transport properties of the transfected 
protein.  
As selectively transfected cell lines for BCRP have not yet been generated, I 
used the BCRP overexpressing cell line MCF7/mx, a mitoxantrone selected human 
breast cancer cell line in a previously established and commonly applied flow 
cytometry-based efflux assay (Minderman, 2002). 
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2.3.6 Tumor xenograft model  
To investigate the in vivo performance of WK-X-34 and antisense treatments, 
a suitable in vivo model needed to be developed.  Numerous rodent models have 
been actualized to simulate the development of ovarian cancer in vivo and to aid in 
the research of human ovarian cancer.  Rodent models of ovarian cancer include the 
chemical/hormonal induced model, the genetic knockout and transgenic model, the 
syngeneic model and the xenograft model (Stakleff, 2003).   
In chemically or hormonally induced tumor models, the tumors are specifically 
induced by a chemical trigger and display all stages of tumorgenesis.  These models 
can therefore proceed through all stages of neoplasia from the initiation and 
promotion to the actual development of the tumor.  The chemical/hormonal induced 
model, however, is difficult to apply in praxis as tumors are not selectively induced 
only in the ovaries.  The model furthermore lacks consistency and reproducibility 
(Silva, 1997; Nishida, 1998).   
Genetic knockout and transgenic models are generated in genetically altered 
mice.  These models are used when the impact of genetic alterations in oncogenes 
or tumor suppressor genes is investigated (Orsulic, 2002; Wang, 1999).   
In syngeneic models, tumors are derived from animal tissues by in vitro 
transformation and re-injected into the same animal species (Rose, 1996).   Although 
this model allows a good evaluation of host-tumor interactions, the development of 
the primary tumor occurs in vitro and does not represent physiological conditions.   
In xenograft models, human tumor specimens are implanted into 
immunocomprimised nude mice, which lack functional T lymphocytes (Croy, 2001).  
In this way, the xenograft model permits the growth of human tumor specimens 
(Massazza, 1989; Elkas, 2002).  The cell lines can be manipulated in vitro before 
being injected into the animal.  In xenografts, multidrug resistant and/or sensitive 
tumors can be selectively generated in the same model (Bradley, 1989).  The lack of 
immune response in the animals, however, does not allow the direct translation into 
clinical reality. 
The xenograft model appeared to be the most suitable for my purposes and 
was used for the in vivo 99mTc-Sestamibi imaging and biodistribution studies.  The 
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same A2780/Adr and A2780/wt cells which were already used for in vitro 
investigation could be inoculated s.c. into the back flank of immunocomprimised 
mice.  Thus, the tumors grew on each back flank of the animals.  This was important 
as imaging studies necessitated a model in which the tumors were localized away 
from all the inner organs (Picture 5, Appendix) to avoid overlap of 99mTc-Sestamibi 
levels between organs and tumors.  Furthermore, the tumor models could be 
generated in such a way that each animal bore one multidrug resistant A2780/Adr 
and one sensitive A2780/wt on each back flank.  This design allowed the comparison 
of the treatments on each tumor simultaneously and within the same animal.     
A literature study based on data from the National Cancer Institute (NCI) 
compared the clinical predictive value of preclinical cancer models including in vitro 
cell lines and human xenografts for different tumors (Voskoglou-Nomikos, 2003).  In 
this study, the human xenograft model turned out to be predictive for non-small lung 
cancer and for ovarian cancer (Johnson, 2001; Taetle, 1987), but not for breast or 
colon cancer.  Overall, the human xenograft models were rated useful in predicting 
the Phase II clinical performance of cancer drugs (Voskoglou-Nomikos, 2003).   
 
2.3.7 99mTc-Sestamibi imaging and biodistribution  
To study in vivo applications of Pgp inhibitors and antisense therapy, an in 
vivo imaging approach combined with a biodistribution analysis using 99mTc-
Sestamibi was chosen.  As previously mentioned in the introduction, the gamma-
emitting complex 99mTc-Sestamibi has been discovered to be a Pgp substrate.  
Therefore, 99mTc-Sestamibi can non-invasively map Pgp expression and functionality 
through changes in organ accumulations (Piwnica-Worms, 1993).  99mTc-Sestamibi 
imaging is widely used to detect multidrug resistant tumors (Zhou, 2001) and to 
monitor the effectiveness of novel Pgp inhibitors in cancer patients (Agrawal, 2003) 
and human tumor xenograft models (Lorke, 2001; Muzzamil, 1999; Ballinger, 2000).  
Moreover, the technique of 99mTc-Sestamibi imaging has been approved by the FDA 
for rapid evaluation of the effectiveness of anti-MDR therapies in clinical trials.  
99mTc-Sestamibi imaging was used to test the third generation Pgp inhibitor XR9576 
in clinical trials Phase II and pivotal Phase III clinical trials (Menefee, 2005).  Other 
99mTc-labeled lipophilic cationic complexes such as 99mTc-tetrofosmin and 99mTc-
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Q12, both myocardial infusion agents (Bernard, 1998; Utsunomiya, 2000), have also 
been evaluated for the use in in vitro and in vivo imaging studies.  A study comparing 
the suitability of these three 99mTc-labeled imaging agents came to the conclusion 
that 99mTc-Sestamibi is the most appropriate agent for tumor imaging due to 
advantages in tumor uptake (Bernard, 1998).   
Therefore, 99mTc-Sestamibi was chosen as the Pgp substrate and detector for 
the imaging and biodistribution studies.  These studies, however, are rather 
expensive and time-consuming, involving the generation of an animal model as well 
as conducting the actual imaging experiments.  Time and resources only permitted 
the testing of the most promising candidate among the MDR inhibitors developed in 
Prof. Dr. M. Wiese’s laboratory, WK-X-34.    
99mTc-Sestamibi imaging enabled to non-invasively monitor the impact of WK-
X-34 on Pgp activity in multidrug resistant and sensitive tumors as well as on 
physiologically expressed Pgp in excreting organs and barrier tissue.  Hence, 
potential interactions and organ toxicities resulting from Pgp inhibition by WK-X-34 
could be evaluated.  Results from 99mTc-Sestamibi imaging were correlated with 
biodistribution studies to verify, whether the detected levels of radioactivity in the 
regions of interest of the selected organs corresponded to the actual 99mTc-Sestamibi 
uptake in these organs.   
  
 
3 Materials and Methods 
 
 
3.1 Materials 
 
3.1.1 Chemicals, Reagents and Materials 
Agarose Bio-Rad Laboratories, Mississauga, ON, Canada 
ALT (Alanin Aminotransferase assay)  ThermoDMA, Arlington, TX, USA 
Antibodies 
  FITC-labeled anti-human Pgp BD Biosciences, San Diego, CA, USA 
  monoclonal antibody  
 
  Primary anti-human BCRP monoclonal  Abcam Inc, Cambridge, MA, USA 
  BXP-21 antibody 
 
  Fluorescein-labeled sheep anti-mouse Ig  Amersham Biosciences, Piscataway, NJ, USA 
  antibody  
   
Bicarbonate buffer (pH 7.5)  Dept. of Radiopharmacy, TGH, Toronto, ON, Canada 
Bio P-2 gel (45-90 µm)  Bio-Rad, Mississauga, ON, Canada 
Bovine serum albumine (BSA) solution Sigma-Aldrich, Steinheim, Germany 
Bovine serum albumin (BSA) powder Sigma, Oakville, ON, Canada 
Bradford protein assay  Bio-Rad, Hercules, CA, USA 
Casy® ton isotonic NaCl solution  Schärfe-Systems, Reutlingen, Germany 
Cellstar Vials (15 ml)  Greiner Labortechnik, Frickenhausen, Germany 
Cellstar Vials (50 ml)  Greiner Labortechnik, Frickenhausen, Germany 
Cellstar Culture Flasks 25 cm2  Greiner Labortechnik, Frickenhausen, Germany 
Cellstar Culture Flasks 75 cm2  Greiner Labortechnik, Frickenhausen, Germany 
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Cellstar Culture Flasks 175 cm2  Greiner Labortechnik, Frickenhausen, Germany 
Cell scraper  Greiner Labortechnik, Frickenhausen, Germany 
5-CFDA  Sigma, Oakville, ON, Canada 
Chloroform Merck, Darmstadt, Germany 
Cover slips for microscope slides  CR Scientific, Lebanon, NJ, USA 
Cremophor EL Sigma Chem. Co, St Louis, MO, USA 
Cryovials  Greiner Labortechnik, Frickenhausen, Germany 
Cyclosporin A  Sigma-Aldrich, Steinheim, Germany 
Daunorubicin  Sigma, Oakville, ON, Canada 
DEPC water  Invitrogen, Carlsbad, CA, USA  
Dimethylsulfoxide Promochem GmbH, Wesel, Germany 
Disodium hydrogen phosphate x 2 H2O  Merck, Darmstadt, Germany 
DMEM-Medium with Glutamax Sigma-Aldrich, Steinheim, Germany 
DMEM-Medium  with high Glucose   Sigma-Aldrich, Steinheim, Germany 
Doxorubicin  Sigma, Oakville, ON, Canada 
Eosin Y  Sigma, Oakville, ON, Canada 
Ethanol 96-100 % (V/V)  Merck, Darmstadt, Germany 
FACS Flow  Becton-Dickinson, Heidelberg, Germany 
FACS Clean Becton-Dickinson, Heidelberg, Germany 
Fetal Calf Serum (FCS)  Sigma, Oakville, ON, Canada 
First Strand cDNA synthesis kit   MBI Fermentas, Flamborough, ON, Canada 
Fluorescein isothiocyanate (FITC) Molecular Probes, Invitrogen Canada Inc. 
Burlington, ON, Canada   
Gene RulerTM (100 bp) Invitrogen, Carlsbad, CA, USA  
Haematoxylin  Fisher Scientific, Nepean, Ontario, Canada 
Halothane MTC Pharmaceuticals, Cambridge, ON, Canada 
Heparin  Organo Teknica, Toronto, ON, Canada 
Human MDR1 antisense and random  Invitrogen, Carlsbad, CA, USA 
phosphorothioated oligodeoxynucleotides  
with aminohexyl modifications (5’-end) 
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Hydrochloric acid 37 % (m/V)  Merck, Darmstadt, Germany  
Indomethacin  Sigma, Oakville, ON, Canada 
Insulin Syringe (1ml) with permanently   BD Canada, Oakville, ON, Canada 
attached 29g x ½" Ultra-fine Needle (U-100)  
 
Isopropanol 100 %  Merck, Darmstadt, Germany 
ITLC-Silica Gel  Gelman, Ann Arbor, MI, USA 
Ketamine Parke-Davis, Scarborough, ON, Canada 
L-Glutamin  Sigma-Aldrich, Steinheim, Germany  
Mitoxantrone  Sigma, Oakville, ON, Canada 
Methanol  Merck, Darmstadt, Germany 
MTT (3-(4,5-Dimethylthiazol-2-yl)  Sigma-Aldrich, Steinheim, Germany 
-2,5-diphenyltetrazoliumbromid) 
Novobiocin  Sigma, Oakville, ON, Canada 
Nuclease-free purified water  Invitrogen, Carlsbad, CA, USA 
PCR primers DNA synthesis facility, Sick Kids Hospital, Toronto, 
ON, Canada 
Penicillin-Streptomycin-solution  Sigma-Aldrich, Steinheim, Germany 
Conc. Penicillin: 10000 I.U./ ml 
Potassium dihydrogen phosphate  Merck, Darmstadt, Germany 
Potassium chloride  Merck, Darmstadt, Germany 
Purelab Plus water  USF Reinstwassersysteme,  
 Ransbach-Baumbach, Germany 
RPMI 1640-Medium Sigma-Aldrich, Steinheim, Germany 
RPMI 1640-Medium phenolred-free Sigma-Aldrich, Steinheim, Germany 
Sodium acetate buffer (1M)  Dept. of Radiopharmacy, TGH, Toronto, ON, Canada 
Sodium azide  Merck, Darmstadt, Germany 
Sodium chloride  Merck, Darmstadt, Germany 
Sodium citrate buffer (100 mM, pH 5.0) Dept. of Radiopharmacy, TGH, Toronto, ON, Canada 
SuperFect® Qiagen, Mississauga, ON, Canada   
SYBR Gold nucleic acid stain  Molecular Probes, Eugene, OR, USA 
Taq polymerase®  MBI Fermentas Inc, Burlington, ON, Canada  
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99mTc-Sestamibi (Cardiolite®) Bristol-Meyers Squibb Medical Imaging, N.   
 Billerica, MA, USA 
TRIzol GIBCO-BR Life Technologies, Gaithersburg, MD,USA 
Trypsin-EDTA  Sigma-Aldrich, Steinheim, Germany 
Tween 40  Sigma, Oakville, ON, Canada 
Verapamil  Sigma-Aldrich, Steinheim, Germany 
6-well culture plates (clear)  Greiner Labortechnik, Frickenhausen, Germany 
24-well culture plates (clear)  Greiner Labortechnik, Frickenhausen, Germany  
96-well culture plates (clear)  Greiner Labortechnik, Frickenhausen, Germany 
96-well culture plates (black)  Greiner Labortechnik, Frickenhausen, Germany  
 
WK-X-34, WK-X-50, WK-X-84, XR9577 synthesized by W. Klinkhammer,  
 Laboratory Prof. Dr. M. Wiese, Pharmaceutical Institute,  
 University of Bonn, Bonn, Germany 
 
Xylazine 100 mg/ml Bayer Inc., Agriculture Division–Animal Health,  
 Etobicoke, ON, Canada 
 
 
 
3.1.2 Buffers and Solutions 
 
 
Blocking-buffer (10 %)    
 BSA      5 g 
 Tween 40      50 µl 
 PBS       ad 50 ml 
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Cell Culture media  
 
A2780/Adr; A2780/wt  
 RPMI 1640-Medium  500 ml 
 FCS       50 ml 
 Penicillin/Streptomycin    5 ml 
 
MDCK/wt; MDCK-MRP2, MDCK-MRP3, MCF7/wt     
 DMEM-Medium with Glutamax  500 ml 
 FCS       50 ml 
 Penicillin/Streptomycin  5 ml 
 
Hela-MRP1    
 DMEM-Medium with high Glucose  500 ml 
 FCS       50 ml 
   Geniticine                                                400µg/ ml  
  
MCF7/mx     
 DMEM-Medium with high Glucose  500 ml  
 Heat inactivated FCS     50 ml 
   Penicillin/Streptomycin    5 ml  
 
 
Dilution Buffer    
 BSA powder     1 g 
   PBS      ad 50 ml 
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Formaldehyde-solution (10 %)    
 Formaldehyde     5 ml 
 PBS       ad 50 ml 
 
Isopropanol / HCL-solution     
 Isopropanol 100 %    50 ml 
 Hydrochloric Acid 37 %     165 µl 
 
Methanol-solution (90 %)    
 Methanol     45 ml 
 PBS       5 ml 
 
MTT-solution     
 MTT      100.0 mg 
 PBS-solution      ad 20.0 ml 
 
PBS-(phosphate-buffered-saline) Buffer     
 Sodium chloride    8.0 g 
 Disodium hydrogen phosphate    1.14 g 
 Potassium dihydrogen phosphate             0.2 g 
 Potassium chloride      0.2 g 
 Purelab Plus Water  ad 1000 ml 
 
Staining-buffer     
 Sodium azide     100 mg 
 BSA powder     500 mg 
 PBS-solution      ad 100.0 ml 
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Washing-buffer I     
 BSA powder     500 mg 
 PBS-solution      ad 100.0 ml 
 
Washing-buffer II     
 Tween 20     10 µl 
 PBS-solution      ad 100 ml 
 
 
3.1.3 Instruments and Software 
ADAC TransCam gamma-camera  ADAC Laboratories Inc, Milpitas, CA  
Beckmann Microfuge® Lite Centrifuge  Beckmann Coulter, Fullerton, USA 
BioRad Gel Doc system  Bio-Rad Laboratories, Mississauga, ON, Canada 
Casy® 1 cellcounter (Model TT) Schärfe System, Reutlingen, Germany  
Cell incubator  WTC Labortechnik, Truttlingen, Germany 
Cell Quest ProTM Software Becton-Dickinson Bioscience, Heidelberg, Germany 
Centrifuge Allegra® 21 R Beckmann Coulter, Fullerton, USA 
DS1D Scientific Imaging software Eastman Kodak Company, Rochester, New York, USA 
FACSCalibur Becton-Dickinson, Heidelberg, Germany 
GeneAmp 2400 thermocycler  Perkin-Elmer, Mississauga, ON, Canada  
GraphPad Prism 3.0 San Diego, CA, USA 
Kodak DC120 camera  Eastman Kodak Company, Rochester, New York, USA 
Laminar-Air-flow workbench Heraeus, Hanau, Germany 
Nikon Eclipse E400 microscope  Nikon, Mississauga, ON, Canada  
Packard Cobra® II Series Auto-Gamma   Model 5003, Packard Instrument Company, Meridien, 
Counting Systems CT, USA 
Pegasys X, Version 4.2 software  ADAC Laboratories Inc, Milpitas, CA, USA 
Polarstar Galaxy Microplate reader BMG-LABTECH GmbH, Offenburg, Germany 
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Polytron homogenizer  Kinematica, Littau, Switzerland 
Purelab Plus water preparation facility  USF Reinstwassersysteme,  
 Ransbach-Baumbach, Germany 
Spectra MAXTM Gemini XS spectrofluorometer Molecular Devices, Sunnyvale, CA, USA 
Ultrasound bath Bandelin, Berlin, Germany 
UV/VIS-spectrometer UltroSpec 2100 pro Amersham Pharmacia Biotech, Uppsala, Sweden 
Vortexer Vortex, Würzburg, Germany 
Waterbath Büchi 461 Büchi, Switzerland 
Win MDI software  Verity Software House Inc., Topsham, ME, USA 
Zeiss Axiovert 200 CarlZeiss AG, Oberkochen,Germany 
Objective LD ACHROPLAN 100x, 63X 
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3.1.4 MDR inhibitors, chemicals and formulations 
The novel MDR inhibitors WK-X-34, WK-X-50 and WK-X-84 (Figure 3.1) were 
designed in Prof. Dr. M. Wiese’s laboratory at the Pharmaceutical Institute, 
University of Bonn, Germany and synthesized by W. Klinkhammer.  All compounds 
posses a tetrahydroisoquinolin-ethyl-phenyl amine partial structure but differ in the 
rest of the structure.  WK-X-34, (N-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-
2(1H)-yl)ethyl) phenylcarbanoyl)phenyl)-3,4-dimethoxybenzamide), contains a 
anthranilic acid linker.  WK-X-50 (N-(2-(3-(4-(2-(3,4-dihydroisoquinolin-2(1H)-
yl)ethyl)phenyl)ureido) phenyl) quinoline-3-carboxamide) is a diaminobenzene 
derivative.  WK-X-84 (N-(2-(2-(4-(2-(6,7-dimethoxy-3,4-dihydroisoquinolin-2(1H)-
yl)ethyl)phenylamino)-2-oxoethoxy)phenyl)-3,4-dimethoxybenzamide) is a  2-(2-
aminophenoxy)acetic acid derivative.  These compounds have been kindly made 
available for this thesis. 
XR9577 was synthesized according to the literature (Roe, 1999) by W. 
Klinkhammer.  Stock solutions (10 mM) of verapamil, XR9577 and the WK-X-
compounds were prepared in DMSO and cyclosporin A was prepared in methanol.  
Stock solutions were further diluted in PBS.   
99mTc-Sestamibi was freshly prepared by the Radiopharmacy Department at 
Toronto General Hospital (UHN, Toronto, Canada) using the reconstituting kits 
(Cardiolite®) and radiochemical purity was routinely determined by thin layer 
chromatography to be greater than 93 %.   
Human MDR1 antisense and random phosphorothioate oligodeoxynucleotides 
with aminohexyl modifications at the 5’-end were reconstituted in purified nuclease 
free water up to a concentration of 1 mg/ml and further diluted in PBS.   
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Figure 3.1   Chemical Structures of novel tetrahydroisoquinolin-ethyl-phenylamine-based MDR inhibitors 
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3.2 Cell culture 
 
3.2.1 Cell lines 
Several different wild-type, resistant or transfected tumor cell lines of human 
or dog origin were used in this thesis.  Human ovarian cancer cell line A2780/wt was 
originally obtained from a drug-sensitive patient with a tumor on one ovary.  The Pgp 
overexpressing and doxorubicin-resistant (= Adriamycin, Adr) variant A2780/Adr had 
been generated through step-wise selection from its sensitive parental cell line 
A2780/wt using doxorubicin (see description of cell line at ECACC).  Therefore, 
doxorubicin (10 µM) needed to be added to the media of A2780/Adr cells for one 
passage every 10 passages in order to prevent cells from losing their high Pgp 
expression levels.  Both cell lines were purchased from ECACC, UK.   
The BCRP-overexpressing MCF7/mx cell line was generated by mitoxantrone 
selection and kindly provided by Dr. E. Schneider, Wadsworth Center, Albany, NY, 
USA.  Human breast cancer cell line MCF7/wt was originally selected from the 
mammary epithelial tissue of a Caucasian woman with adenocarcinoma.   
HeLa cells transfected with human MRP1 were kindly provided by Dr. S. Cole, 
Queen’s University, Kingston, ON, Canada.  HeLa cells originate from a cervix 
carcinoma isolated from a patient named Henrietta Lachs.   
MRP2- and MRP3- transfected MDCK (Madin-Darby Canine Kidney) epithelial 
cells from dog origin were engineered by transfecting them with human MRP2 or 
MRP3 plasmid.  These cells were generated and kindly provided by Dr. P. Borst, the 
Netherlands Cancer Institute, Amsterdam, Netherlands. 
 
3.2.2 Growing and subculturing of cells 
All cell lines used in this thesis are adherent cells, which grow in monolayers.  
Thus, ordinary culture flasks were utilized.  Cells were cultivated in an incubator, 
which constantly maintained an atmosphere of 37°C and 5 % CO2.  Medium needed 
to be replaced when the indicator phenolred changed its color from red to yellow, 
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which occurred about every three days, depending on the density of plated cells and 
the growth rate of the particular cell line.  Cells needed to be subcultured, when the 
flask was entirely covered with cells (100 % confluency).  For subculturing cells were 
washed once with PBS to remove floating cells and the additives fetal bovine serum 
and antibiotics.  Two ml of trypsin were then added and cells were incubated at 37°C 
until they separated from each other.  Cells were washed off the culture dish and 
placed into a 15 ml tube.  Cells were now separated from trypsin-containing medium 
by centrifugation (1200 x g, 4 min and 4°C) and resuspended in 10 ml fresh growth 
medium. One to three ml of cell suspension depending on the cell line were placed 
into a new culture flask containing fresh growth medium. 
 
3.2.3 Counting cells 
20 µl of cell suspension were pipetted into 10 ml of sterile Casy®ton solution 
and analyzed with the Casy® 1 cell counter.  Based on the techniques of a “coulter-
counter”, this instrument measures the cell number together with the mean cell 
diameter and can thus provide information on the status and integrity of the analyzed 
cell population.   
 
3.2.4 Storing, freezing and defrosting cells 
To generate long-lasting backups, trypsinized cells from a confluent T75 flask 
were centrifuged and redissolved in 1 ml growth medium containing 10 % of DMSO.  
The cell suspension was pipetted into a cryovial.  The cryovials were kept in the        
-80°C freezer for one week and then transferred into a liquid nitrogen tank (-190°C) 
for storage.  Under these conditions, cells can be stored for some years.  To re-
culture frozen cells, vials were carefully warmed in a 37°C waterbath until cells were 
defrosted. Cells were then quickly transferred into T25 or T75 culture flasks filled 
with warm (37°C) fresh growth medium and placed into the incubator.  The next day, 
growth medium was replaced and floating cells were removed. 
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3.3 In vitro methods 
 
3.3.1 RT-PCR analysis 
For RT-PCR analysis, RNA needed to be isolated from all cell lines.  Total 
RNA was isolated from a confluent 10 cm2 Petri dish of cells using the TRIzol 
extraction kit. Growth medium was removed and one ml of TRIzol was added onto 
the cells.  After 5 min of incubation cells were scraped off the dish and lysed by 
pipeting up and down.  The cell lysates were placed into an eppendorf cap and 
0.2 ml of chloroform was added.  Caps were shaken and incubated at RT for 10 min.  
Tubes were then centrifuged at 12000 x g for 15 min and at 4˚C.  The upper 
aquaeous phase containing the RNA was transferred into a clean cap and 0.5 ml of 
isopropyl alcohol was added.  Samples were incubated for 10 min at RT and then 
centrifuged for 10 min at 12000 x g and 4˚C. At this step, RNA precipitated and 
formed a gel-like pellet.  The supernatant was removed and the pellet was washed 
with ethanol (75 %).  Ethanol was removed by centrifugation at 7500 x g and RNA 
pellet was air-dried before redissolving it in demineralised autoclaved water 
containing DEPC.  RNA samples were stored at -20˚C.   
RNA was quantified using UV-spectrophotometry at 260 nm.  1 µl of RNA-
solution was dissolved in 49 µl of DEPC water and RNA concentration in µg/µl was 
quantified in a UV/VIS-spectrometer UltroSpec 2100 pro at 260 nm.  The ratio of 
RNA/protein (260/280 nm) was furthermore determined and served as an indicator of 
the quality of the RNA isolation.  An RNA quality with a ratio of above 1.5 was 
accepted for RT-PCR.  Ratios between above 1.8 are commonly obtained for highly 
purified DNA; however the obtained value is strongly dependant on the pH of the 
solution buffer (Wilfinger, 1997). 
MDR1 expression was examined by RT-PCR analysis (Lee, 2001).  A 
quantitative RT-PCR assay was used based on previously reported methods 
(Hartmann, 2001; Sukhai, 2001).  mRNA levels of human MDR1 were determined 
and GapDH served as a housekeeping gene to normalize MDR1 expression.  Primer 
sequences and PCR conditions can be found in table 3.1.  Reverse transcription of 
0.5 µg of RNA was performed using the First Strand cDNA Synthesis kit in a total 
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volume of 20 µl.  One µl of reverse transcription product (see standard curve in 
chapter 4.1.1.1) was used for amplification of specific DNA sequences in the 
presence of 1 mM MgCl2, 200 µM dNTP, and 50 pmol of each primer in a total 
volume of 100 µl DEPC water using a GeneAmp 2400® thermocycler.  The reaction 
was initiated by addition of 2.5 units of Taq polymerase® and amplification 
proceeded through different cycle numbers, depending on relative expression levels 
of the genes.  The parameters are summarized in table. 3.1. 
PCR products were separated on 2 % agarose gels by electrophoresis 
(150 V, 500 mA, 45 min).  Gels were stained with PBS containing SYBR Gold 
nucleic acid stain (1:10000) and visualized by UV light.  DNA band sizes were 
confirmed using the Gene Ruler 100 bp DNA ladder.  Optical densities of bands 
obtained from agarose gels were quantified on gel pictures taken with a Kodak 
DC120 camera and DS1D Scientific Imaging software.  Linear conditions were 
established from standard curves.  For the generation of standard curves, dilutions 
containing 5, 2.5, 1.25, 0.625, 0.313, 0.156, 0.078 or 0.039 µl cDNA were prepared 
and ran using the conditions in table 3.1.  Optical densities of bands obtained from 
the PCR products were plotted against the amount of cDNA template and a cDNA 
amount within the linear range was chosen for RNA quantifications.  Levels of mRNA 
expression are reported as percentages of normalized values, as compared to 
control values. Optical densities were normalized to GapDH band intensities and 
calculated as ratios: (OD MDR1 mRNA) / (OD GapDH mRNA).  Standard PCR 
curves were generated for each PCR product to establish linearity of the RT-PCR 
reaction and determine optimal template concentrations. 
The expression of the MRP1, MRP2 and MRP3 transporters in selectively 
transfected cell lines was verified by RT-PCR analysis.  Likewise, BCRP expression 
in MCF7/mx and lack of BCRP expression in MCF7/wt, A2780/Adr and A2780/wt 
were examined.  Primer sequences and PCR conditions for all transporters are given 
in table 3.1. 
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Gene Primer Sequence Product # cycle PCR cycle 
name size 
 
MDR1 fwd: 5’-GTA CCC ATC ATT GCA ATA GC-3’          237 bp 28 95°C (45 sec) 
 rev: 5’-CAA ACT TCT GCT CCT GAG TC-3’                           Xen 29 55°C (120 sec) 
  72°C (60 sec) 
 
GapDH fwd: 5’-TCC CAC CAC CCT GTT GCT GTA-3’      450 bp 26 95°C (60 sec) 
 rev: 5’-TCC CAC CAC CCT GTT GCT GTA-3’ 54°C (120 sec) 
  72°C (90 sec) 
 
MRP1 fwd: 5’-AGG TGG ACC TGT TTC GTG AC-3’      183 bp 30 95°C (60 sec) 
 rev: 5’-ACC CTG TGA TCC ACC AGA AG-3’ 52°C (120 sec) 
  72°C (90 sec) 
 
MRP2 fwd: 5’-CTG CCT CTT CAG AAT CTT AG-3’       220 bp 28 95°C (60 sec) 
 rev: 5’-CCC AAG TTG CAG GCT GGC C-3’ 54°C (120 sec) 
  72°C (90 sec) 
 
MRP3 fwd: 5’-GCC ATC GAC CTG GAG ACT GA-3’       117 bp 30-33 94°C (30 sec) 
 rev: 5’-GAC CCT GGT GTA GTC CAT GAT AGT-3’ 55°C (30 sec) 
   72°C (60 sec) 
 
BCRP fwd: 5’-GGC CTC AGG AAG  ACT TAT GT-3’       342 bp 27 94°C (45 sec) 
 rev: 5’-AAG GAG GTG GTG TAG CTG AT-3’ 55°C (30 sec) 
  72°C (90 sec) 
 
18S fwd: 5’-GTC TGT GAT GCC CTT AGA TG-3’       185 bp Xen 20 94°C (45 sec) 
 rev: 5’-AGC TTA TGA CCC GCA CTT AC-3’ 55°C (30 sec) 
  72°C (45 sec) 
 
Table 3.1   Primer sequences and parameters for PCR analysis 
 
Fwd: forward primer, Rev: reverse primer.  The cycle numbers refer to cell material, unless otherwise indicated 
(Xen = tumor xenograft). 
The primer sequences were based on the following references: 
MDR1: Lingya, Chinese Med J 2001; 114:929-932 
MRP3: Ros, J of Pathol 2003; 200: 553-560 
BCRP: Krishnamurthy, J Bio Chem 2004; 279:24218-24225   
All other primer sequences were obtained using the GenBank cDNA sequences and PRIMER3 online software 
at: http://www-genome.wi.mit.edu/cgi-bin/primer/primer3_www.cgi 
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3.3.2 Protein expression analysis 
 P-glycoprotein surface expression in A2780/Adr and A2780/wt control cells 
before and after antisense treatments was analyzed using an FITC-conjugated 
mouse anti-human monoclonal Pgp antibody in an assay with flow cytometry 
detection.  The antibody is a 17F9 clone and binds to the surface of the viable, 
unfixed multidrug resistant cell.  The 17F9 epitope is located on the outside of the 
cell, therefore cells can be analyzed directly without preceding permeabilization. 
 Attached cells were washed three times with PBS.  Two ml of trypsin were 
added and cells were washed off with growth medium 10 min later.  Cells were then 
counted (see chapter 3.2.3) and aliquots of 106 cells were sampled into 15 ml flasks.  
Samples were washed with 1 ml of washing buffer I (for preparation of buffers and 
solutions see chapter 3.1.2).  Samples were then dissolved in 1 ml of staining buffer 
and 20 µl of the FITC-labeled anti-human monoclonal Pgp antibody were carefully 
added to each sample.  Tubes were quickly protected from light and incubated on ice 
for 40 min.  To terminate incubation period, cells were washed with 1 ml of ice-cold 
staining buffer.  Unbound antibody was removed from the cell suspension and cells 
were resuspended in washing buffer I.  The amount of antibody-bound FITC on the 
cell surface per cell was analyzed on the FACSCalibur using an excitation 
wavelength of 488 nm.  Emitted light signals were collected through a 530/15 nm 
band pass filter for FITC (FL1-H).  Acquisition was set to 10,000 events and 
fluorescence intensities were collected while gating on physical parameters (forward 
and side scatter) to exclude cell debris.  The number of events within the gate for 
intact cells remained consistently well above 75 % for all measurements. 
Autofluorescence of A2780/Adr and A2780/wt cells were tested to be identical.  
 BCRP expression in MCF7/mx and MCF7/wt control cells was analyzed using 
the primary anti-human BCRP antibody BXP-21 together with a secondary anti-
mouse Ig fluorescein-linked whole antibody (Minderman, 2002).  The BCRP-specific 
BXP-21 antibody, a mouse IgG antibody, reacts with an internal epitope of BCRP, 
therefore, cells needed to be fixed and permeabilized.  As previously described, 
attached cells were trypsinized, counted and aliquots of 106 cells in PBS sampled 
into 15 ml flasks.  Cells were then fixed in formaldehyde-solution (10 %) for 10 min at 
RT and subsequently incubated with an ice-cold methanol-solution (90 %) for 
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10 min.  After washing with washing-buffer II, cells were incubated with blocking-
buffer (10 %) for 1 h at RT.  After thoroughly washing the cells three times with 
washing-buffer II, 100 µl of a 1:100 dilution of the primary monoclonal antibody BXP-
21 (final concentration 2.5 µg/ml) in dilution-buffer were added onto the cells and 
tubes were placed on ice for 60 min.  To terminate incubation period, cells were 
washed with 1 ml of ice-cold washing buffer II so that unbound primary antibody was 
removed from the cell suspension.  100 µl of a 1:50 dilution of the fluorescein-linked 
anti-mouse IgG antibody in washing-buffer II were added onto the cells.  Tubes were 
protected from light and incubated for 20 min on ice.  The secondary antibody was 
removed by washing.  Cells were resuspended in washing buffer II and stored on ice 
until flow cytometry analysis. The amount of cell-bound fluorescein on the cell 
surface was detected as previously described for Pgp.  Autofluorescence of 
MCF7/mx and MCF7/wt cells were tested to be identical.   
 As A2780/Adr and A2780/wt cell lines do not express BCRP, non-specific 
binding to the BCRP binding antibody BXP-21 was used to evaluate unspecific 
binding.  Likewise, as MCF7/mx and MCF/wt cell lines do not express Pgp, non-
specific binding to the FITC-labeled anti-human Pgp antibody was used to measure 
unspecific binding. Minimal non-specific binding was detected for all four cell lines 
and no differences in fluorescence intensities were detected between the resistant 
and wild-type cell lines.  
 
3.3.3 Transfections with MDR1 antisense ODNs  
The expression of P-glycoprotein can be specifically inhibited by transient 
transfection using human MDR1 antisense oligodeoxynucleotides. Sequences of 
phosphorothioated oligodeoxynucleotides with aminohexyl modifications at the 5’-
end against the promoter region of the human MDR1 gene were as follows:  
Antisense:  Aminohexyl-5’-CCA TCC CGA CCT CGC GCT CC-3’ 
Random: Aminohexyl -5’-GCT CCC CCA CGC GCC TCC AT-3’  
(Sequence taken from Alahari et al. 1998 (sequence: ISIS 13758)).   
  Materials and Methods 
 
54 
Experiments were carried out with ODN concentrations of 50, 100 and 200 nM 
according to previously published methods (Jekerle, 2005).  For ODN treatments, 
A2780/Adr and A2780/wt cells were plated onto 6-well plates at a concentration of 
33,000 cells per well and allowed to attach and recover for 24 h.  Treatment mixtures 
of different concentrations (50 nM-200 nM) of AS and random ODNs were prepared 
in 100 µl of growth medium without the additives fetal calf serum and antibiotics.  
Growth medium without any additives was used for controls.  SuperFect® and DNA 
were then added according to manufacturer’s instructions in such a way that the ratio 
between SuperFect® was 12 µl per 1 µg of DNA.  Transfection mixtures were 
thoroughly vortexted and incubated at RT for 10 min to allow formation of 
transfection complex. The transfection mixture was added drop-wise onto the cells 
and plates were placed into the incubator.  After 6 h, the transfection medium was 
removed, cells were washed and fresh growth medium was added.  Cells were 
treated daily on three consecutive days so that the total transfection period was 72 h.  
After final ODN treatments, nonviable, floating cells were removed by several PBS 
washing steps.  Only viable, attached cells were used for further experiments 
including antibody staining.   
ODN stability, as routinely examined in 37°C tempered PBS containing bovine 
serum albumin (Takei, 2002), did not detect reduction in stability over a 24 h time 
period.  All samples remained stable under these conditions and no degradation 
products were detected.  As fresh ODN were replaced in the media every 24 h 
during the treatment periods, this implies that stable ODNs were present over the 
entire span of the transfection period. 
 
3.3.4 FITC-labeling of MDR1 antisense ODNs 
To evaluate the efficacy of ODN uptake into A2780/Adr and A2780/wt cells 
during transient transfection, antisense ODNs needed to be labeled with a 
fluorescent tracer.  Fluorescence-labeled ODNs permit to visualize the uptake and 
intracellular distribution of ODNs.  For FITC-labeling of AS ODNs, a 1 mg/ml 
fluorescein-isothiocyanate solution was prepared in 100 mM sodium bicarbonate 
buffer (pH 9).  50 µg of aminohexyl-modified antisense ODNs were incubated with 
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300 µl of fluorescein-isothiocyanate solution (total ratio aminohexyl-group to FITC 
ratio: 1:100) for 30 min at room temperature in the dark.  To separate FITC-labeled 
ODNs from unbound FITC, ODN material was purified by size-exclusion 
chromatography on a P-2 column.   
Bio P-2 gel consists of fine porous polyacrylamid beads with a grain size 
between 45 and 90 µm.  To prepare the P-2 column, a small piece of glass wool was 
placed into a Pasteur pipette to seal the bottom.  The Pasteur pipette was now filled 
with P-2 gel, soaked in sodium chloride solution (1 M) for 2 h and washed with 2 ml 
of saline.  
20 µl of ODN solution was loaded onto the P-2 column and saline was slowly 
added.  17 fractions of 100 µl volume each were collected.  The absorbance of the 
eluated fractions was detected at 495 nm (FITC-chromophore) and 260 nm (DNA) 
and fractions 10-13, containing the FITC-labeled antisense molecules were pooled 
and used for uptake experiments (see figure 3.2)   
 
 
 
 
 
 
 
 
 
Figure 3.2   P-2 separation of FITC-labeled ODNs from unbound FITC   
FITC-labeled ODN material was placed on a P-2 column and eluated in different fractions.  The absorbance of 
the collected fractions was detected at 495 nm (fluorescein-chromophore) and at 260 nm (DNA).  The fractions 
10 to 13 contain FITC-labeled ODNs as overlapping local maxima can be detected for both curves.  Free FITC is 
eluated after fraction 15.   
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3.3.5 MTT viability assay 
Cellular toxicities of all inhibitors and oligodeoxynucleotides were analyzed in 
A2780/Adr, A2780/wt and in MCF7/wt and MCF7/mx cells using the 
methylthiazolyldiphenyl-tetrazolium bromide (MTT) cell viability assay.  This assay 
measures the viability status of the cell after a specific treatment.  In viable cells, 
MTT is reduced by mitochondrial dehydrogenases to the blue formazan precipitate 
(Figure 3.3).  Formazan can be visualized as blue crystals with a light microscope.  
When solubilized, formazan can also be detected and quantified by absorption 
measurements at 595 nm.   
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Figure 3.3   Chemical reaction of the MTT assay 
 
 
Experiments were performed according to previously established methods 
from our laboratory (Mueller, 2004).  Cells were plated onto 96-well plates at a 
consistent density of 3 x 104 cells/well and in a volume of 90 µl.  At this initial plating 
density, cells remained in the exponential growth phase over the entire span of the 
incubation period (72 h).  10 µl of different concentrations (100 nM-10 mM) of the 
inhibitor prepared in PBS were added to a total volume of 100 µl and plates were 
incubated at 37˚C and 5 % CO2 for 72 h.  20 µl of a 5 mg/ml MTT solution (for 
preparation see chapter 3.1.2) were added to each well.  After an incubation period 
of about 1 h the formation of blue formazan needles became detectable under the 
light microscope.  Cells were then solubilized by adding 150 µl of an isopropanol-HCl 
mitochondrial 
dehydrogenases 
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solution and plates were placed into the Polarstar Galaxy Microplate reader.  The 
absorption of solubilized formazan in each well was detected at 595 nm.  Values 
were corrected for background absorbance at 690±6 nm.  Cell viability was 
calculated as a percentage of controls treated only with PBS.  EC50 values (effective 
concentration= concentration that produced a 50 % reduction of cell viability) were 
derived by nonlinear regression analysis, assuming a sigmoidal concentration-
response curve using Prism 3.0 software as described in statistical analysis (see 
chapter 3.3.11).  Three independent experiments were performed and the mean 
value ± S.D. was calculated.    
 
3.3.6 Pgp transport assays 
In transport assays the impact of MDR inhibitors on Pgp transport function 
was studied.  Two transport assays with different substrates of Pgp were used.   
Substrate efflux and substrate accumulation were both examined in the Pgp-
overexpressing A2780/Adr cell line in comparison to the drug sensitive A2780/wt cell 
line.  
 
3.3.6.1 99mTc-Sestamibi accumulation assay  
99mTc-Sestamibi (Figure 3.4) is a gamma imaging complex and a substrate of 
Pgp.  The molecule 99mTc-Sestamibi (99mTc-hexakis(2-methoxy-isobutylisonitrile) 
consists of technetium in the 1+ oxidation state bound to six alkyl isonitrile groups in 
an octahedral geometry (Jones, 1984).  In Pgp overexpressing cells, the cellular 
accumulation of 99mTc-Sestamibi is depending on the degree of Pgp inhibition and 
can be easily quantified by gamma counting.   
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Figure 3.4   Chemical structures of 99mTc-Sestamibi 
 
 
The 99mTc-Sestamibi accumulation assay was carried out according to 
previously described methods (Utsunomiya, 2000).  A2780/Adr and A2780/wt cells 
were plated into 24-well plates at a constant density of 200,000 cells/well and grown 
until confluency.  Cells were preincubated with different concentrations of the 
inhibitors.  After 60 min, 15 µl (= 8.25 kBq) of a 99mTc-Sestamibi solution in PBS 
(specific activity: 0.55 MBq/ml) were added to each well.  99mTc-Sestamibi uptake 
was terminated at different time points (0, 15, 30, 60 min) by washing the cells and 
subsequently trypsinizing them with 200 µl trypsin.  Media and cells were carefully 
and quantitatively collected and samples were distributed into three 300 µl PCR 
tubes.  Tubes were placed into the Packard Cobra® II gamma counter and counted 
along with a Cardiolite® standard of known activity.  The relative cellular 
accumulation (AccCell) of 99mTc-Sestamibi was determined for each well of confluent 
cells according to E1:  
 
 
medium
cells
Cell cpm
cpmAcc 100⋅=   E1 
1+ 
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Furthermore, EC50 values for each inhibitor were determined using 99mTc-
Sestamibi accumulation.  For determination of EC50 values, the transport assay was 
terminated at 1 h and levels of relative intracellular 99mTc-Sestamibi were measured.  
Relative amounts of intracellular 99mTc-Sestamibi were plotted against the logarithm 
of the inhibitor concentration and EC50 values were derived by nonlinear regression 
analysis, assuming a sigmoidal concentration-response curve as described in 
statistical analysis.  
Protein content from cell lysates was determined using the Bradford assay.  
2 µl of cell lysates were added to 1 ml of Bio-Rad-Protein Assay (1:5 in 
demineralised water), incubated for 10 min and absorbance at 595 nm was detected 
in the UV spectrophotometer.  Three aliquots of each sample were measured.  A 
BSA standard (1 mg/ml) was prepared in PBS and different amounts of BSA 
standard (0, 0.5, 1, 2, 4, 8 and 16 µl) were dissolved in 1 ml of Bio-Rad-Protein 
Assay, incubated for 10 min and absorbance measured.  Protein amounts did not 
differ significantly between wells as confluent wells were used for experiments.   
To confirm no involvement of BCRP in 99mTc-Sestamibi transport across 
cellular membranes as previously published (Chen, 2000), 99mTc-Sestamibi 
accumulation studies were performed in the BCRP expressing MCF7/mx cells.   
 
3.3.6.2 Daunorubicin efflux assay  
Efflux assays permit to measure the efflux component separately from all 
other transport processes.  The assay was performed according to previously 
described methods (Brooks, 2003).  A2780/Adr or A2780/wt cells were harvested, 
counted and 106 cells were placed into 15 ml flasks.  Cells were washed and 
incubated in 1 ml phenolred-free RPMI medium containing 3 µM of daunorubicin at 
37˚C in a shaking waterbath.  Brooks and coworkers choose an uptake period of 
30 min and an efflux period of 90 min.  Using these time intervals, a detection 
window, sensitive enough to detect significant differences between daunorubicin 
levels after efflux was confirmed for controls and treated cells (see figure 4.20).  
Thus, after a 30 min uptake the probe was washed twice with ice-cold PBS to 
remove free daunorubicin and incubated in fresh and daunorubicin-free medium in 
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the presence of 0.1, 1 and 10 µM of each inhibitor.  After 90 min, efflux was 
terminated by washing the samples and storing them protected from light on ice.  
The amount of intracellular daunorubicin per cell after 90 min of efflux was quantified.  
Daunorubicin levels were measured with the FACSCalibur using an excitation 
wavelength of 488 nm with detection in the FL-2 channel (585/22 band pass filter).  
Each data point represents an average of the gated, viable cell population of a total 
of 5000 cells.  Three aliquots were measured per sample and experiments were 
performed on three separate occasions.  Changes in the efflux of daunorubicin which 
reflects inhibition of Pgp are expressed as the relative amount of Pgp ihibition, 
calculated as the IPgp according to E2.  A derivation of E2 is described for 
mitoxantrone efflux in chapter 3.3.7.   
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IPgp = relative inhibition of Pgp 
Ct = Intracellular concentration of daunorubicin at time t (90 min) 
 
 
3.3.6.3 Daunorubicin accumulation assay  
In contrast to the efflux assay, the accumulation assay measures the retained 
amount of daunorubicin in the cell and is depending on uptake and efflux 
parameters.  The assay was performed as previously described and published 
(Jekerle, 2006a).  Likewise, aliquots of 106 A2780/Adr or A2780/wt cells were placed 
into 15 ml flasks, washed and preincubated in 1 ml phenolred-free RPMI medium 
containing different concentrations (10 nM-0.1 mM) of inhibitor.  After 15 min, 3 µM 
of daunorubicin were added to each sample and tubes were placed in a tempered 
(37˚C) shaking waterbath.  When steady state was reached at 180 min, samples 
were washed and analyzed on a FACSCalibur.  The amount of intracellular 
daunorubicin per cell was quantified using an excitation wavelength of 488 nm with 
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detection in the FL-2 channel (585/22 band pass filter) and EC50 values were 
determined using GraphPad Prism 3.0 software by nonlinear regression analysis. 
Data are expressed as the calculated mean value ± S.D. as indicated.  The analysis 
was repeated three times to confirm reproducibility of the obtained value.   
 
3.3.7 BCRP-mediated transport assay 
Inhibition of BCRP activity was examined using the BCRP substrate 
mitoxantrone in a flow cytometry-based efflux assay. The BCRP-overexpressing 
MCF7/mx cell line (Figure 3.5) was used according to previously published methods 
(Minderman, 2002).   
 
 
  
 
 
Figure 3.5   BCRP expression in MCF7/mx cells 
RT-PCR analyses were performed to confirm expression of BCRP in mitoxantrone selected MCF7/mx cells.  A 
representative PCR gel is depicted and bands for BCRP are visible.  The product size of 342 bp was verified 
using the 100 bp gene ruler (GR).   
 
 
GR MCF7/mx
342 bp 
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To evaluate specificity for BCRP, mitoxantrone accumulation was examined in 
the non-expressing wild-type MCF7/wt cell line.  Furthermore, the overexpression of 
BCRP mRNA and protein and the absence of Pgp were verified using RT-PCR (see 
chapter 3.3.1) and protein staining (see chapter 3.3.2).  MCF7/mx and MCF7/wt cells 
were harvested, counted and 106 cells were sampled into 15 ml flasks with 1 ml of 
media containing 3 µM of mitoxantrone.  Flasks were incubated in a tempered 
(37ºC), shaking waterbath for 30 min.  After mitoxantrone uptake was terminated, an 
aliquot per each tube was collected.  To remove unbound mitoxantrone, cells were 
washed with ice-cold PBS and media were replaced with mitoxantrone-free media in 
the presence and absence of various concentrations of the inhibitors (1-1000 µM).  
The well-established BCRP inhibitor novobiocin (Shiozawa, 2004; Yang, 2003) was 
used as a positive control.  Efflux was terminated after 90 min; cells were washed 
and redissolved in ice-cold PBS.  The amount of intracellular accumulated 
mitoxantrone after 90 min of efflux was quantified on a FACSCalibur using an 
excitation wavelength of 488 nm with detection in the FL-4 channel (633 nm).  A 
base fluorescence of fewer than 5 % of all values detected in the presence of 
mitoxantrone, was measured for all MDR inhibitors.  A total of 5000 events per 
sample were acquired and results were gated for the viable cell population in the 
forward and side scatter plot.  Three aliquots were studied per sample and 
experiments were performed on three separate occasions.  The relative 
concentration of mitoxantrone retained after 90 min of efflux was calculated using 
E6, which was derived from a basic transport function E3:   
 
tk
t ecc
⋅−⋅= 0                                        tkc
c
t
⋅=0ln
 E3 
 
ct = intracellular mitoxantrone concentration at time t (y= 90 min) 
c0 = intracellular mitoxantrone concentration at time t0 (y= 0 min) 
k = transport constant (velocity of transport) 
t = time of efflux  
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 Transport across the plasma membrane is influenced by two independent 
determinants: passive diffusion (kD) and active transport via BCRP (ka).  Hence, the 
transport constant k is actually the sum of passive diffusion and active transport via 
BCRP (E4).  Whereas passive diffusion is thought to be equal in control and treated 
cells, BCRP-mediated active transport (ka) is depending on the degree of BCRP 
inhibition.   
Da kkk +=  E4 
ka = “active” BCRP-mediated transport 
kD = passive transport via diffusion 
 
By insertion of E4 into E3 for control and modulator (Mod) treatment the 
following equation is obtained (E5).   
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  f ≤ 1  
The factor f indicates the degree of inhibition of mitoxantrone efflux which 
reflects BCRP-mediated active transport ka.  The smaller f the greater is the inhibition 
of BCRP activity.  As C0 values could not be measured with reasonable accuracy, C0 
was removed from the equation, assuming an unknown but constant starting 
concentration, and E6 was obtained.  Results were calculated according to E6 and 
the data is expressed as the delogarithmized value of IBCRP for the different MDR 
inhibitors. 
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3.3.8 MRP-mediated transport assay 
 5-CFDA (5-carboxyfluorescein diacetate) can be used to quantify effects on 
MRP-mediated transport.  After entering the cells by rapid passive diffusion, the 
nonfluorescent ester 5-CFDA is hydrolysed by intracellular carboxylesterases and 
forms the fluorescent moiety 5-CF, which is a specific substrate of the MRP 
transporters (Figure 3.6).   
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5-carboxyfluorescein diacetate (5-CFDA)                                               5-carboxyfluorescein (5-CF)     
non-fluorescent                                                                            fluorescent anion and MRP substrate 
 
Figure 3.6   Chemical reaction of the 5-CFDA assay 
 
 
 For the 5-CFDA assay selectively transfected HeLa-MRP1 cells and MDCK-
MRP2 and –MRP3 cells were used.  Wild-type MDCK cells served as a negative 
control and the WK-X-compounds, XR9577, verapamil and cyclosporine A were 
examined.  The assay was performed according to previously described methods 
(Lee  2001).  Confluent cells were preloaded with 4 µM of 5-CFDA for 30 min.  Cells 
were then washed and 5-CFDA containing medium was replaced with 5-CFDA-free 
media in the presence and absence of the inhibitors (10 or 200 µM).  As selectively 
transfected cell lines were used, the concentration necessary to obtain significant 
MRP inhibition for MRP1, MRP2 and MRP3 was relatively high.  To date, no highly 
effective and multi-functional MRP inhibitors could be identified.  Therefore, the well-
established but fairly unspecific MRP inhibitor indomethacin was used at commonly-
used concentration of 200 µM (Draper, 1997) in order to obtain sufficient inhibition to 
characterize all three MRP subtypes.  Therefore, the concentrations of the MDR 
inhibitors needed to be adjusted to 10 and 200 µM.   
hydrolysis 
carboxylesterases 
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 Efflux was terminated after 5 min; incubation medium was removed and cells 
were washed two times with ice-cold PBS.  Cells were then lysed with 1 ml of 1 % 
Triton solution.  Three aliquots of cell-lysates per well were sampled (200 µl) into 
individual wells of a black 96-well plate and plates were protected from light.  5-
carboxyfluorescein (5-CF) fluorescence per well was detected with the Spectra 
MAXTM Gemini XS spectrofluorometer at an excitation wavelength of 490 nm and an 
emission wavelength of 540 nm.  Values were normalized for background 
fluorescence and calculated as mean values ± S.D.   
 The selective expression of human MRP1, MRP2 and MRP3 in each 
genetically engineered cell line was verified by RT-PCR analysis.  Conditions are 
presented in table 3.1.  As presented in figure 3.7, the presence of the artificially 
introduced human genes MRP1, 2 or 3 were confirmed in the respective transfected 
cell lines  
 
 
                                                                                                A.  
183 bp 
HeLa-MRP1    GR 
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 B.  
Figure 3.7   MRP1, MRP2 and MRP3 expression in HeLa-MRP1, MDCK-MRP2 and -MRP3 cells.  
RT-PCR analyses were performed to confirm expression of MRP1 in HeLa-MRP1 cells (A) and MRP2 and MRP3 
in MDCK-MRP2 and MDCK-MRP3 cells, respectively (B).  Experiments were performed as specified in 3.3.1.  
Representative PCR gels show bands for MRP1 (183 bp), MRP2 (220 bp) and MRP3 (117 bp).  Product sizes 
were confirmed using the 100 bp gene ruler (GR).   
 
 
3.3.9 Chemosensitivity assay 
In contrast to transport assays, chemosensitivity assays are a measurement 
of the overall MDR phenotype towards the examined chemotherapeutic drug such as 
daunorubicin or mitoxantrone.   
Chemosensitivity assays were used to characterize the degree of resistance 
of the MDR cell lines towards the chemotherapeutic agents used to select the MDR 
phenotype.  Hence, Pgp-overexpressing A2780/Adr cells, initially selected using 
doxorubicin, were tested for sensitivity towards doxorubicin and BCRP-
overexpressing MCF7/mx cells, select in the presence of mitoxantrone, were tested 
for sensitivity towards mitoxantrone (Jekerle, 2006b).  The degree of resistance 
towards these selecting agents was quantified for the MDR cell line and the parental 
cell.  EC50 value, derived by nonlinear regression analysis (see chapter 3.3.11), 
permitted to calculate a resistance factor (RF) using equation E7: 
 
 
 
    MDCK-MRP3      GR    MDCK-MRP2 
240 bp 
117 bp 
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RF = Resistance factor 
 
Chemosensitivity assays were used as a functional assay to examine the 
ability to reverse MDR by different MDR inhibitors.  The A2780/Adr, A2780/wt and 
MCF7/mx with MCF7/wt cells were employed to investigate inhibition of the MDR 
phenotype by WK-X inhibitors.  Cells were harvested, counted and 3 x 104 cells/well 
were plated into 96-well plates.  Cells were preincubated in a total volume of 90 µl of 
media containing 10 µM of the inhibitor or PBS for one hour.  10 µl of different 
concentrations of daunorubicin or mitoxantrone (100 nM-10 mM) were added to the 
cells and plates were stored in the incubator.  After 72 h, the assay was continued 
according to the MTT assay as described in chapter 3.3.5.  From MTT results, EC50 
values were derived by plotting the absorption values against the logarithm of the 
daunorubicin or mitoxantrone concentration.  Nonlinear regression analyses were 
performed with sigmoidal concentration-response curve using GraphPad Prism 3.0 
Software.  EC50 concentrations for sensitivity towards daunorubicin were expressed 
in micromole (µM) and EC50 concentrations for sensitivity towards mitoxantrone were 
expressed in nanomole (nM).  A sensitizing factor (S.F.) was calculated by dividing 
the EC50 obtained in the presence of inhibitor by the EC50 in the absence of inhibitor 
(control) for each cell line.  The sensitizing factor (S.F.) describes the factor by which 
the chemosensitivity of the specific cell line towards daunorubicin/ mitoxantrone 
increases in the presence of 10 µM of inhibitor.  A ratio of sensitizing factors 
(S.F.Adr/wt; S.F.mx/wt) was calculated in order to normalize for Pgp- or BCRP-specific 
effects, respectively.  S.F.Adr/wt; S.F.mx/wt were calculated by dividing the S.F. of the 
Pgp- or BCRP-expressing cell line by the S.F. of the non-expressing wild type cell 
line.  All experiments were performed at least in triplicates on three independent 
occasions.  
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3.3.10 Cellular examinations with fluorescence microscopy 
Uptake of fluorescence-labeled ODNs on the one hand and daunorubicin in 
the presence or absence of inhibitor or antisense treatment on the other hand were 
examined by fluorescence microscopy.   
Glass supports were placed into 6-well plates, and A2780/wt and A2780/Adr 
cells were grown on these glass supports.  At 60 % confluency, cells were treated 
with 200 nM of FITC-labeled MDR1 antisense ODNs for three hours.  For nuclear 
morphology analysis, cells were additionally incubated with a 1 µg/ml DAPI (4'-6-
Diamidino-2-phenylindole) solution in PBS for 5 min.  DAPI forms a fluorescent 
complex with natural double-stranded DNA.  Therefore, DAPI is commonly used to 
visualize cell nuclei.  Cells were washed and examined in the FITC, DAPI and light 
channel under a 100x1.30 oil immersion objective using the Nikon Eclipse E400 
microscope.  Exposure time for fluorescent light pictures was set to 8 seconds.   
Functional inhibition of Pgp-mediated efflux of daunorubicin (3 µM) was 
visualized both, in the presence of 10 µM of WK-X-34 and in MDR1 antisense (200 
nM) treated cells, by fluorescence microscopy.  Cells analyzed under the microscope 
were treated as described in chapter 3.3.6.3 (“Daunorubicin accumulation assay”) 
and chapter 3.3.3 (“Transfection with MDR1 antisense ODNs”).  Antisense and WK-
X-34 treated cells were incubated with 3 µM of daunorubicin for 60 min.  Finally, cells 
were washed with ice-cold PBS to remove unbound daunorubicin and redissolved in 
PBS.  Samples were protected from light and stored on ice.  5 µl of the cell 
suspension were pipetted onto a microscopy glass support, covered with a glass 
cover plate and placed under a Zeiss Axiovert 200 fluorescence microscope.  Cells 
were examined at an excitation wavelength of 485 nm using an oil immersion 63x 
objective.   
 
3.3.11 Statistical analysis  
All in vitro cell accumulation and efflux studies were performed at least in 
triplicate on three separate occasions.  Data are reported as mean values ± S.D. and 
calculated with Microsoft Excel® software.  For cell experiments the unpaired two-
tailed Student’s t-test was used for statistical comparison between the treatment 
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group and the control group.  A p-level of α < 0.05 was considered statistically 
significant and is indicated by *; a p-level of α < 0.01 is indicated by **.    
EC50 values (=effective concentration for 50 % of the measured effect) were 
calculated for results obtained from the Pgp transport assays (99mTc-Sestamibi 
accumulation and daunorubicin accumulation) and for the BCRP-mediated 
mitoxantrone efflux assay.  Moreover, data obtained from MTT viability assays such 
as in vitro toxicity and chemosensitivity data was expressed as EC50 values.  EC50 is 
the concentration required to reduce the measured effect.  The measured effect can 
be either a transport function (e.g. Pgp efflux or accumulation) or a reduction in cell 
viability caused by a cytotoxic drug (e.g. MTT assay, chemosensitivity assay).  In 
MTT assays, EC50 is the concentration required to reduce the cell viability (e.g. cell 
proliferation) by 50 %.  EC50 values were generated according to the mathematical 
model of concentration-response relationships by nonlinear regression using 
GraphPad Prism 3.0 Software.  Classical concentration-response relationships apply 
to agonist-receptor binding phenomenons and can be extended for other biological 
binding events such as transporter binding.  Standard concentration-response 
curves are defined by four parameters: the baseline response (Bottom), the 
maximum response (Top), the slope (Hill slope) and the drug concentration that 
provokes 50 % of the maximum response (EC50).  For nonlinear regression analysis, 
these parameters are incorporated in the so called “Four parameter logistic 
equation”, which is derived from the Hill equation (E8): 
 
HillSlopeXEC
BottomTopBottomY ⋅−+
−+= loglog 50101    E8 
Bottom =baseline response 
Top =maximum response 
Hill Slope = slope at the turning point 
EC50 = drug concentration, that provokes 50 % of the maximum response 
 
As experiments were conducted on three separate occasions, three EC50 
values were obtained. The data is expressed as mean values ± S.D.  Concentration-
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response curves were normalized to top and bottom values for inhibition of Pgp- or 
BCRP-mediated transport activity and to top values only for MTT assays.   
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3.4 In vivo methods 
 
3.4.1 Experimental setup of 99mTc-Sestamibi imaging studies  
The effects of WK-X-34 and MDR1 antisense ODN treatments on the 
accumulation of the Pgp substrate 99mTc-Sestamibi in multidrug resistant and 
sensitive tumor xenograft models were evaluated in two separate sets of imaging 
experiments. 
 
3.4.1.1 WK-X-34 imaging  
In a series of studies, the impact of the novel 3rd generation Pgp inhibitor WK-
X-34 on the accumulation of 99mTc-Sestamibi was evaluated in resistant and 
sensitive tumors.  Furthermore, the potential inhibition of physiological Pgp in the 
organs liver, kidney, brain, intestine and heart was investigated.  The experimental 
design of this study is depicted in figure 3.8.  Human ovarian cancer xenografts were 
developed in such a way that mice were bearing a sensitive (A2780/wt) tumor on the 
left flank and a Pgp overexpressing resistant (A2780/Adr) tumor on the right flank.  
The same animal was injected with 99mTc-Sestamibi and imaged twice on two 
consecutive days.  On Day 1, mice were preinjected with vehicle (control) 1 h prior to 
the injection and imaging of 99mTc-Sestamibi.  On Day 2, mice were preinjected with 
20 mg/kg of WK-X-34 prior to the injection and imaging of 99mTc-Sestamibi.  This 
way, the changes in 99mTc-Sestamibi accumulation between control and WK-X-34 
treatments could be directly compared in the same tumors and tissues of the same 
animal.  Animals were imaged 15 min, 30 min, 1 h, 2 h and 4 h postinjection. After 
imaging experiments mice were sacrificed and tissues isolated for biodistribution 
analysis and examinations of MDR1 mRNA and Pgp expression.    
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Figure 3.8   Schematic presentation of experimental design for 99mTc-Sestamibi imaging of “WK-X-34 imaging 
studies” in the absence (Day 1) and presence (Day 2) of WK-X-34. 
 
 
3.4.1.2 WK-X-34 + antisense imaging  
The impact of Pgp downregulation caused by antisense treatments alone and 
in combination with WK-X-34 was examined by determining the tissue uptake of 
99mTc-Sestamibi into the resistant and sensitive tumor xenografts.  The experimental 
design of this study is depicted in figure 3.9.  Here, human ovarian cancer xenografts 
were developed in such a way that mice were bearing two resistant (A2780/Adr) 
tumor on each back flank.  One tumor of each animal was randomly selected for 
antisense treatment.  The selected tumor was treated with 200 µg of human MDR1 
antisense ODNs intratumorally on three consecutive days.  The animals were then 
randomly divided into two groups: a verum and a control group.  After antisense 
treatments, the control group received an i.p. injection of vehicle (control) 1 h prior to 
the injection and imaging of 99mTc-Sestamibi.  Animals in the WK-X-34 group were 
preinjected with 20 mg/kg of WK-X-34 prior to the injection and imaging of 99mTc-
Sestamibi.  Animals were imaged 15 min and 1 h postinjection.  After imaging 
A2780/wt A2780/Adr 
Day 1: Day 2:
A2780/wt 
99mTc-Sestamibi 99mTc-Sestamibi 
A2780/Adr 
WK-X-34 
20 mg/kg 
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experiments were terminated mice were sacrificed and tissues were isolated for 
biodistribution analysis and examinations of MDR1 mRNA and Pgp expression.    
 
Day 4: 
 
Figure 3.9   Schematic presentation of experimental design for 99mTc-Sestamibi imaging of “WK-X-34 + 
antisense imaging studies”.  In all animals, one of two A2780/Adr tumors on the back flanks was treated with 
MDR1 antisense (AS) ODNs for three days prior to imaging experiments.  Imaging was performed on Day 4 in 
the absence (Control) and presence (WK-X-34) of WK-X-34.  
 
 
3.4.2 Animals  
All animal studies were conducted in accordance with the guidelines of the 
Canadian Council on Animal Care.  Eight-week-old male CD1 mice (25-35 g) and 
five week old female BalbC nu/nu mice (20-25 g) were supplied by Charles River (St. 
Constant, QC, Canada).   
The coat-color white albino CD1 mice originate from a non-inbred stock in the 
laboratory of Dr. de Coulon, Centre Anticancereux Romand, Lausanne, Switzerland 
and were imported into the United States to the Rockefeller Institute in 1926.   
BalbC nu/nu immunodeficient mice have initially been developed at Charles 
River Japan.  The mice are hairless and have albino background.  The inbred 
A2780/Adr 
 
A2780/Adr
Control: 
99mTc-Sestamibi
MDR1 AS  
Day 1-3 
WK-X-34: 
99mTc-Sestamibi 
A2780/Adr
WK-X-34 
A2780/Adr 
MDR1 AS  
Day 1-3 
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animals lack a thymus and are T-cell deficient.  Five-week old male CD1 nu/nu mice 
(20-25 g) were obtained from the breeding colony, established by breeding pairs of 
homozygous male CD1 nu/nu mice and heterozygous female CD1 nu/wt (Charles 
River, St. Constant, QC) mice.  This breeding colony was initiated by Prof. Dr. M 
Piquette-Miller at the Department of Comparative Medicine at the Faculty of 
Medicine, University of Toronto.  The colony was developed and maintained by V. 
Vassileva from the Department of Pharmaceutical Sciences, University of Toronto. 
In vivo work using wild-type CD-1 mice was carried out in the animal facility at 
the Leslie Dan Faculty of Pharmacy, University of Toronto, Canada.  
Immunocomprimized BalbC nu/nu and CD1 nu/nu mice were maintained in a 
pathogen-free environment using sterile working techniques only.  These studies 
were carried out at the Department of Comparative Medicine at the Faculty of 
Medicine, University of Toronto and at the Animal Facility of the Toronto General 
Hospital, UHN, Toronto.   
 
3.4.3 Xenograft model  
For “WK-X-34 imaging studies” (see chapter 3.4.1.1) drug resistant and drug 
sensitive xenografts were established in the right and left flank regions of BalbC 
nu/nu mice by subcutaneous implantation of A2780/Adr and A2780/wt cells, 
respectively (see 1. in figure 3.10).  Cell injections were prepared with an amount of 
5 × 106 cells in an injection volume of 100 µl.  Cells were harvested, counted and 
washed two times using PBS.  The pellets were resuspended in 100 µl of RPMI 
medium without FCS and antibiotics. After cleaning the skin with alcohol, tumor cell 
suspensions were injected s.c. using a 1 ml insulin syringe.  Mice were injected 
randomly to avoid any errors resulting from inconsistencies during cell harvesting 
etc.  Animals were monitored daily and tumor weights estimated by calliper 
measurements (E9):   
 
Tumor weight = (length × width2) / 2  E9 
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For “WK-X-34 + antisense imaging studies” (see chapter 3.4.1.2), murine 
xenograft models were established in the right and left flank region of male CD1 
nu/nu mice (see 2. in figure 3.10).  5 × 106 A2780/Adr cells in an injection volume of 
100 µl were subcutaneously implanted into each back flank.  For tumor inoculations 
and development of tumors see Pictures 1, Appendix. 
 
1.   WK-X-34 imaging:              A2780/wt A2780/Adr     (BalbC nu/nu mice) 
 
2.   Antisense ODN  
      + WK-X-34 imaging:          A2780/Adr                                               A2780/Adr     (CD1 nu/nu mice)  
 
 
Figure 3.10   Experimental setup for A2780/Adr and A2780/wt xenografts 
 
 
3.4.4 Formulation and toxicity of WK-X-34 
For the in vivo application of WK-X-34, a formulation in Cremophor EL was 
chosen.  Cremophor EL is a white viscous liquid with an approximate molecular 
weight of 3000 Da.  It is produced by a reaction of castor oil with ethylene oxide at a 
molecular ratio of 1:35.  Castor oil, a yellowish fixed oil, can be obtained from the 
seeds of Ricinus Communis (Euphorbiacea).  The poly-hydroxylated castor oil has a 
highly variable composition of mainly oxyethylated triglycerides of ricinoleic acid (Van 
Zuylen, 2001) (Figure 3.11).  Cremophor EL is commonly used to solubilize highly 
  Materials and Methods 
 
76 
hydrophobic compounds such as paclitaxel for in vivo use and clinical applications.  
However, Cremophor EL is associated with some toxic effects and hepatotoxicity in 
animals (Le Garrec, 2004) and humans (e.g. hyperlipidemia, peripheral neuropathy) 
(Gelderblom, 2001; Jie, 2005). 
                                                                                                    
    CH2-O-(CH2-CH2-O)x-CO-(CH2)7-CH=CH-CH2-CHOH-(CH2)5-CH3 
    CH-O-(CH2-CH2-O)y-CO-(CH2)7-CH=CH-CH2-CHOH-(CH2)5-CH3 
    CH2-O-(CH2-CH2-O)z-CO-(CH2)7-CH=CH-CH2-CHOH-(CH2)5-CH3 
    (x + y + z ~ 35)                 
 
Figure 3.11   Chemical structure of the major component of Cremophor EL 
 
Therefore, WK-X-34 in a formulation with Cremophor EL had to be carefully 
examined for potential toxic effects in mice.  For toxicity evaluations, doses of 20 and 
50 mg/kg of WK-X-34 in a total injection volume of 100 µl were prepared.  A stock 
solution of 0.025 mg/µl in a 1:1 mixture of Cremophor EL ethanol was made.  Mice 
were weighted, marked and amounts of WK-X-34 stock solution for each animal 
receiving either 20 mg/kg or 50 mg/kg were calculated.  Amounts of WK-X-34 –
Cremophor EL ethanol (1:1) stock solutions for each mouse were further diluted in 
saline to a final treatment volume of 100 µl.  For example, a mouse in the 50 mg/kg 
treatment group with a body weight of 20.5 g received a dose of 41 µl WK-X-34 stock 
solution further diluted by 59 µl of saline.  Control animals received Cremophor EL 
ethanol (1:1) dilution in saline only.  In the 20 mg/kg WK-X-34 preparation as well as 
in the vehicle formulation, the amount of Cremophor EL ethanol (1:1) was increased 
so that animals in all treatment groups received the same amount Cremophor EL 
ethanol (1:1).   
In vivo toxicities of the WK-X-34 formulations in Cremophor EL ethanol (1:1) 
were studied in 8-week old male CD1 mice.  The animals were injected i.p. daily with 
a 100 µl containing a dose of 20 or 50 mg/kg of WK-X-34; control mice received the 
vehicle.  Mice were examined for general toxicities using common toxicity 
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measurements including behavioural observations and weight recordings (Delaney, 
2002).   
The widely applied alanin aminotransferase (ALT) assay was used to study 
potential hepatotoxicity of WK-X-34.  The ALT test is a blood test that measures 
levels of alanin aminotransferase, a liver enzyme that is produced in higher amounts 
when the liver is inflamed.  The reaction is initiated by the addition of α-ketoglutarat 
as a second reagent (ALT reagent). The concentration of NADH is measured by its 
absorbance at 340 nm, and the rate of absorbance decrease is proportional to the 
ALT activity.  High levels of ALT due to acute hepatitis, for example, are indicated by 
a rapid transformation of the ALT reagent.  Thus, a loss in absorption can be 
detected.   
Animals were monitored daily, behaviour was observed and body weights 
were recorded.  On day 14, mice were sacrificed by cervical dislocation and blood 
samples were obtained by heart puncture using a needle pretreated with heparin.  
Blood plasma was obtained by centrifuging the blood samples immediately at 
6000 G at 4˚C for 10 min.  The plasma in the supernatant was carefully removed and 
cooled on ice.  50 µl of blood plasma were incubated in 450 µl of 37˚C warm ALT 
reagent for 1 min.  Samples were quickly transferred into the UV-spectrophotometer 
and absorption was detected at 340 nm at 0 sec, 30 sec and 60 sec.  The absorption 
was plotted against the time and the loss of absorption over time.  A significantly 
stronger loss of absorption expressed as the negative slope in the treatment groups 
versus controls indicates hepatotoxicity of the treatment. 
 
3.4.5 Treatment of xenografts with WK-X-34 
On Day 2 of the “WK-X-34 imaging studies” (see chapter 3.4.1.1) and on Day 
4 of the “WK-X-34 + antisense imaging studies” (see chapter 3.4.1.2), animals were 
treated with a dose of 20 mg/kg WK-X-34 in the formulation with Cremophor EL-
ethanol 1 h prior to the injection of 99mTc-Sestamibi.  Control mice received the 
vehicle containing Cremophor EL-ethanol.  For preparation of the doses, the mice 
were weighted.  Doses of 20 mg/kg of WK-X-34 in a total injection volume of 100 µl 
were prepared.  Amounts of WK-X-34 in Cremophor EL ethanol (1:1) stock solutions 
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for each mouse were further diluted with saline up to the final injection volume of 
100 µl.  Mice had a fairly constant weight of around 15 g; therefore doses ranged 
around 0.3 mg WK-X-34 per animal.  A stock solution of 3 mg WK-X-34 was 
prepared in a total volume of 200 µl.  20 µl of stock solution were then further diluted 
in 80 µl of saline to obtain a total injection volume of 100 µl.  WK-X-34 formulations 
were freshly prepared before each animal experiment.    
 
3.4.6 Treatment of xenografts with antisense ODNs 
 For “WK-X-34 + antisense imaging studies” (see chapter 3.4.1.2), animals 
were treated with antisense ODNs on three consecutive days. On Day 4, imaging 
experiments were performed. 
When tumor xenografts reached a weight of approximately 0.5 g, one tumor 
per animal was randomly selected for antisense treatments.  Lyophilised antisense 
ODNs were dissolved in saline to a final concentration of 2 µg/µl.  On three 
consecutive days at the same time of the day, tumors were locally injected with 
100 µl (200 µg) of antisense ODN-solution, containing 200 µg of DNA or vehicle as 
previously described (Kuss, 2002). 
 
3.4.7 99mTc-Sestamibi imaging  
99mTc-Sestamibi imaging studies were performed according to previously 
reported methods (Muzzammil, 1999).  Mice were injected with 5 MBq of 99mTc-
Sestamibi into one of the lateral tail veins (see picture 2, Appendix). The animals 
were subsequently anaesthetized with an i.p. injection of a mixture of ketamine and 
xylazine.  When the animal needed additional anaesthetic in order to keep it in deep 
anaesthesia, a tube containing a tissue soaked with halothane was prepared and 
opened in front of the animal’s head for occasional inhalation.  For picture 
acquisition, the animal was placed on the imaging counter in such a way, that all legs 
were stretched away from the torso.  Dorsal views were obtained at 15 min, 30 min, 
1 h, 2 h, and 4 h post-injection (“WK-X-34 imaging studies”; see chapter 3.4.1.1) or 
15 min and 1 h post-injection (“WK-X-34 + antisense imaging studies”; see chapter 
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3.4.1.2) of the radiopharmaceutical using a small field-of-view gamma-camera ADAC 
TransCam equipped with a pinhole collimator (4 mm aperture).  Static images were 
acquired for 5 minutes at earlier imaging time points and up to 20 minutes for later 
time points.  At later time points, the radioactivity of 99mTechnetium was reduced, due 
to its relatively short half life of about 6 h.  Therefore, acquisition time needed to be 
extended at later imaging time points in order to obtain images with the same 
number of total counts. Images were acquired into a 256 × 256 matrix with a 32 keV 
(22.8 %) window set around the 140 keV photopeak of 99mTechnetium.  
As described in chapter 3.4.1.1, the design of the “WK-X-34 imaging studies” 
required injection of 99mTc-Sestamibi and imaging on two consecutive days.  
Although 99mTc-Sestamibi is rapidly eliminated from the system, whole body images 
were acquired prior to the second dose of 99mTc-Sestamibi to ensure minimal 
contribution of residual radioactivity.  99mTc-Sestamibi levels detected on Day 2 were 
less than 2 % of the original dose see picture 4, Appendix.  After completion of 
imaging experiments, mice were sacrificed by cervical dislocation and dissected.  
Tumors were used for biodistribution studies and kept for immunohistochemistry and 
RT-PCR analysis.  
 
3.4.8 Analysis of 99mTc-Sestamibi images  
All images were analyzed with Pegasys X, Version 4.2 software.  In “WK-X-
34 imaging studies” (see chapter 3.4.1.1) regions of interest were drawn around the 
whole body, brain, heart, liver, right kidney, intestine, and both tumors (Picture 5, 
Appendix).  In “WK-X-34 +antisense imaging studies” (see chapter 3.4.1.2) regions 
of interest were drawn around the whole body and both tumors.  Organ regions (e.g. 
heart) were identified by varying the radio intensity.  99mTc-Sestamibi organ uptake 
(UpTc) from each region was expressed as counts/pixel/acquisition time in seconds 
(cts/pix/sec) and then normalized to the region of the whole body and corrected for 
background radiation (Wang, 2005).  The total amount of administered 99mTc-
Sestamibi is represented in the whole body region.  Additional corrections were 
made for radioactive decay (At) at every imaging time point (tmin) using equation E10 
and E11: 
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( )tDc
t eAA
⋅⋅= 0  E10 
At = Activity at time t 
A0 = Activity at time 0 min 
e = base of natural logarithm 
t = elapsed time 
Dc = Decay constant 
 
 
( )
2
1
2ln
t
Dc =   E11 
ln 2 = natural logarithm of 2 (=0.693) 
t1/2 = half-life of the radioisotope 
 
 
This correction was necessary in order to plot the radioactivity form each 
individual organ against all timepoints.  The values for the AUC between all time 
points were calculated using equation E12:  
 
AUCt1-t2 = (cpm1 + cpm2) × (t2-t1) / 2   E12 
 
The AUC values for each organ in the presence and absence of WK-X-34 
were calculated and the mean values ± S.D. were compared.  Radioactive intensities 
obtained from these images correlated with results obtained from 99mTc-Sestamibi 
biodistribution studies. 
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3.4.9 99mTc-Sestamibi biodistribution  
Biodistribution studies were performed for both experimental designs 
described in chapters 3.4.1.1 and 3.4.1.2.  For biodistribution studies mice were 
sacrificed by cervical dislocation four hours (chapter 3.4.1.1) and two hours (chapter 
3.4.1.2) after 99mTc-Sestamibi injection.  Blood samples were obtained by heart 
puncture using a needle previously treated with heparin.  The different tissues of 
interest (e.g. tumors, brain, heart, liver, kidney and intestine) were carefully isolated 
and weighted (see picture 3, Appendix).  Tissues and blood were then gamma-
counted along with a Cardiolite® standard of known activity using the Packard 
Cobra® II Series Auto-Gamma Counting System.  Relative tissue accumulation of 
99mTc-Sestamibi was calculated as a % dose/gram of tissue.  The relative injected 
dose (Drel) was calculated by subtracting the remaining amount of radioactivity in the 
needle after injection (Drem) from the absolute dose (Dabs) according to E13:   
 
Drel = Dabs - Drem  E13 
 
Drel  = relative injected dose 
Dabs = absolute injected dose 
Drem = remaining amount of radioactivity in the needle after injection 
 
The detected counts per 1 kBq (Cts1kBq) of the Cardiolite® standard allowed the 
transformation of the corresponding counts (Ctscorr) of the relative injected dose (Drel) 
using E14:   
 
Ctscorr = Drel · Cts1kBq  E14 
 
Ctscorr = corresponding counts (e.g. 5.33 MBq = 55879187 cpm) 
Drel = relative injected dose 
Cts1kBq = counts per 1 kBq of Cardiolite® Standard 
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The % dose/gram of tissue (% Drel/gtis) was calculated from counts per minute 
detected per gram of tissue (cpm/gtis) in E15: 
 
 
corr
tis
tisrel Cts
gcpmgD 100//% ⋅=    E15 
 
% Drel/gtis  = % dose/ gram of tissue 
cpm/gtis = counts per minute detected per gram of tissue 
Ctscorr = corresponding counts 
 
99mTc-Sestamibi organ levels were strongly depending on the quality of the tail 
vein injection and the excretion parameters for 99mTc-Sestamibi.  Thus, 99mTc-
Sestamibi organ and tumor levels were normalized to an internal factor such as 
blood and muscle.  Results were calculated as tissue to blood and tissue to muscle 
ratios.  Results normalized to the non-Pgp expressing deep tissue muscle were more 
consistent than blood levels.  Blood levels change with time and are strongly 
influenced by the extent of 99mTc-Sestamibi excretion and metabolism. Therefore the 
tissue/muscle ratios were used for presentation and discussion of biodistribution 
data. 
 
3.4.10 Immunohistochemical and RT-PCR analyses of tumors    
Following gamma counting (< 1 h after tissue isolation), tumors obtained from 
both experimental designs described in chapters 3.4.1.1 and 3.4.1.2 were divided 
into two parts and snap-frozen in liquid nitrogen for RNA isolation or fixed in saline 
containing 5 % of formaldehyde for immunohistochemistry.   
For RNA isolation, about 50 mg of tumor tissue per sample were used.  
Tissues were homogenized for 60 min using the Polytron tissue homogenizer.  Total 
RNA was isolated from tumor tissue using the TRIzol extraction kit and cDNA 
synthesized according to table 3.1.  mRNA levels of human MDR1 were determined 
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by semi-quantitative RT-PCR and normalized to human 18S.  Primer sequences and 
PCR conditions were used as indicated in table 3.1.    
Tumor tissue sections were prepared using the routine stain of hematoxylin 
and eosion (H and E).  Hematoxylin, the oxidized product of the logwood tree, has 
an affinity to the nucleic acids of the cell nucleus.  Eosin is an acidic dye with an 
affinity for cytoplasmic components of the cell.  The fixed tumor tissue was paraffin 
embedded and 5 µm sections were cut and stained with hematoxylin and eosin as 
follows.  Paraffin slides were washed in water and placed in filtered hematoxylin for 
5 min.  After washing with water, slides were rinsed with 1 % of acid alcohol for a few 
seconds and washed.  Slides were then placed in a 1 % eosin solution in water for 
5 min.  Slides were finally washed in tap water and dried. 
Immunohistochemical staining was prepared by Kelvin So at the Department 
of Pathology, Toronto General Hospital, UHN.  Expression of Pgp was visualized on 
paraffin-embedded tissue slides applying the FITC-linked monoclonal Pgp antibody 
(1:500 dilutions) for 18 h at 21˚C.  Slides were examined under a 40x/0.65 oil 
immersion objective using a Nikon Eclipse E400 fluorescence microscope.  Pictures 
were acquired under fluorescent light from the FITC channel with an acquisition time 
of 8 seconds.  For negative controls, A2780/Adr slides were incubated in the 
absence of antibody.  To distinguish false-positive responses from non-specific 
binding of the FITC-labeled antibody, A2780/wt slides were incubated in the 
presence of FITC-labeled monoclonal Pgp antibody and examined.   
 
3.4.11 Statistical analysis  
A paired, two-tailed Student’s t-test was used to compare in vivo imaging of 
99mTc-Sestamibi within the same tumor of one animal.  A difference in mean values 
with a p-level of α < 0.05 was considered statistically significant (p-levels:  * α< 0.05; 
** α<0.01). 
99mTc-Sestamibi imaging and biodistribution experiments in xenografts treated 
with MDR1 antisense and vehicle were performed in groups of 4 animals for WK-X-
34 treatments and controls.  For these experiments an unpaired, two-tailed Student’s 
t-test was used to compare 99mTc-Sestamibi uptake between two tumors in two 
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different animals.  A difference in mean values with a p-level of α < 0.05 was 
considered statistically significant (p-levels:  * α< 0.05; ** α<0.01).   
For MDR1 mRNA quantification of tumors, 4 tumors from 4 animals per group 
were used.  Statistical analysis of mRNA expression was performed using an 
unpaired, two-tailed Student’s t-test.  Likewise, a difference in mean values with a p-
level of α < 0.05 was considered statistically significant (p-levels: * α< 0.05; ** 
α <0.01). 
  
 
4 Results – in vitro 
 
 
4.1 Characterization of cell models  
The Pgp-overexpressing human ovarian cancer cells, A2780/Adr, and the non 
Pgp-expressing wild-type cells, A2780/wt, were used for in vitro and in vivo 
investigations.  To study interactions with BCRP and the MRPs in transport and 
chemosensitivity assays, BCRP-overexpressing MCF7/mx and wild-type MCF7/wt 
cells and selectively transfected cell lines such as Hela-MRP1 were used.  To 
characterize these cell lines, different biomolecular techniques were applied.  These 
techniques include analyses of gene expression using RT-PCR and protein 
expression using antibody staining techniques with flow cytometry detection.  
Moreover, chemosensitivity assays were used to examine the degree of resistance 
towards cytotoxic drugs. 
 
4.1.1 RT-PCR analyses   
Pgp-overexpressing A2780/Adr cells were used as a model of human 
multidrug resistant cancer.  Results generated in A2780/Adr cells were compared to 
those obtained from the non Pgp-expressing wild-type cell line A2780/wt.  Therefore, 
MDR1 overexpression and lack of MDR1 expression was confirmed in A2780/Adr 
and A2780/wt, respectively.  For quantification of mRNA results (e.g. MDR1 
expression in tumor xenografts), a standard curve needed to be generated.  
 
4.1.1.1 Standard curve for the human MDR1 gene 
A standard curve enables one to determine the linear range at which the 
relative amount of PCR product, detected on the PCR gel directly, corresponds to 
the relative amount of template present in the probe.  Standard curves were 
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generated using the conditions described in chapter 3.3.1.  In figure 4.1, a 
representative standard curve is depicted.  The linear range for the PCR reaction at 
a cycle number of 28 was found to be at amounts of cDNA template of up to 1.25 µl.  
Thus, a template amount of 1 µl was chosen for further MDR1 mRNA quantifications.   
 
 A. 
 
 
 
 
 
 
 
 B.  
Figure 4.1   Standard curve for MDR1 mRNA expression  
Gel electrophoresis for different amounts of cDNA template (5.0-0.04 µl).  PCR products (size: 237 bp) were 
separated by gel electrophoresis (A).  Optical densities of PCR bands were determined (in arbitrary units (AU)) 
and plotted against the amount of cDNA template (B).  The linear range (red line) was found to be up to 1.25 µl of 
template at a cycle number of 28. 
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4.1.1.2 MDR1 mRNA expression in A2780/Adr and A2780/wt 
Expression of human MDR1 mRNA in A2780/Adr and A2780/wt cells was 
examined by RT-PCR analysis as specified in chapter 3.3.1.  As derived from 
standard curves (see above), 1 µl of template was used for the PCR reaction.  
Results confirm high expression levels of MDR1 mRNA in A2780/Adr cells but no 
detectable levels in wild-type A2780/wt cells (Figure 4.2)  
 
 A. 
  B. 
 
Figure 4.2   MDR1 mRNA expression in A2780/Adr and A2780/wt  
MDR1 mRNA expression in A2780/Adr (A1-3) and lack of MDR1 mRNA expression in A2780/wt (W1-3) cells is 
depicted on a representative RT-PCR gel (A).  The gene ruler (GR) confirms the PCR product size of 237 bp for 
the MDR1 gene.  Quality and amount of template were verified by the housekeeping gene GapDH (B).    
 
A1  A2   A3    W1  W2  W3  GR 
A2780/Adr      A2780/wt 
MDR1 gene 
GapDH gene 
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4.1.1.3 MRP and BCRP mRNA expression in A2780/Adr and /wt 
Expression levels of other ABC transporters including MRP1, MRP2, MRP3 and 
BCRP in A2780/Adr and A2780/wt were examined in order to evaluate potential 
interactions of Pgp substrates with these transporters.  Primer sequences and PCR 
conditions for these PCR reactions are presented in table 3.1.  A basal and 
increased expression of MRP1 was detectable in both, A2780/wt and A2780/Adr 
cells.  No mRNA expression of MRP2 was visible in both, A2780/Adr and A2780/wt 
cells, and only basal levels of MRP3 could be measured for both cell lines (Figure 
4.3).  Likewise, no BCRP mRNA expression could be detected in A2780/Adr and 
A27807wt cell lines (Figure 4.4).  Taken together, MRP1 was identified as the only 
transporter with expression levels high enough to interfere with Pgp functionality in 
A2780/Adr cells.  The relative amount of MRP1 mRNA was under 10 % of mRNA 
levels detected for Pgp.  MRP1 expression present in A2780/wt and A2780/Adr cells 
showed interactions or interferences in some of the functional assays which were 
based on Pgp and MRP1 substrates (e.g. daunorubicin).  In the daunorubicin 
chemosensitivity assay using A2780/wt cells (see chapter 4.3.5.1.), for example, 
MRP1 effects could be detected for verapamil.  
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Figure 4.3   MRP1, MRP2 and MRP3 mRNA expression in A2780/Adr and A2780/wt 
Expression of MRP1 and MRP3 mRNA and non-expression of MRP2 in A2780/Adr (A1-3) and A2780/wt (W1-3) 
cells is depicted on representative RT-PCR gels.  The gene ruler (GR) confirms the PCR product size of 183 bp 
(black arrow) for the MRP1 gene and 117 for the MRP3 gene.  Quality and amount of template, confirmed by 
GapDH expression, were similar in all probes.    
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4   Lack of BCRP mRNA expression in A2780/Adr and A2780/wt 
Lack of BCRP mRNA expression in A2780/Adr (A1-3) and in A2780/wt (W1-3) cells.  The gene ruler (GR) 
confirms the PCR product size of 342 bp (black arrow) for the BCRP gene. The quality and amount of template, 
confirmed by GapDH expression, were similar in all probes.    
A1   A2   A3    W1  W2  W3    GR
A2780/Adr A2780/wt
A1  A2  A3    W1 W2 W3  GR
A2780/Adr     A2780/wt
A1  A2  A3    W1 W2 W3  GR
A2780/Adr     A2780/wt
MRP1 MRP2
A1  A2  A3    W1 W2 W3  GR
A2780/Adr     A2780/wt
MRP3
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4.1.2 Protein analyses  
4.1.2.1 Pgp expression in A2780/Adr and A2780/wt 
 Pgp surface expression was analyzed directly using the FITC-labeled anti-
human Pgp antibody with detection on a FACSCalibur.  Corresponding to mRNA 
results, high expression levels of Pgp were seen in the multidrug resistant A2780/Adr 
cells but not in A2780/wt cells (Figure 4.5).  Thus, these cell lines served as a model 
of Pgp-overexpressing and non-expressing tumors and were utilized for 
examinations of Pgp functionality as well as for in vivo tumor xenograft models in 
immunocomprimised mice.   
 
Figure 4.5   P-glycoprotein overexpression in A2780/Adr 
Pgp expression in A2780/wt and A2780/Adr. Levels of surface Pgp were detected with a FITC-labeled anti-
human Pgp antibody using the FL-1 channel of the FACSCalibur. The fluorescence intensity of cellular bound 
FITC is plotted against the cell number (= events).  Geometric means were: A2780/Adr 402; A2780/wt 23. 
 
 
Pgp levels were strongly increased in those A2780/Adr cells which were 
routinely treated with doxorubicin every 10 passages as indicated in chapter 3.2.1.  
To demonstrate the magnitude in overexpression of Pgp in doxorubicin treated 
A2780/Adr cells, Pgp surface expression was examined in several different cell lines.  
As presented in figure 4.6, doxorubicin treated A2780/Adr cells (A2780/Adr*D) 
showed a considerably higher overexpression than untreated A2780/Adr cells.  Pgp 
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expression levels in other MDR cell lines including HepG2 and Caco-2 were 
marginal in comparison to A2780/Adr cells.   
 
 
Figure 4.6   Relative P-glycoprotein expression in several cell lines 
Pgp expression in several cell lines compared to non-Pgp expressing A2780/wt cells.  Doxorubicin treated 
A2780/Adr are indicated as A2780/Adr*D.  Results are expressed as relative Pgp surface expression, detected 
as geometric means of the FITC fluorescence and ** indicates a p-level of < 0.01 as determined using an 
unpaired, two-tailed t-test.  Some arrow bars were too small to be depicted in some samples. 
 
 
4.1.2.2 Lack of Pgp expression in MCF7/mx  
 Many substrates or inhibitors of Pgp also interact with BCRP.  Therefore, it is 
necessary to verify that the cell line used for BCRP-specific assays does not express 
considerable levels of Pgp.  A lack of Pgp expression was confirmed for MCF7/mx 
cells, which were used for BCRP functional assays (Mitoxantrone transport and 
chemosensitivity assays; see chapters 4.3.3 and 4.3.5.2).  The experiments were 
performed as described in chapter 3.3.2.   
 Indeed, MCF7/mx cells did not display any detectable levels of Pgp.  In 
A2780/Adr cells, high levels of surface Pgp were measured in contrast to MCF7/mx 
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and A2780/wt, which both did not express detectable levels of Pgp.  The histogram 
obtained from MCF7/mx cells overlapped with the histogram obtained from the non 
Pgp-expressing A2780/wt cells, however, showed no overlap with the histogram 
obtained from A2780/Adr cells (Figure 4.7).   
 
 
 
 
 
                                                                   
 
 
 
 A.  B.  
 
Figure 4.7   Lack of P-glycoprotein surface expression in MCF7/mx 
Pgp surface expression in MCF7/mx in comparison to A2780/wt (A) and A2780/Adr (B).  Levels of surface Pgp 
are visualized using a FITC-labeled anti-human Pgp antibody with detection in the FL-1 channel of the 
FACSCalibur. The fluorescence intensity of FITC bound to the cell (in arbitrary units) is plotted against the cell 
number (= events).  Geometric means are: A2780/Adr 406; A2780/wt 24; MCF7/mx 27. 
 
 
4.1.2.3 BCRP overexpression in MCF7/mx  
 Overexpression of BCRP was confirmed in MCF7/mx cells, before using them 
for BCRP functional assays.  The detection was based on protein staining 
techniques using a primary anti-human BCRP monoclonal BXP-21 antibody together 
with a secondary fluorescein-conjugated antibody.  The amount of cellular-bound 
fluorescein was quantified using flow cytometry techniques as outlined in chapter 
3.3.2.  In comparison to wild-type MCF7/wt and A2780/Adr cells, BCRP was 
overexpressed in MCF7/mx cells (Figure 4.8).  These results agree with results 
obtained from BCRP mRNA expression analysis (see chapter 4.1.1.3).   
 
MCF7/mx
A2780/Adr
MCF7/mx
A2780/wt
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 A.  B.  
 
Figure 4.8   BCRP overexpression in MCF7/mx 
BCRP expression in MCF7/mx (A) and A2780/Adr (B) in comparison to wild-type MCF7/wt cells.  Protein levels 
were detected in the FL-1 channel of the FACSCalibur using the monoclonal BCRP antibody BXP-21 and a 
fluorescein-conjugated secondary antibody.  The fluorescence intensity of cellular-bound fluorescein is plotted 
against the cell number (= events).  Geometric means were: MCF7/mx 117; MCF7/wt 23; A2780/Adr 33. 
 
 
4.1.3 Chemosensitivity in MDR cell lines 
Chemosensitivity towards the chemotherapeutic agent, which was used to 
select the multidrug resistant cell line from its sensitive parental cell line, is a 
characteristic commonly used to determine the degree of resistance.  
Chemosensitivity was determined in multidrug resistant and sensitive cell lines.  An 
MTT-based chemosensitivity assay was applied as described in chapter 3.3.9.  The 
degree of chemosensitivity is expressed as an EC50 value. 
 
4.1.3.1 Chemosensitivity towards doxorubicin in A2780/Adr 
Chemosensitivity towards the anthracycline doxorubicin was measured in the 
A2780/Adr and to sensitive A2780/wt.  In figure 4.9, dose-effect curves are shown 
from which EC50 values were derived as described in chapter 3.3.11.   
 
 
A. 
MCF7/mx
MCF7/wt
A2780/Adr
MCF7/wt
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 A.  
 
 
 
 
 
 
 
 
    B. 
 
 
Figure 4.9   Chemosensitivity towards doxorubicin 
EC50 values of doxorubicin (DOXO) were determined for A2780/Adr (A) and A2780/wt (B) cells using the MTT 
assay.  EC50 values, as derived from nonlinear regression analysis, were 5.4 µM (log EC50: -5.27 ± 0.1; Hill slope:      
-1.16) for A2780/Adr and 713 nM (log EC50: -6.15 ± 0.04; Hill slope: -1.37) for A2780/wt cells.  Some error bars 
are smaller than data symbols. 
 
 
EC50 values of 5.4 µM and 713 nM were calculated for doxorubicin in 
A2780/Adr and A2780/wt cells, respectively.  A degree of resistance of A2780/Adr 
towards A2780/wt of 7.5 was obtained.   
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4.1.3.2 Chemosensitivity towards mitoxantrone in MCF7/mx 
The BCRP-overexpressing MCF7/mx cells were initially generated by 
selection using mitoxantrone.  Therefore, the degree of chemosensitivity towards 
mitoxantrone was determined for MCF7/mx and the parental MCF7/wt cells (see 
chapter 3.3.9).  According to figure 4.10, EC50 values of 26 µM and 317 nM were 
obtained for MCF7/mx and MCF7/wt cells, respectively.  The calculated degree of 
resistance of MCF7/mx towards MCF7/wt was 82.   
 
 
 
 
 
 
 
 
 
  A. 
 
 
 
 
 
 
 
 
      B. 
Figure 4.10   Chemosensitivity towards mitoxantrone 
EC50 values of mitoxantrone were determined for MCF7/mx (A) and MCF7/wt (B) cells using the MTT assay.  
EC50 values, as derived from nonlinear regression analysis, were 26 µM (log EC50: -4.6 ± 0.2; Hill slope: -0.62) for 
MCF7/mx and 317 nM (log EC50: -6.5 ± 0.1; Hill slope: -1.03) for MCF7/wt cells.  Some error bars are smaller 
than data symbols. 
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4.2 Characterization of MDR1 antisense ODNs 
Antisense oligodeoxynucleotides (ODNs) are a commonly used tool to 
transcriptionally downregulate the expression of the target gene MDR1 and thus 
prevent the translation into the gene product Pgp.  The antisense sequence used in 
this study (see chapter 3.3.3) has been previously shown to downregulate the 
expression of MDR1 mRNA in cell culture (Alahari, 1998) and xenograft models 
(Brigui, 2003).  In order to apply these sequences to the human ovarian cancer 
model used in the present work, the antisense sequences and transfection 
conditions needed to be evaluated in vitro in A2780/Adr cells.  Their effectiveness in 
downregulating Pgp expression and functionality was investigated using Pgp surface 
expression analysis and functional transport assays.  Cellular uptake and distribution 
were examined with FITC-labeled antisense ODNs.  Finally, potential toxic effects 
were evaluated using cell proliferation assays. 
 
4.2.1 Downregulation of Pgp expression 
Downregulation of Pgp expression after antisense treatments (see chapter 
3.3.3) was examined by surface protein staining according to chapter 3.3.2.   
A significant downregulation of Pgp expression upon treatments with MDR1 
antisense ODNs for 72 h was detected in A2780/Adr cells (Figure 4.11).  As the half 
life of Pgp is 14 h, this corresponds to treatment periods of three to five Pgp half lives 
(Aleman, 2003).  The downregulation was dose-dependent with reductions to about 
82 %, 67 % and 55 % of control levels in the presence of 50 nM, 100 nM and 200 nM 
of MDR1 antisense ODNs, respectively.  Furthermore, even low antisense 
concentrations of 50 nM resulted in a significant downregulation of Pgp by about 
20 %.  Antisense effects appeared to be specific as treatments with random controls 
did not induce any alterations of Pgp expression.   
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Figure 4.11   Pgp downregulation by MDR1 antisense ODNs  
A2780/Adr cells have been treated with different concentrations of ODNs.  Pgp surface expression in antisense 
and random treated cells was detected using the FITC-labeled anti-human Pgp monoclonal antibody.  Results 
are normalized to untreated controls.  * and ** indicate p-level of α< 0.05 and α< 0.01, respectively, as 
determined by an unpaired, two-tailed t-test. 
 
 
4.2.2 Downregulation of Pgp functionality 
Decreases in Pgp expression by antisense treatments resulted in a reduced 
Pgp functionality.  This could be identified in A2780/Adr cells via a reduced efflux of 
the substrate or increased sensitivity towards the cytotoxic drug.  An increased 
accumulation of daunorubicin due to impaired efflux was detected in MDR1 
antisense pretreated A2780/Adr cells as compared to control A2780/Adr.  In figure 
4.12-A, the increased intracellular fluorescence of accumulated daunorubicin could 
be nicely visualized by fluorescence microscopy.  Likewise, increased daunorubicin 
levels in MDR1 antisense treated A2780/Adr cells were detected using flow 
cytometry-based transport assays (Figure 4.12-B).    
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A. 
 
 
 
 
 
 
 
 
 B. 
 
Figure 4.12   Increased daunorubicin accumulation in antisense treated A2780/Adr 
Daunorubicin uptake in MDR1 antisense pretreated A2780/Adr (solid grey), control A2780/Adr (black) and 
A2780/wt (blue) is visualized by fluorescence microscopy  (on a 63x objective) (A) and flow cytometry (B)  In the 
FACS histogram (B), the fluorescence of daunorubicin in arbitrary units (AU) was detected in the FL-2 channel 
and is plotted against the cell number (= events).  Cells were incubated with 3 µM of daunorubicin for 60 min.  
Geometric means as determined by flow cytometry in the FL-2 channel were: A2780/Adr control 26; A2780/wt 
control 57; A2780/Adr + MDR1 AS ODN 68.  
 
 
Decreases in Pgp expression and functionality by antisense treatments 
resulted in a diminution of the Pgp-mediated MDR phenotype.  This was detectable 
as a stronger cellular sensitivity of A2780/Adr cells towards the cytotoxic drug 
daunorubicin in chemosensitivity assays (see chapter 3.3.9).  The sensitivity towards 
daunorubicin in A2780/Adr cells was significantly and dose-dependently increased 
upon antisense treatments.  In table 4.1, EC50 values for different antisense 
concentrations are summarized.  The daunorubicin concentration tolerated by 50 % 
of the cell population decreased with treatments of MDR1 antisense ODNs in a 
dose-dependent manner. 
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Table 4.1   Daunorubicin chemosensitivity after MDR1 antisense ODN treatments in A2780/Adr 
 
                                                                         EC50  ± S.D. / µM 
 
Treatments (dose)           0 nM        50 nM  100 nM  200 nM                      
                                      
MDR1 AS ODNs           19,0 ± 0,8*    9,7 ± 0,9*     7,7 ± 0,9*               
Controls                          37,9 ± 0,8                                    
 
 
Table 4.1   A2780/Adr pretreated with 50 nM, 100 nM or 200 nM of MDR1 antisense ODNs or PBS (controls) 
were incubated with different concentrations of daunorubicin for 72 h. Cell viability after ODN treatments was 
analyzed with the MTT-assay.  EC50 values were calculated and results represent the mean of six samples in two 
separate experiments. * indicates a p-level of α< 0.05 versus control treatment 
 
 
4.2.3 Cellular uptake of FITC-labeled MDR1 antisense ODNs 
Cellular uptake and distribution of FITC-labeled MDR1 antisense ODNs were 
further examined by fluorescence microscopy.  ODNs enter the cells via endocytosis 
and accumulate in vesicles in the cytoplasm (Jensen, 2002).  In figure 4.13, the 
cellular uptake and retention of FITC-labeled antisense was greater in A2780/Adr 
(A), as compared to the non-Pgp expressing A2780/wt cells (B).  Furthermore, 
accumulation of fluorescein in vesicles was detectable on both pictures.  
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Figure 4.13   Fluorescence microscopy of intracellular ODN delivery 
FITC-fluorescence microscopy analysis was compared in A2780/Adr (A) and A2780/wt (B) cells.  Cells were 
transfected with MDR1 antisense ODNs for 3 h.  
 
According to Jensen and coworkers (Jensen, 2003), two hours following 
uptake and accumulation in cytosolic vesicles, oligonucleotides begin to leave the 
vesicles and escape into the cytosole, from which they enter the nucleus. To 
examine whether FITC-labeled MDR1 antisense ODNs, used in this work, 
penetrated into the nucleus, phase-contrast, DAPI and FITC microscopic pictures of 
A2780/Adr cells after uptake of FITC-labeled antisense ODNs were acquired.  As 
DAPI selectively stains the cell nucleus, overlapping DAPI (see chapter 3.3.10) and 
FITC-marked regions indicate nuclear localization.  According to fluorescence 
microscopy analysis (Figure 4.14), antisense ODNs were distributed within cells and 
also accumulated in the nucleus.   
 
 
 
Figure 4.14   Fluorescence microscopy of nuclear ODN delivery 
For nuclear localization analysis, phases contrast (A, grey), DAPI nuclear stain (B, blue) and FITC-fluorescence 
(C, green) microscopy images were acquired for antisense uptake in A2780/Adr cells.  Overlapping stains in B 
and C (white arrows) indicate nuclear localization of FITC-labeled ODNs. 
A. B. 
A. B. C.
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4.2.4 Toxicity of MDR1 antisense transfections 
Cellular toxicity has been associated with the exposure to phosphorothioated 
ODNs (Kurreck, 2003) and remains a major challenge in antisense applications.  
Furthermore, the transfection agent Superfect itself possibly has some toxic effects 
on cells (Axel, 2000).  Therefore, the potential toxicity of the MDR1 antisense ODN 
Superfect preparation compared to untreated controls was examined.  The number 
of cells proliferated over 72 h was measured using the Casy 1® cell counter (see 
chapter 3.2.3).  The cell number was dose-dependently decreased up to about 23 % 
for the treatment with 200 nM of ODNs (Figure 4.15), as a result of reduced cell 
proliferation over the span of the transfection. 
 
 
 
 
 
 
 
 
Figure 4.15   Reduced cell number after 72 h of antisense treatments 
Effects of different concentrations of MDR1 antisense ODNs on the number of proliferated A2780/Adr cells after 
72 h of transfection.  To evaluate toxicity of ODN preparations with SuperFect, untreated A2780/Adr cells were 
used as controls.  Cell numbers were quantified using the Casy1® cell counter and are expressed as the means ± 
S.D. of three data points and normalized to untreated controls.  Similar results were obtained in three individual 
experiments.   
 
Significant reductions in cell number occurred during the course of antisense 
treatments due to reduced proliferation rates.  For protein staining experiments, only 
viable cells were harvested; dead cells were washed off.  All aliquots contained the 
same cell number for protein staining.  Thus, differences in cell number after 
transfection regiments did not impact the quality of the protein measurements.  
During FACS measurements, the number of events within the gate for intact cells 
remained consistently well above 75 % for all treatment groups. 
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4.3 Characterization of novel MDR inhibitors 
MDR mechanisms can be functionally modulated by specific MDR inhibitors 
which inhibit the activity of ABC transporters involved in MDR.  Whereas the 
overexpression of Pgp is the best characterized and most prevalent MDR 
mechanism, others such as MRP- or BCRP-mediated MDR mechanisms are often 
coexpressed in tumor cells.  Therefore, Pgp, MRP and BCRP-functional assays were 
included in the in vitro characterization of the novel MDR inhibitors.  First of all, 
general toxicities of the novel compounds were examined in comparison to 
cyclosporin A and verapamil.  
 
4.3.1 Toxicity of MDR inhibitors 
The cellular toxicity of all inhibitors was analyzed in A2780/Adr, A2780/wt, 
MCF7/wt and MCF7/mx cells using the MTT viability assay.  Cells were incubated 
with increasing concentrations of the inhibitors and EC50 values were derived.  EC50 
values were well above 10 µM for all compounds with the exception of cyclosporin A 
(Table 4.2).  Here, the EC50 values obtained for A2780/wt, MCF7/wt and MCF7/mx 
were between 1 µM and 10 µM.  Thus, concentrations of 10 µM, which were used for 
transport and chemosensitivity assays, did not severely impact the cell viability.  
Solely cyclosporin A imposed additional toxic effects at concentrations used in the 
transport assays. 
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Table 4.2   Effects of MDR inhibitors on cell viability in different cell lines 
 
 A2780/wt  A2780/Adr  MCF7/wt  MCF7/mx 
EC50 MTT ± S.D.(µM)  
 
XR9577 48.6 ± 12 77 ± 12  25 ± 0.3 444 ± 84  
     
WK-X-34 124 ± 28 221 ± 37 24 ± 3 50 ± 6  
   
WK-X-50 36 ± 19  256 ± 153 26 ± 4 76 ± 6  
   
WK-X-84 53 ± 18 50.6 ± 19 77 ± 23 43 ± 15  
     
Cyclosporin A 7 ± 0.6 27 ± 7 4 ± 0.3 2 ± 0.8  
   
Verapamil 294 ± 192  182 ± 6 28 ± 3 42 ± 3 
 
Table 4.2. Toxicity of WK-X-compounds, XR9577, cyclosporin A and verapamil was evaluated in different cell 
lines using the MTT viability assay and expressed as an EC50 value.  Experiments were performed in triplicates 
on three separate occasions and results are expressed as means ± S.D. 
 
 
4.3.2 Pgp-mediated transport assays  
To examine potential inhibition of Pgp-mediated transport, three different Pgp 
transport assays were chosen (see chapter 2.3.4), the 99mTc-Sestamibi 
accumulation, the daunorubicin accumulation and the daunorubicin efflux assay.   
 
4.3.2.1 99mTc-Sestamibi accumulation assay 
Cellular accumulation studies of 99mTc-Sestamibi were performed using 
A2780/Adr and A2780/wt cells (see chapter 3.3.6.1).  RT-PCR analysis confirmed 
high Pgp-overexpression in A2780/Adr cells and lack of Pgp-expression in A2780/wt 
cells (see chapters 4.1.1.2 and 4.1.2.1).  Considerably lower levels of MRP1 and a 
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lack of BCRP were detected in both A2780/Adr and A2780/wt cells (see chapter 
4.1.1.3).  The gamma emitter and Pgp substrate 99mTc-Sestamibi served as a direct 
tracer of Pgp transport activity.  As 99mTc-Sestamibi is actively effluxed by Pgp, 
intracellular accumulation levels of 99mTc-Sestamibi were inversely proportional to 
the Pgp transport capacity.   
In figure 4.16, the uptake kinetics of 99mTc-Sestamibi into untreated A2780/Adr 
and A2780/wt cells are shown.  Furthermore, effects of WK-X-34 in comparison to 
cyclosporin A and verapamil are depicted.  A2780/Adr cells have been pretreated 
with 10 µM of either WK-X-34, cyclosporin A or verapamil and were compared to 
vehicle treated A2780/Adr or wild-type A2780/wt.   
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Figure 4.16   Impact of WK-X-34, cyclosporin A and verapamil on 99mTc-Sestamibi uptake   
Effects of WK-X-34, verapamil and cyclosporin A on the uptake kinetics of 99mTc-Sestamibi in A2780/Adr in 
comparison to A2780/wt cells.  Cells have been preincubated with 10 µM of inhibitor or vehicle for 1 h.  Results 
represent means of three samples ± S.D. Similar results were obtained in three independent experiments. 
 
 
10 µM of WK-X-34 completely inhibited Pgp functionality and increased 
intracellular retention of 99mTc-Sestamibi to levels in A2780/wt cells for all examined 
time points (15 min – 60 min).  Smaller effects were seen for cyclosporin A and no 
inhibition could be detected for verapamil.  The effects of all other inhibitors at a 
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tested concentration of 10 µM and after 60 min of uptake are presented in figure 
4.17.  XR9577 and WK-X-34 completely reversed the Pgp-mediated 99mTc-Sestamibi 
efflux and led to accumulation levels seen in A2780/wt cells.  All other inhibitors did 
not show any significant effects on Pgp inhibition with the exception of cyclosporin A. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17   Impact on 99mTc-Sestamibi accumulation – overview  
Effects of WK-X-compounds, XR9577, verapamil and cyclosporin A (10 µM, 60 min uptake) on 99mTc-Sestamibi 
accumulation in A2780/Adr.  Results are expressed in relative 99mTc-Sestamibi accumulation (in % of medium) 
and compared to levels obtained in A2780/wt and represent means of three samples± S.D. Similar results were 
obtained in three independent experiments. 
 
 
Based on the results in figure 4.17, dose-response analyses of 99mTc-
Sestamibi accumulation were performed for XR9577, WK-X-34 and cyclosporin A 
(Figure 4.18).  EC50 values were obtained in the nanomolar range for XR9577 
(300 nM) and WK-X-34 (416 nM) and in the lower micromolar range for cyclosporin 
A (5.5 µM).   
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Figure 4.18   EC50 values of Pgp inhibition using the 99mTc-Sestamibi accumulation assay 
A2780/Adr cells were preincubated with concentrations of 10 nM to 100 µM of XR9577, WK-X-34 and 10 nM to 
1 µM of cyclosporin A.  99mTc-Sestamibi accumulation levels were determined after 60 min of uptake and plotted 
against the logarithm of the inhibitor concentration in molarity.  EC50 values were determined by nonlinear 
regression analysis.  Results are expressed as means ± S.D. and normalized to top and bottom values; some 
error bars are smaller than the data symbols.   
XR9577 
EC50 : 300 nM 
Log EC50 : -6.52 ± 0.16 
WK-X-34 
EC50 : 416 nM 
Log EC50 : -6.38 ± 0.16 
Cyclosporin A 
EC50 : 5.5 µM 
Log EC50 : -5.26 ± 0.25 
Results – in vitro   
    
107
 
For in vivo characterizations of WK-X-34 and MDR1 antisense ODNs, an 
imaging approach was chosen based on the accumulation of 99mTc-Sestamibi in 
resistant and sensitive tumor xenografts (see chapter 3.4.1).  As BCRP and Pgp are 
often coexpressed in different tissues and tumors (Doyle, 2003), potential 
contributions of BCRP in the efflux of 99mTc-Sestamibi were investigated.  Studies in 
the MCF7/mx cells did not detect any contribution of BCRP to the cellular 
accumulation of 99mTc-Sestamibi (Figure 4.19).  If 99mTc-Sestamibi was a substrate of 
BCRP, intracellular 99mTc-Sestamibi levels would be elevated in novobiocin treated 
MCF7/mx and MCF7/wt as compared to MCF7/mx.  Novobiocin-treated MCF7/mx 
and MCF7/wt have no functional BCRP, thus no potential transport activity.  
However, MCF7/mx cells possessing functional BCRP do not decrease 99mTc-
Sestamibi levels.  Therefore, 99mTc-Sestamibi cannot be a substrate for BCRP.  
Intracellular 99mTc-Sestamibi levels were slightly increased in MCF7/mx, which can 
be explained by the lack of novobiocin in competition for uptake processes.  As 
previously published (Chen, 2000), the results confirm no involvement of BCRP in 
99mTc-Sestamibi transport across cellular membranes.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19    99mTc-Sestamibi accumulation in MCF7/mx and MCF7/wt 
Time-dependent cellular accumulation of 99mTc-Sestamibi is shown in BCRP-expressing MCF7/mx and non-
BCRP-expressing MCF7/wt cells.  MCF7/mx cells have been additionally treated with 200 µM of the BCRP 
inhibitor novobiocin.  Cells have been pretreated with novobiocin or vehicle for 1 h prior to addition of 99mTc-
Sestamibi as specified above.  Results represent the means ± S.D. of three independent experiments.  Some 
error bars are smaller than the data symbols. 
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4.3.2.2 Daunorubicin efflux assay 
The daunorubicin efflux assay was performed in A2780/Adr as described in 
chapter 3.3.6.2.  As daunorubicin is also a weak substrate of BCRP and MRP1, RT-
PCR analyses were performed to examine the mRNA expression of those MDR 
transporters.  As summarized in chapter 4.1.1.3, A2780/Adr displayed no detectable 
levels of BCRP and only very low levels of MRP1.  Cells were incubated in the 
presence of daunorubicin and the amount of intracellularly retained daunorubicin 
after 90 min of efflux was measured by flow cytometry 
Results from the daunorubicin efflux assay (Figure 4.20) partly corresponded 
to results from the 99mTc-Sestamibi efflux assay.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20   Inhibition of Pgp-mediated daunorubicin efflux 
Effects of WK-X-compounds, XR9577, verapamil and cyclosporin A (10, 1 µM) on Pgp-mediated daunorubicin 
efflux were detected by flow cytometry.  Values are normalized to 100 % of controls and values above 100% 
indicate Pgp-inhibition. Results represent means ± S.D. Similar results were obtained in three independent 
experiments. 
 
 
Likewise, the compounds XR9577, WK-X-34 and cyclosporin A significantly 
inhibited daunorubicin efflux at both tested concentrations of 10 and 1 µM.  In 
contrast to results from the 99mTc-Sestamibi accumulation assay, concentrations of 
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10 µM  of verapamil and WK-X-84 also demonstrated some Pgp inhibition.  Studies 
comparing the reliability of the substrates 99mTc-Sestamibi or anthracyclines (e.g. 
doxorubicin, daunorubicin) for Pgp transport assays have indicated differences 
between these two assays (see chapter 2.3.4).  Thus, a combination of both assays 
allows for a more predictive analysis of Pgp inhibition.   
 
4.3.2.3 Daunorubicin accumulation assay 
Daunorubicin accumulation after a 180 min incubation period in the presence 
and absence of inhibitors could be quantified as an indicator of Pgp-mediated 
transport.  In this assay, the intracellular daunorubicin concentration was inversely 
proportional to the activity and expression of Pgp.  The assay was performed as 
outlined in chapter 3.3.6.3.  To visualize these effects, microscopy pictures of 
daunorubicin accumulation in A2780/Adr cells pretreated with 1 and 10 µM of WK-X-
34 were acquired and are depicted in figure 4.21-A.  Furthermore, the daunorubicin 
uptake in A2780/Adr was compared to untreated A2780/wt cells (Figure 4.21-Aiiii).  
The modulating effects on daunorubicin accumulation could also be detected by flow 
cytometry (Figure 4.21-B).   
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 A. 
untreated                        1 µM WK-X-34                10 µM WK-X-34             untreated   
A2780/Adr                       A2780/Adr                       A2780/Adr                     A2780/wt 
 
 
 
 
 
 
 
 
 B. 
 
 
 
 
Figure 4.21   Impact of WK-X-34 on daunorubicin accumulation  
A2780/Adr and A2780/wt cells were pretreated with 1 and 10 µM of WK-X-34, incubated with daunorubicin 
(3 µM) (for 60 min (A) and 180 min (B)) and examined by fluorescence microscopy (on a 63x objective) (A) and 
flow cytometry (B).  As compared to untreated A2780/Adr (Ai) and A2780/wt (Aiiii) cells, daunorubicin uptake 
was dose-dependently increased in A2780/Adr treated with 1 µM WK-X-34 (Aii) and 10 µM WK-X-34 (Aiii).  
Daunorubicin uptake in WK-X-34-treated A2780/Adr was detectable on FACS histograms (B).  Cells were gated 
for the intact cell population using forward and side scatter dot plots and 10000 events were acquired per sample.  
Geometric means as determined by flow cytometry in the FL-2 channel were: A2780/Adr control 44; + WK-X-34 
(1 µM) 170; + WK-X-34 (10 µM) 235; A2780/wt 234.  
 
 
For EC50 determination, the daunorubicin accumulation assay has been 
extensively used in our laboratory.  A2780/Adr cells were preincubated with different 
concentrations of inhibitors and daunorubicin accumulation after 180 min was 
quantified.  EC50 and log EC50 values were derived by nonlinear regression analysis.  
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These experiments were performed by Kerstin Breitbach and are the subject of her 
PhD thesis.  A representative curve of the characterization of WK-X-34 is depicted in 
figure 4.22.  
 
 
 
 
 
 
 
 
 
 
Figure 4.22   EC50 determination of Pgp inhibition using daunorubicin accumulation 
Representative EC50 determination of WK-X-34 in A2780/Adr cells as determined by daunorubicin accumulation.  
Results represent means of three samples ± S.D. and are normalized to top and bottom values.  Error bars are 
smaller than the data symbols.  Three independent experiments were performed.  (The data and graph were 
kindly provided by K. Breitbach) 
 
EC50 values were determined for all the other MDR inhibitors.  The following 
values were obtained:  XR9577 (EC50: 136 nM; log EC50: -6.87 ± 0.01); WK-X-50 
(EC50: 1.55 µM; log EC50: -5.81 ± 0.02); WK-X-84 (EC50: 1.06 µM; log EC50: -5.98 ± 
0.01); verapamil (EC50: 4.77 µM; log EC50: -5.32 ± 0.03) and cyclosporin A (EC50: 
2.47 µM; log EC50: -5.61 ± 0.01). 
 
4.3.2.4 Summary of Pgp transport assays 
The MDR inhibitors were characterized for Pgp-mediated transport by three 
different Pgp transport assays: the 99mTc-Sestamibi accumulation assay; the 
daunorubicin efflux assay and the daunorubicin accumulation assay.  These assays 
combine two different Pgp substrates and two different transport parameters 
(accumulation and efflux).  Results from these three different assays are not 
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consistent.  Thus, the results need to be interpreted in conjunction and discrepancies 
noted.  Table 4.3 presents an overview of the results. 
 
Table 4.3   Summary of Pgp transport assays 
 
 Pgp Transport Assays 
Inhibitor   99mTc-Sestamibi accum.  Daunorubicin efflux  Daunorubicin accum. 
 
XR9577 ++   (EC50: 300 nM) ++ ++   (EC50: 136 nM) 
WK-X-34 ++   (EC50: 416 nM) + ++   (EC50: 82 nM)  
WK-X-50 - - +     (EC50: 1.55 µM) 
WK-X-84 - + +     (EC50: 1.06 µM) 
Verapamil - ++ +     (EC50: 4.77 µM) 
Cyclosporin A +   (EC50: 5.5 µM) + +     (EC50: 2.47 µM) 
 
Table 4.3. Results from three different Pgp transport assays are summarized.  A significant and strong inhibition 
at a 1 µM concentration or with an EC50 value in the nanomolar range is indicated by ++; a weaker but yet 
significant inhibition at a 10 µM concentration or with an EC50 value in the micromolar range is indicated by +. 
 
 
XR9577 and WK-X-34 showed substantial and significant Pgp inhibition in all 
three transport assays.  The effects of cyclosporin A were weaker, yet significantly 
detectable in all three assays.  Consistently, WK-X-50 showed no effects in all three 
assays.  For all other MDR inhibitors, results of Pgp inhibition were rather 
inconsistent between the three assays.  This was particularly seen for verapamil.  
Whereas verapamil showed no effects in the 99mTc-Sestamibi assay, a significant 
Pgp inhibition with an EC50 value in the lower micromolar range was detected in the 
daunorubicin accumulation assay.  This was likely due to unspecific MDR inhibition 
and interaction with other transporters such as MRP1.  As the resistant A2780/Adr 
cells were selected through continuous exposure to doxorubicin, other cellular non-
classical mechanisms (see chapter 1.1.1.1) might be present in these cells and could 
contribute to unspecific MDR inhibition (also see results from daunorubicin 
chemosensitivity assays, chapter 4.3.5.1). 
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4.3.3 BCRP-mediated transport assays  
 Inhibition of BCRP-mediated transport of the BCRP substrate mitoxantrone 
was examined in MCF7/mx cells.  The cell model was confirmed to overexpress 
BCRP but to lack detectable expression of Pgp (see chapter 4.1.2).  Overexpression 
of BCRP led to a MDR phenotype towards mitoxantrone, detectable as a strong 
mitoxantrone efflux in MCF7/mx (Figure 4.23-A) but not in MCF7/wt cells (Figure 
4.23-B). 
 
 
 
 
 
 
 
 
 
 A.  MCF7/mx B.  MCF7/wt 
 
Figure 4.23   BCRP-mediated efflux of mitoxantrone in MCF7/mx 
Representative histograms demonstrating mitoxantrone intracellular levels after 90 min efflux in MCF7/mx (A) in 
comparison to MCF7/wt (B) cells.  Intracellular mitoxantrone levels after 180 min incubation with 3 µM of 
mitoxantrone were detected on a FACSCalibur in the FL4 channel. Geometric means as determined by flow 
cytometry were: MCF7/mx (0 min) 230; MCF7/mx (90 min) 89; MCF7/wt (0 min) 243; MCF7/wt (90 min) 215. 
 
 
 Inhibition of BCRP-mediated mitoxantrone efflux was tested for all compounds 
at a concentration of 10 and 200 µM.  WK-X-34 and XR9577 were found to be the 
most potent inhibitors in this assay.  At both tested concentrations, these compounds 
significantly retained intracellular mitoxantrone with a potency that was comparable 
to that of the well-established BCRP inhibitor novobiocin (Figure 4.24).  BCRP 
inhibition with a comparable potency was detectable for WK-X-50 and WK-X-84, yet 
a comparable level of significance could not be reached due to a higher variability 
time: 0 min
time: 90 min
time: 0 min
time: 90 min
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between the individual experiments.  No major interactions with BCRP were seen in 
the verapamil and cyclosporin A treated cells.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.24   Inhibition of BCRP-mediated mitoxantrone efflux 
Inhibition of mitoxantrone efflux in the presence of 10 and 200 µM of novobiocin (Nvb), XR9577, WK-X-34, -50, -
84, verapamil (Vrp) and cyclosporin A (CyA).  Retained mitoxantrone accumulation after 90 min of efflux was 
detected by flow cytometry.  Data was calculated as described in methods and are expressed as a percent of 
control with a control value of 100 %.  Results represent mean values ± S.D. of three individual experiments with 
p-levels of * α = 0.05 and ** α = 0.01. 
 
 
For quantification and comparison of BCRP inhibitors, EC50 values were 
derived by quantifying the mitoxantrone efflux in MCF7/mx cells in the presence of 
various concentrations (1-1000 µM) of MDR inhibitors.  Novobiocin was included as 
a positive control (Shiozawa, 2004; Yang, 2003).  Apparent EC50 values of BCRP 
inhibition (Figure 4.25) were calculated for novobiocin and each MDR inhibitor.   
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                                                         Novobiocin 
                                                                                              EC50 :  25 µM 
                                                                                              Log EC50 :  -4.60 ± 0.03 
 
 
 
 
 
 
 
 
                                                     XR9577 
                                                                               EC50 :  21 µM 
                                                                                   Log EC50 :  -4.68 ± 0.05 
 
 
 
 
 
 
 
 
                                      WK-X-34 
 EC50 :  27 µM 
                                                                                   Log EC50 :  -4.57 ± 0.1 
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                       WK-X-50 
                EC50 :  10 µM 
                                                                                   Log EC50 :  -4.99 ± 0.08 
                          
 
 
 
 
 
 
 
 
 
                                   WK-X-84 
 EC50 :  21 µM 
                                                                                   Log EC50 :  -4.68 ± 0.04 
 
 
 
 
 
 
 
Figure 4.25   EC50 values of BCRP inhibition 
MCF7/mx cells were preincubated with mitoxantrone and different concentrations of novobiocin, XR9577, WK-X-
34, -50 and -84.  Retained mitoxantrone accumulation was measured after 90 min efflux by flow cytometry and 
plotted against the inhibitor concentration.  EC50s were determined by nonlinear regression from data normalized 
to top and bottom values and represent mean values ± S.D. of three independent experiments.  Error bars can be 
smaller than data symbols. 
 
 
As expected from results in figure 4.24, EC50 values in the same range were 
obtained for XR9577 and WK-X-34 in comparison to novobiocin.  Unexpectedly, WK-
X-50 and WK-X-84 displayed EC50 values which were comparable to those of WK-X-
34 and novobiocin.  Results from mitoxantrone efflux assays as presented in figure 
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4.24, however, indicated a comparable inhibition for WK-X-50 and WK-X-84 as 
compared to XR9577, for instance.  These results, however, did not reach 
significance due to the higher variability between the different runs of the assay.  In 
summary, all three WK-X-compounds appear to inhibit BCRP-mediated mitoxantrone 
efflux with a potency comparable to that of novobiocin. 
 
4.3.4 MRP-mediated transport assays  
 Interactions of the WK-X-compounds, XR9577, verapamil and cyclosporin A 
with the MRP transporters were examined using the 5-CFDA efflux assay in 
selectively transfected cell lines, HeLa-MRP1 and MDCK-MRP2 and -MRP3 (see 
chapter 3.3.8). 
 
4.3.4.1 Interaction with MRP1 
 In comparison to the MRP inhibitor indomethacin, the effects of most 
compounds on MRP1 inhibition were weak and only significant at high 
concentrations of 200 µM (Figure 4.26).  Interestingly, cyclosporin A, even though 
fairly weak at 200 µM, already showed a highly significant MRP1 inhibition at 10 µM.  
Potent inhibition of the MRP transporters, particularly MRP1, has previously been 
reported for cyclosporin A (Quadir, 2005). 
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Figure 4.26   Interaction with MRP1 activity 
Effects of 10 µM and 200 µM of WK-X-compounds, XR9577, verapamil (Ver) or cyclosporin A (CyA) on MRP1-
mediated efflux of 5-CF were analyzed in HeLa-MRP1 cells.  Indomethacin (Ind) (200 µM) was used as a positive 
control.  The cellular bound 5-CF after efflux was measured.  Results are calculated as a % of control and 
represent means ± S.D. with p-levels of α= * < 0.05;** <0.01; * < 0.001 as determined using an unpaired t-test.  
Similar results were obtained in three separate experiments.  
 
 
4.3.4.2 Interaction with MRP2 
MRP2-mediated efflux in MDCK-MRP2 cells was significantly inhibited by 
WK-X-50 at 10 and 200 µM whereas other WK-X-compounds showed no effects on 
MRP2 (Figure 4.27).  These results identify WK-X-50 as an MRP2 inhibitor. Solely 
verapamil showed some significant but weak MRP2 interactions at concentrations of 
200 µM.  The MRP inhibitor indomethacin displayed only very weak inhibition of 
MRP2 when compared to MRP1 inhibition, for example. 
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Figure 4.27   Interaction with MRP2 activity 
Effects of 10 µM and 200 µM of WK-X-compounds, XR9577, verapamil (Vrp) or cyclosporin A (CyA) on MRP2-
mediated efflux of 5-CF were analyzed in MDCK-MRP2 cells. Indomethacin (Ind) (200 µM) was used as a 
positive control.  The cellular bound 5-CF was quantified after efflux.  Results are calculated as a % of control 
and represent means ±S.D. with p-levels of α= * < 0.05;** <0.01; * < 0.001 as determined using an unpaired t-
test.  Similar results were obtained in three separate experiments.  
 
 
4.3.4.3 Interaction with MRP3 
 In comparison to indomethacin, cyclosporin A showed potent MRP3 inhibition 
at concentrations of 200 µM in MDCK-MRP3 cells (Figure 4.28).  No MRP3 inhibition 
was detected for the other MDR inhibitors with the exception of some weak but 
significant effects of verapamil at concentrations of 200 µM.   
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Figure 4.28   Interaction with MRP3 activity 
Effects of 10 µM and 200 µM of WK-X-compounds, XR9577, verapamil (Vrp) or cyclosporin A (CyA) on MRP3-
mediated efflux of 5-CF were analyzed in MDCK-MRP3 cells.  Indomethacin (Ind) (200 µM) was used as a 
positive control.  The cellular bound 5-CF after efflux was measured.  Results are calculated as a % of controls 
and represent means ±S.D. with p-levels of α= * < 0.05;** <0.01; *** < 0.001 as determined using an unpaired t-
test.  Similar results were obtained in three separate experiments.  
 
 
4.3.4.4 Summary of MRP-mediated transport assays 
The MDR inhibitors XR9577, WK-X-34 and -84 showed no interactions with 
the MRP inhibitors, with the exception of some high dose MRP1 effects.  The 
specificity for Pgp and BCRP inhibition appeared to be enhanced for XR9577, WK-X-
34 and -84 in comparison to the first generation Pgp inhibitors cyclosporin A and 
verapamil, which demonstrated substantial unspecific MRP interactions.  Of note, 
WK-X-50 was identified as a weak MRP2 inhibitor. 
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4.3.5 Chemosensitivity Assays 
Corresponding to results presented in chapter 4.2.2, decreased Pgp 
functionality by treatments with MDR inhibitors resulted in both, a weakened Pgp- 
and BCRP-mediated MDR phenotype.  The cellular sensitivity towards the cytotoxic 
drugs daunorubicin and mitoxantrone, as detected in chemosensitivity assays (see 
chapter 3.3.9), was significantly altered in the presence of some of the novel MDR 
inhibitors.  
Chemosensitivity assays were performed in A2780/Adr and A2780/wt for 
daunorubicin and in MCF7/wt and MCF7/mx for mitoxantrone, respectively (Table 
4.4 and 4.5).  As outlined in chapter 3.3.9, the sensitizing factor (S.F.) describes the 
factor by which the chemosensitivity of the specific cell line towards daunorubicin/ 
mitoxantrone increases in the presence of 10 µM of inhibitor.  Since the effect of an 
inhibitor is not solely dependent on the expression of Pgp/BCRP, both Pgp/BCRP 
expressing and non-expressing cell lines were examined.  The non-specific MDR 
inhibitor verapamil (see chapter 4.3.4) was included as an unspecific control.  For 
example, an increased sensitivity towards daunorubicin was detected for verapamil 
in non-Pgp expressing A2780/wt (S.F. 6.8), likely due to partial MRP inhibition (see 
table 4.4).  The S.F.Adr/wt or S.F.mx/wt give a normalized value.  A ration of S.F.Adr/wt 
and S.F.mx/wt was calculated by dividing the S.F. obtained for the Pgp/BCRP 
expressing (Adr, mx) cell line by the S.F. of the wild-type (wt) cell line. 
 
4.3.5.1 Daunorubicin chemosensitivity in A2780/Adr 
The chemosensitivity towards daunorubicin was increased in the presence of 
10 µM of WK-X-34, WK-X-84 and XR9577, as sensitizing factors (S.F.Adr/wt) above 7 
were calculated for these treatment groups (Table 4.4).  These S.F.Adr/wt were higher 
than the S.F.Adr/wt for verapamil (S.F.Adr/wt: 4.1) and cyclosporin A (S.F.Adr/wt: 3.2).  
Unspecific effects were detectable for verapamil and cyclosporin A as treatment of 
A2780/wt cells with verapamil or cyclosporin A also showed significant induction of 
chemosensitivity.  This can be explained by an unspecific interaction of these 
compounds with other MDR mechanisms particularly MRP1, which was expressed at 
detectable levels in A2780/Adr and A2780/wt cells.  The same effects were not 
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detectable upon treatments with the MRP2 inhibitor WK-X-50.  This seems plausible 
as A2780/Adr and A2780/wt cells did not have any levels of MRP2 as presented in 
figure 4.3. 
 
 
Table 4.4   Daunorubicin chemosensitivity in A2780/Adr and A2780/wt 
      
                    A2780/wt    A2780/Adr   S.F.Adr/wt                                                
EC50 MTT / µM ± S.D. (S.F.: control/treatment)       
                                                            
Control    1.29 ± 0.1      40.4 ± 9.8           (R.F. 31)                   
 
XR9577        0.99 ± 0.1 (1.3)               3.8 ± 0.9 (10.5)*     8.1               
      
WK-X-34 1.06 ± 0.1 (1.2)      4.5 ± 0.7 (8.9)*     7.4               
      
WK-X-50 1.13 ± 0.06 (1.1) 18.5 ± 0.9 (2.2) 2                    
     
WK-X-84 1.18 ± 0.03 (1.1) 5.1 ± 12.1 (7.9)* 7.1                  
     
Verapamil 0.19 ± 0.08 (6.8)** 1.5 ± 0.2 (28)* 4.1                  
     
Cyclosporin A  0.18 ± 0.16 (7.3)* 1.7 ± 0.3 (24)* 3.2         
           
 
Table 4.4. Different concentrations of daunorubicin were added to cells preincubated with 10 µM of different 
inhibitors as indicated.  Cell viability was examined after 72 h with MTT assays and EC50 values were calculated 
by nonlinear regression (with hill slopes ranging between -10 and -3.5 for A2780/wt and -4 for A2780/Adr cells, 
respectively).  Chemosensitivity was expressed as a sensitizing factor (S.F.) and normalized for effects not 
related to Pgp overexpression in A2780/Adr cells (S.F.Adr/wt).  Experiments were performed in triplicates on three 
individual occasions.  EC50 results represent means ± S.D. and p-levels (* α< 0.05, ** α< 0.01) were determined 
between drug treatment and controls within one cell line.  
 
 
4.3.5.2 Mitoxantrone chemosensitivity in MCF7/mx 
Sensitivity towards mitoxantrone was substantially higher in MCF7/wt (EC50: 
107 ± 13 nM) than in MCF7/mx (EC50: 22 ± 4 µM) cells (Table 4.5).  In MCF7/wt 
cells, none of the inhibitors showed any detectable effects and all S.F. 
control/treatment factors were close to 1.  10 µM of WK-X-34, XR9577 and 
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novobiocin were able to restore sensitivity towards mitoxantrone to levels of 
MCF7/wt with S.F.mx/wt of 298, 385 and 423, respectively.  Sensitivity towards 
mitoxantrone in MCF7/mx was increased to a lesser extent, yet significantly in the 
presence of WK-X-50 (by 48-fold) and WK-X-84 (by 109-fold).   
 
Table 4.5   Mitoxantrone chemosensitivity in MCF7/mx and MCF7/wt  
          
                    MCF7/wt   MCF7/mx   S.F.mx/wt                                                 
EC50 MTT / nM ± S.D. (S.F.: control/treatment)       
                                                            
Control    104 ± 13                 22000 ± 4000               (R.F. 211)    
 
XR9577        85 ± 6 (1.2) 62 ± 40 (357)*             298 
 
WK-X-34 81 ± 8 (1.3)            44 ± 8 (506)*     389    
 
WK-X-50 83 ± 3 (1.3)            460 ± 300 (48)*           37                  
 
WK-X-84 87 ± 11 (1.2)          202 ± 190 (109)*      91 
 
Verapamil 83 ± 5 (1.3)            22500 ± 14000 (0,9)     0.7 
 
Cyclosporin A  98 ± 6 (1.1)  86000 ± 21000 (0.26)   0.24 
 
Novobiocin 81 ± 7 (1.3)             40 ± 18 (550)*             423 
 
 
 
Table 4.5. Different concentrations of mitoxantrone were added to cells preincubated with 10 µM of different 
inhibitors as indicated.  Cell viability was examined after 72 h with MTT assays and EC50 values were calculated 
by nonlinear regression (with hill slopes ranging around -7).  Chemosensitivity was expressed as a sensitizing 
factor (S.F.) and normalized to effects not related to BCRP overexpression (S.F.mx/wt).  Experiments were 
performed in triplicates on three individual occasions.  EC50 results represent means ± S.D. and p-levels (*α 
<0.05, ** α <0.01) were determined between drug treatment and controls within one cell line.  
 

  
 
5 Discussion - in vitro 
 
 
In the following chapter, in vitro results presented in chapter four will be 
discussed.  The two MDR-reversing strategies outlined in “Rational and hypothesis”, 
transcriptional downregulation by MDR1 antisense ODNs and MDR inhibition using 
small molecule multi-targeted inhibitors (see chapter 2.1), will be evaluated and 
compared to each other.   
 
5.1 Cell model A2780/Adr 
The characterization of the cell model is of importance for every in vitro and in 
vivo investigation.  In particular, the differential expression of genes and proteins 
involved in MDR mechanisms between the multidrug resistant and the sensitive 
variant exemplify the “pathological condition” of resistance.  In comparison to other 
Pgp expressing cell lines such as Caco-2 and HepG2 cells, A2780/Adr cells showed 
considerably higher Pgp levels.  When A2780/Adr cells were challenged with 
doxorubicin, their Pgp expression was even higher (chapter 4.1.2.1).  Hence, the 
detection window for Pgp expression (see figure 4.5 and 4.6) and Pgp-mediated 
effects was greatest between doxorubicin challenged A2780/Adr and wild-type 
A2780/wt cells.  A resistance factor of 7.5 for doxorubicin and 31 for daunorubicin 
was obtained for this cell pair.  This was important in order to sensitively detect Pgp 
inhibition in vitro, and particularly in vivo in the tumor xenografts.  Moreover, as such 
highly overexpressed levels are common in multidrug resistant solid tumors (Leith, 
1999); this cell model reflects conditions, which might occur in clinically untreatable 
tumors.   
The ovarian cancer cells A2780/Adr are sourced from a human solid tumor.  
To obtain a multidrug resistant phenotype, these cells have been selected with the 
chemotherapeutic agent doxorubicin.  In vitro data indicates that the multidrug 
resistant phenotype is mainly characterized by Pgp overexpression.  However, other 
  Discussion – in vitro 
 
126 
cellular mechanisms of resistance (see chapter 1.1) are likely to be involved 
(Vikhanskaya, 1997) as RT-PCR analyses have confirmed expression of MRP1 in 
A2780/Adr cells (see figure 4.3).   
Although concurrent resistance mechanisms might interfere with 
investigations of the Pgp phenotype, chemoselected, rather than transfected, cells 
are favored by most researchers when studying the MDR phenotype.  In contrast to 
genetically engineered cell lines, chemoselected cells more closely mimic a situation 
in which a tumor develops an MDR phenotype as a response to chemotherapeutic 
treatment.  In clinical reality, multidrug resistant tumors are characterized by a 
predominant mechanism of resistance in concert with a variety of other non-cellular 
and cellular MDR mechanisms (Fojo, 2003).  Hence, the clinical relevance is 
increased when experiments can be conducted in chemoselected, rather than 
transfected cell lines.  In the present thesis, the chemoselected cell lines A2780/Adr 
and MCF7/mx were used in line with most in vitro and in vivo studies characterizing 
or targeting the MDR phenotype (see table 5.2).    
 
 
5.2 MDR1 antisense ODNs 
MDR1 antisense ODNs have been previously used by different researchers to 
inhibit the expression of Pgp in cell culture and animal models.  Results from the in 
vitro characterization of antisense ODNs are discussed in the following.  To begin 
with, results from delivery and toxicity studies will be discussed. 
 
5.2.1 Intracellular uptake and toxicity   
Cellular uptake and distribution, as examined using FITC-labeled antisense 
ODNs, were greater in A2780/Adr, when compared to the non-Pgp expressing 
A2780/wt cells (see chapter 4.2.3).  This was likely due to an increased retention of 
the MDR1 antisense ODNs in cells, which offer a higher availability of target RNA.  
Cellular uptake of DNA is generally thought to occur through receptor-mediated 
endocytosis.  A temperature–dependent, saturable transport process across plasma 
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membranes was described for oligonucleotides (Loke, 1989).  Once inside the cells, 
antisense molecules leave their transfection complex and are distributed within the 
cytoplasm.  In the cytoplasm they hybridize to their target mRNA (Jensen, 2001).  As 
A2780/wt cells do not express detectable levels of MDR1 (see chapter 4.1.1.2), 
these cells do not possess the target mRNA for MDR1 antisense molecules.  In 
A2780/Adr cells, however, high levels of MDR1 mRNA are available for binding.  
Therefore, antisense molecules are more likely to be retained in these cells.   
The FITC-labeled ODNs were also able to penetrate into the nucleus.  This 
observation is in agreement with previously published reports (Chin, 1990; Fisher, 
1993; Lorenz, 1998).   
Cellular toxicity has been associated with the exposure to phosphorothioated 
ODNs and remains a major challenge in antisense application (Kurreck, 2003).  
Results in chapter 4.2.4 demonstrate a substantial suppression of the proliferation 
capacity of A2780/Adr cells upon antisense treatments.  The effects were dose-
dependent and decreased the proliferation rate of A2780/Adr cells by over to 70 % 
(see figure 4.15).  These results point to a major impact of antisense treatments on 
cell viability and are in accordance with reports of ODN-related toxicities upon 
treatments with phosphorothioated ODNs (Galderisi, 1999).   
The transfection agent SuperFect contributes to the overall toxicity.  In MTT-
based viability assays, SuperFect was found to also reduce mitochondrial activity 
(Axel, 2000).  Thus, the observed toxic effects were likely due to a combination of 
the transfection reagent and the antisense molecules.  As ‘naked’ antisense 
molecules are not easily being incorporated into cells (Axel, 2000) the use of a 
transfection reagent like SuperFect is essential for activity.  Hence, SuperFect-
related toxicities cannot be avoided.  Antisense-associated toxicities represent a 
disadvantage and uncertainty linked to their experimental and potential therapeutic 
use.   
  
5.2.2 Pgp expression and functionality   
Antisense ODNs directed against MDR1 (Alahari, 1998) were effective in 
downregulating Pgp expression and functionality in A2780/Adr cells (see figure 
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4.11).  Changes in Pgp surface expression resulted in an impaired MDR phenotype 
which was detectable by investigations of daunorubicin chemosensitivity and 
intracellular accumulation.  The degree of Pgp downregulation, however, was limited 
to about 50 % of controls.  Lower Pgp levels could not be achieved even with the 
highest tolerated concentration.   
Daunorubicin accumulation and chemosensitivity are depending on the 
degree of Pgp expression (Coley, 2002; Marks, 1992).  Results confirmed that 
decreasing levels of Pgp expression lead to a decrease of Pgp activity, which was 
detectable as a reduced daunorubicin efflux.  Thus, higher intracellular levels of 
daunorubicin were seen in antisense treated cells (see chapter 4.2.2).  This 
relationship was dose-dependent and translated into an increased chemosensitivity 
towards daunorubicin, as determined using the MTT assay (see table 4.1).  Likewise, 
a saturation of the anti-MDR effect against daunorubicin was detectable by MTT 
assays.  The antisense concentration of 200 nM versus 100 nM caused a smaller 
increase in daunorubicin chemosensitivity than 100 nM versus 50 nM (compare EC50 
values for 50nM, 100 nM and 200 nM in table 4.1) pointing to a saturation of the 
downregulating effect.  The saturable effect might result from limitations in ODN 
uptake.  This seems plausible as reports have indicated an energy-dependant 
saturable uptake process for ODNs (Loke, 1989) (see chapter 5.2.1).   
To evaluate the usefulness of antisense treatments, Pgp inhibition caused by 
a functional inhibitor like WK-X-34 was compared to that caused by MDR1 antisense 
ODNs.  These two treatment strategies are based on totally different mechanisms of 
action.  In antisense treated cells, two events leading to the inhibition of Pgp take 
place: 1. Antisense molecules target and downregulate the expression of MDR1 
mRNA.  2. Reductions in MDR1 mRNA levels are then being translated into reduced 
Pgp surface expression, which leads to a reduced Pgp activity.  Therefore, Pgp is 
indirectly targeted by antisense ODNs.  In contrast, WK-X-34 directly interacts with 
surface Pgp and causes a functional inhibition of the transport activity without 
altering the expression of Pgp.   
When the Pgp substrate daunorubicin is added to the system it has to be 
actively effluxed in order to enable the cell to survive.  For effective efflux, however, 
the cell needs functional Pgp to be expressed in the plasma membrane.  Through 
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treatment with both, antisense ODNs as well as WK-X-34, the activity of surface Pgp 
is decreased.  In the case of antisense treatment, the lack of Pgp activity is caused 
by a decrease in the number of functional Pgp molecules on the cell surface. 
How effective is the in vitro treatment using antisense ODN in comparison to a 
direct Pgp inhibition using WK-X-34?  To better compare these two treatments, 
results from daunorubicin chemosensitivity assays in WK-X-34 and antisense treated 
cells are summarized in table 5.1. 
 
Table 5.1   EC50 values (daunorubicin chemosensitivity) after WK-X-34 and antisense treatments 
 
  EC50  (µM)   S.F.  EC50  (µM)    S.F. 
Controls A2780/Adr 40,4 ± 9.8      
 A2780/wt 1.29 ± 0.1     31   
     
Treatment  
(in A2780/Adr) 
WK-X-34   
(10 µM) 
4.5 ± 0.7       9 AS (50 nM) 19.0 ± 0.8      2.1 
   AS (100 nM) 9.7 ± 0.9        4.2 
   AS (200 nM) 7.7 ± 0.9        5.2 
Abbreviations used in the table: S.F. Sensitizing Factor (A2780/Adr Control / Treatment); AS Antisense (MDR1 
AS ODNs). 
 
From the results in table 5.1, it can be concluded that both treatment 
strategies effectively inhibit the Pgp-mediated MDR phenotype towards 
daunorubicin.  Although the highest sensitizing factor (S.F. 9) was reached for the 
treaement with WK-X-34 (10 µM), EC50 values were considerably reduced after 
antisense treatments up to a sensitizing factor of 5.2 for a concentration of 200 nM of 
antisense ODNs.  Hence, it does not appear to make a difference whether the 
activity of Pgp is decreased by a functional inhibition or by a decrease of functional 
Pgp molecules in the plasma membrane.  The effectiveness of both treatments 
strategies, however, was unequal.  The S.F. of 5.2 could only be obtained in 
A2780/Adr cells after a three-day treatment with the highest tolerated dose of 
antisense ODNs (200 nM).  In contrats, the S.F. of 9 was easily obtained after a 
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single dose of WK-X-34 at a concentration (10 µM) much lower than the maximum 
tolerated dose of 200 µM (see table 4.2).  Therefore, it can be concluded that WK-X-
34 more effectively reverses the Pgp-mediated MDR phenotype in vitro in 
comparison to antisense treatments. 
Moreover, the data presented in table 5.1 reveals a discrepancy between the 
inhibition of Pgp transport function and MDR phenotype.  As the EC50 value for WK-
X-34 was determined to be around of 80 nM in a daunorubicin transport assay 
(figure 4.22), a concentration 125 times as high (10 µM) is expected to completely 
inhibit the Pgp-mediated MDR phenotype towards daunorubicin to levels seen in 
A2780/wt cells.  However, the S.F. of 31 as obtained for A2780/wt cells could not be 
reached even with the treatment of 10 µM of WK-X-34 (S.F. 9).   
Thus, a discrepancy between the inhibition of Pgp-mediated transport and 
MDR phenotype towards daunorubicin has to be noted.  The toxicity of daunorubicin 
in the multidrug resistant tumor cell is most likely determined by a combination of 
factors, among which the transport capacity of Pgp plays an important role.  
However, other MDR mechanisms towards daunorubicin as well as the cytotoxicity 
of the drug itself contribute to the anti-MDR effect.  For A2780/Adr cells, several non-
transporter-based MDR mechanisms have been described in the literature.  In 
doxorubicin resistant A2780-DX3 cells, for example, an altered localization of p53 in 
the cytoplasm, rather than the cell nucleus was detected in comparison to wild-type 
A2780, suggesting an involvement of p53 in resistance mechanisms towards 
doxorubicin (Vikhanskaya, 1997).  Moreover, resistance against the Toposiomerase 
II enzyme, which is involved in DNA replication processes, has been associated with 
the overexpression of Pgp (Kunikane, 1990).  It is very likely that such additional 
MDR mechanisms are present in A2780/Adr but not in A2780/wt cells and might 
contribute to the protection of WK-X-34 treated A2780/Adr cells from daunorubicin.  
To confirm the contribution of additional MDR mechanisms towards daunorubicin in 
A2780/Adr cells, however, further experiments have to be undertaken.   
Nevertheless, the results indicate that the reversal of the Pgp-mediated MDR 
phenotype towards a specific cytotoxic drug like daunorubicin can only be predicted 
by a transport assay in combination with a chemosensitivity assay.   
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5.3 MDR inhibitors 
Results from in vitro characterization of the novel multi-targeted MDR 
inhibitors will be discussed in the following chapter.  Particularly, interactions with 
Pgp as well as with other ABC transporters will be elaborated with regard to the 
hypothesis formulated in chapter 2.1 (Novel multi-targeted MDR inhibitors (I.)).  The 
most promising candidate for further development will be selected on the basis of in 
vitro results and compared to current third generation MDR inhibitors.   
 
5.3.1 Characterization of novel MDR inhibitors 
Novel MDR inhibitors from our laboratory were characterized for their efficacy 
in reversing the MDR phenotype in several cell lines.  Three novel MDR inhibitors, 
WK-X-34, WK-X-50 and WK-X-84 were developed and selected.  One Xenova 
compound XR9577, formerly described (Roe, 1999) but never characterized in 
vitro/in vivo, was included.  As outlined in chapter 2.3.1, the well-established first 
generation Pgp inhibitor cyclosporin A (Smeets, 2001; List, 2001) was used as a 
reference compound.   
 
P-glycoprotein inhibition 
Consistently, WK-X-34 and XR9577 were the most effective Pgp inhibitors in 
all three Pgp transport assays: 99mTc-Sestamibi accumulation, daunorubicin 
accumulation and daunorubicin efflux (see chapter 4.3.2.4).  These compounds 
significantly increased intracellular accumulation of daunorubicin with EC50 values in 
the nanomolar range (136 and 82 nM, respectively).  EC50 values of other recently 
characterized third generation Pgp inhibitors were found to be in a similar range.  For 
example, EC50 values of 12-38 nM and 32 nM were measured for Pgp-mediated 
MDR reversal by XR9576 and OC144-093, respectively (Mistry, 2001; Newman, 
2000).  Recent analyses of structure-activity relationships of Tariquidar (XR9576) 
analogs have revealed that the presence of a bulky aromatic ring system with a third 
position heteroatom in direction to the anthranilamide structure such as found in 
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XR9576 and WK-X-34 (compare XR9576 in figure 1.7 and WK-X-34 in figure 3.1) 
are likely to be associated with a strong Pgp inhibitory potency (Globisch, 2006). 
In comparison to WK-X-34 and XR9577, EC50 values in the lower micromolar 
range (4.8 and 2.5 µM) were obtained for verapamil and cyclosporin A (chapter 
4.3.2.3).  Daunorubicin efflux and 99mTc-Sestamibi accumulation were most strongly 
affected by WK-X-34 and XR9577.  In these two assays, inhibition by WK-X-34 and 
XR9577 was also superior to that of cyclosporin A and all other inhibitors.  EC50 
values for 99mTc-Sestamibi accumulation, for instance, were more than 10-fold lower 
for WK-X-34 and XR9577 as compared to cyclosporin A.   
As 99mTc-Sestamibi is not a substrate of BCRP and only a very weak 
substrate of MRP1 (Chen, 2000), results from the 99mTc-Sestamibi transport assay 
are very specific for Pgp.  Yet the threshold of this assay appears to be higher than 
for daunorubicin-based assays.  These differences might result from parameters 
related to the Pgp substrates used, 99mTc-Sestamibi and daunorubicin, and variations 
in the experimental setups of both assays.  As outlined in chapter 2.3.4, the 
substrates 99mTc-Sestamibi and daunorubicin display differences in their affinity to 
and selectivity for Pgp (Muzzammil, 2001).  Therefore, only consistent results from a 
combination of these two transport assays provide reliable information about Pgp 
inhibition.  In contrast to the other MDR inhibitors, WK-X-34 and XR9577 
demonstrated a consistent and potent Pgp inhibition in assays utilizing either 99mTc-
Sestamibi or daunorubicin as the transported substrate.    
Results from transport assays were in accordance with results generated with 
chemosensitivity assays (See chapter 4.3.5.1).  As chemosensitivity assays were 
conducted in Pgp-expressing A2780/Adr and non-Pgp expressing A2780/wt cells, 
interactions with other non-Pgp-related MDR mechanisms towards daunorubicin 
could be detected.  In comparison to verapamil and cyclosporin A, WK-X-34 and 
XR9577 demonstrated a potent and selective reversal of resistance towards 
daunorubicin in A2780/Adr but not in the wild-type A2780/wt cells (Table 4.4).   
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Recent characterizations in the literature 
Other recently characterized third generation Pgp inhibitors including 
GF120918 and XR9576 are summarized in table 5.2.  WK-X-34 and XR9577 can be 
compared to these compounds as they comparably inhibited Pgp efflux activity and 
reversed Pgp-mediated multidrug resistance with EC50 values in the nanomolar 
range.  In table 5.2 the targets as well as the experimental setup for the 
characterization are presented for each novel inhibitor.  
  Discussion – in vitro 
 
134 
 
 
Table 5.2   Novel third generation Pgp inhibitors in the literature –in vitro characterization 
    
Reference MDR inhibitor Target Cell Model 
In vitro 
/in vivo 
in vitro 
Experiments 
Hyafil, 1993 
Laboratoire 
GLAXO 
GF120918 
Pgp,  
later 
BCRP1 
3 human 
MDR cell 
lines 
In vitro  
/in vivo 
Efflux R* 
Ph*-labeling 
CS (DOX, VCR) 
Dantzig, 1996 
Lilly Research 
LY335979 Pgp2 
CEM/  
VLB100 cells 
In vitro  
/in vivo 
Ph*-labeling 
CS (VNB, DOX, ETP, 
TAX) 
Dale, 1998 
Xenova Ltd 
XR9051 Pgp 
Several 
human + 
murine MDR 
cell lines 
In vitro      
CS (DOX, VCR, ETP) 
Ph*-labeling 
Efflux R* 
Binding VNB* 
Newman, 2000 
Ontogen 
Corporation 
OC144-
093 
Pgp 
Several 
human MDR 
cell lines 
In vitro     
/in vivo 
ATPase assay 
Ph*-labeling 
CS (VNB) 
Uptake R*  
Efflux DNR 
Mistry, 2001 
Xenova Ltd 
XR9576 
Pgp 
later 
BCRP3 
Several 
human + 
murine MDR 
cell lines 
In vitro     
/in vivo 
CS (DOX, PTX, VCR, 
ETP) 
Ph*-labeling 
Efflux R*/ F* 
Jekerle, 2006a 
University of 
Bonn/ Toronto 
WK-X-34 
Pgp 
+ BCRP  
human Ppg, 
BCRP & 
MRP cell 
lines 
In vitro     
/in vivo 
Uptake R*/ DNR 
Efflux DNR, MITX, 5-
CFDA 
CS (DNR, MITX) 
 
Abbreviations used in this table: 
R*: radiolabeled Pgp substrate; Ph*: photoaffinity labeling using [3H]azidopine; CS: Chemosensitivity assay; 
DOX: doxorubicin; VCR: vincristine; VNB: vinblastine; ETP: etoposide; PTX: paclitaxel; TAX: taxol; MITX: 
mitoxantrone 
1  Malipaard, 2001; 2  Shepard, 2003; 3  Robey, 2004 
For in vivo characterization see table 7.1. 
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As all of these compounds have been developed with aims to specifically 
inhibit Pgp, the initial target was Pgp for all compounds.  Only later, some 
compounds were discovered to also target BCRP, while others like LY335979 were 
confirmed to be selective for Pgp (Shepard, 2003).  GF120918 (Malipaard, 2001) 
and XR9576 (Robey, 2004) are such examples as they have been shown to interact 
with BCRP.  Similarly to GF120918 and XR9576, BCRP inhibition was verified for 
WK-X-34 and XR9577. 
Like WK-X-34, most of these third generation Pgp inhibitors have been 
characterized using functional in vitro and in vivo assays.  In vitro experiments were 
typically carried out in a number of different multidrug resistant human cell lines.  
Newman and coworkers, for example, applied a combination of multidrug resistant 
human cancer cell lines for the characterization of OC144-093.  The researchers 
used human lymphoma (CCRF-CEM) and ovarian carcinoma cells (SKOV3), which 
they incubated in the presence of vinblastine to obtain the MDR variant.  Additionally, 
they used human breast cancer cells (MCF7) which were challenged with 
doxorubicin in order to obtain the MDR variant MCF/Adr (Newman, 2000).  XR9576 
was studied (Mistry, 2001) using the same A280/Adr cell model as for WK-X-34.   
Similarly to WK-X-34, other in vitro characterizations contained a combination 
of assays.  Pgp transport assays were used with different radiolabeled or non-
labeled substrates and combined with chemosensitivity assays using different 
chemotherapeutic agents.  For WK-X-34 one radiolabeled substrate (99mTc-
Sestamibi) and one non-labeled substrate (daunorubicin) were used.  Parts of this 
present thesis, containing the characterization of WK-X-34 and other inhibitors, have 
been summarized and published (Jekerle, 2006a; Jekerle, 2006b; also see table 5.2 
and 5.3).  In these reports, WK-X-34 has been examined applying a combination of 
MDR transport and chemosensitivity assays, comparable to other third generation 
Pgp inhibitors.  Some important techniques, however, including photoaffinity labeling 
with [3H]azidopine, unfortunately, could not be conducted for WK-X-34 due to the 
lack of resources and facilities for this technique.   
In the photoaffinity labelling experiments, the compound and [3H]azidopine 
compete for binding to the Pgp molecule.  Hence, the technique allows the 
examination of direct binding between a compound and Pgp.  However, as up to 
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seven different binding sites (Safa, 2004) were identified on the Pgp molecule, it 
remains to be evaluated whether the investigated compound and [3H]azidopine 
actually compete for the same binding site.  The technique was applied by most 
groupes for the characterization of novel Pgp inhibitors.  It must be kept in mind, 
however, that most groups applying photoaffinity labelling are based in large 
pharmaceutical companies such as Lilly Research, Glaxo Laboratories or Xenova 
Ltd which develop Pgp inhibitors solely with a commercial aim.  Obviously, their 
financial resources, techniques and manpower available for screening experiments 
are much greater than those of laboratories within an academic setting.  
 
5.3.2 Interactions with other ABC transporters 
Thus far, inhibition of a single MDR mechanism like Pgp alone could not 
successfully reverse MDR in clinical applications.  As several other ABC transporters 
such as BCRP and MRP1-3 have been found to be implicated in the development of 
multidrug resistant tumors (Sarkadi, 2004; Allen, 2002; Borst, 2002), the interaction 
profile with these transporters was further characterized.   
 
Breast cancer resistance protein 
The breast cancer resistance protein, BCRP, was potently inhibited by all WK-
X-compounds and XR9577 with EC50 values in the low micromolar range. Indeed, 
inhibition of BCRP-mediated efflux of mitoxantrone was comparable to that of the 
well-established BCRP inhibitor novobiocin (Yang, 2003).  This is of particular 
interest as histological studies have identified an extensive overlap between BCRP 
and Pgp in many tumors.  BCRP has been found to be overexpressed in over 40 % 
of different tumor tissues including colon or melanoma (see chapter 1.2.2).  Hence, 
BCRP is believed to play a more important role in drug resistance than originally 
thought (Allen, 2002).  Only recently, the involvement of BCRP in the development 
and protection of drug resistant cells was confirmed with the discovery that high 
levels of BCRP are expressed in leukemic stem cell subpopulations.  These stem 
cells are highly resistant towards chemotherapeutic treatments (Raaijmakers, 2005; 
Doyle, 2003).  Incomplete eradication of cancer stem cells is thought to be a main 
Discussion – in vitro     
    
137
cause for tumor relapse.  Therefore, treatment strategies designed to target the 
tumor together with its stem cell subpopulation would considerably improve the 
clinical outcome.  Additional BCRP modulating effects can thus be of great 
advantage, when choosing an adequate Pgp inhibitor for the treatment of MDR 
resistant tumors.   
Findings from chemosensitivity assays underline the ability of XR9577 and 
WK-X-34 to target BCRP-protected cells and to reverse their resistance towards 
BCRP substrates.  Chemosensitivity towards the mitoxantrone was strongly 
increased for XR9577 and WK-X-34 by 200- and 400-fold, respectively (see table 
4.5).  In comparison, cyclosporin A showed little effects.   
Interestingly, WK-X-34 and XR9577 show a strong similarity to the structures 
of GF120918 and XR9576, both potent BCRP and Pgp inhibitors.  Like XR9576 and 
GF1209188 (see figure 1.7), WK-X-34 and XR9577 (see figure 3.1) consist of a 
tetrahydroisoquinolin-ethyl-phenyl amine partial structure which is connected to a 
highly hydrophobic rest via an amide bond.  Therefore, it is likely that these common 
structures within the molecules might contain the BCRP binding domain.  This is of 
particular interest as no BCRP pharmacophore model has been developed to date.    
 
Multidrug resistance associated proteins 
MDR-associated proteins MRP1, MRP2 and MRP3 have been shown to be 
implicated in the development of MDR in many different tumors (Kruh, 2003; Kool, 
1999).  Moreover, the MRP transporters are widely expressed in different organs and 
tissues, where they are involved in many physiological functions such as the 
excretion of xenobiotics and endogenous substrates, protection of tissues and cell 
signalling (see chapter 1.2.3).  Accidental inhibition of the MRP transporters by MDR 
inhibitors can cause a substantial interference of important protection mechanisms 
which contributes to clinical toxicities, particularly in the presence of 
chemotherapeutic agents (see chapter 1.2.3).  Thus, it is important to analyze the 
interaction profile of novel MDR inhibitors with the three transporters MRP1-3.   
Interactions with MRP1, MRP2 or MRP3 were not detected for WK-X-34.  
XR9577 only showed some high dose MRP1 interference.  In contrast, the unspecific 
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MDR inhibitor verapamil displayed various unspecific inhibitions of MRP1-, MRP2- 
and MRP3-mediated transport.  Consistent with previously published reports (Qadir, 
2001), cyclosporin A was identified as an MRP1 inhibitor with some additional effects 
on MRP3.   
Cyclosporin A, however, appears to be an unselective broad-spectrum 
inhibitor with effects in resistant and sensitive cells.  Cyclosporin A displayed 
moderate effects on Pgp and the MRPs, particularly MRP1 (Qadir, 2005).  In 
daunorubicin chemosensitivity assays, for example, it was detected that cyclosporin 
A increased sensitivity towards daunorubicin by 7-fold in sensitive non-Pgp 
expressing A2780/wt cells.  This observation can only be explained by interaction 
with MDR mechanism, other than Pgp.  The interfering mechanisms appear to be 
sensitive for daunorubicin, but not for mitoxantrone (Table 4.5).  Daunorubicin is a 
fairly unspecific substrate of Pgp; it is also transported by MRP1 and BCRP 
(Chauvier, 2002; Jia, 2005).  As MRP1, but not Pgp, is expressed in A2780/wt cells, 
and cyclosporin A is an inhibitor of MRP1 (see chapter 4.3.4.1), it is likely that MRP1 
contributes to the increase of sensitivity towards daunorubicin in the presence of 
cyclosporin A in wild-type A2780/wt cells.  The observations above indicate that 
unselective MDR inhibition by the first generation MDR inhibitor cyclosporin A, for 
example, may cause highly unpredictable interactions such as with sensitive tumor 
celllines that do not express the target. 
 
Summary of BCRP and MRP inhibition 
The two novel MDR inhibitors, WK-X-34 and XR9577, demonstrated potent 
and specific inhibition of BCRP- and Pgp-mediated transport and functionality with 
no effects on wild-type cells like A2780/wt and MCF7/wt.  For potential clinical 
applications, a specificity of the MDR inhibitor for multidrug resistant cells is 
anticipated in order to prevent interactions and toxicities resulting from unspecific 
effects in different tissues and organs.  The findings suggest that target specificity is 
considerably improved for WK-X-34 and XR9577 as compared to the first generation 
inhibitors verapamil and cyclosporin A.  
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5.3.3 Multi-targeted MDR inhibitors  
Recent discoveries have confirmed that many multidrug resistant tumors and 
important cancer stem cell populations express multiple MDR transporters.  These 
findings have highlighted the importance of MDR inhibitors with broad-spectrum 
properties (Ross, 2000; Brooks, 2003).  For the modulation of multiple MDR 
mechanisms, a combination of specific MDR inhibitors or one multi-targeted 
compound can be used.   The use of one effective broad-spectrum inhibitor versus 
single-spectrum inhibitors in combination may offer some advantages.  Cumulative 
toxicities, for instance resulting from a potential competition for excretion pathways, 
are easier to prevent when only one compound is administered in combination with 
the chemotherapy.  Moreover, potential interactions with non-cancer related targets 
are decreased.  Finally, the pharmaceutical compliance of the therapy is ameliorated 
when fewer drugs are administered at the same time.   
Among numerous disappointing attempts to use novel MDR inhibitors in 
clinical investigations, the first generation Pgp inhibitor, cyclosporin A, showed some 
encouraging results in AML-patients (Smeets, 2001; List, 2001).  The recent 
discovery that cyclosporin A actually is a broad-spectrum inhibitor with effects on 
Pgp, BCRP, MRP1 and the lung resistance protein (LRP) (Qadir, 2005) underlines 
the importance of a “broad-spectrum therapeutic approach”.  In this thesis, these 
findings could be confirmed for MRP1 and Pgp but only vaguely for BCRP (see 
chapter 4.3.3 and 4.3.4).  Interactions with LRP were not investigated.  
Overexpression of MRP1 and LRP could be associated with MDR in AML and other 
malignancies (Kruh, 2003; List, 1996).  Their prognostic relevance, however, 
remains unclear, as studies have been published showing that there is no correlation 
between high MRP1 (Filipits, 1997) and LRP (Damiani, 1998) expression and clinical 
response in AML.  As previously discussed, BCRP has been discovered to be a 
crucial component in the MDR of many tumors and seems to be implicated in the 
protection of tumor stem cell subpopulations.   
Therefore, treatment strategies directed against Pgp and BCRP in 
combination might target the tumor together with its self-renewing cancer stem cell 
subpopulation.  It therefore appears likely that successful clinical trials in ALM 
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patients for cyclosporin A were mainly due to its Pgp inhibition in combination with a 
potentially much lower BCRP inhibition (Ross, 2004).  
In comparison to cyclosporin A, our novel WK-X- compounds, particularly WK-
X-34 and XR9577 demonstrate stronger BCRP and Pgp modulating properties.  
They effectively inhibited BCRP-mediated efflux and chemosensitivity towards 
mitoxantrone in a way that was comparable to novobiocin.   
Furthermore, cyclosporin A, despite convincing performance in clinical trials, 
is associated with many interactions and toxicities, particularly neurotoxicities 
(Calney, 1979; Gijtenbeek, 1999).  As clinical toxicities are a major limitation to the 
successful therapeutic application of MDR inhibitors, this might present an 
advantage of the novel WK-X-compounds and XR9577, which demonstrated 
significantly lower in vitro toxicities compared to cyclosporin A.  Of note, toxicity 
studies in mice revealt that WK-X-34 was well tolerated both in wild-type and 
immunocomprimised mice. 
 
Novel multi-targeted MDR inhibitors 
With the latest discoveries about the complexity of MDR mechanisms in mind, 
our group and other researchers have begun to develop MDR inhibitors with targets 
other than Pgp.  In 2002, Allen and coworkers published a report introducing a novel 
BCRP inhibitor, Ko143, a non-toxic, synthetic analog of fumitremorgin C.  This 
compound was thoroughly characterized in vitro and in vivo.  Ko143 appears to be 
the most potent BCRP inhibitor to date and was shown to effectively reverse BCRP-
mediated MDR with low activity against Pgp and MRP1.  In vivo, Ko143 markedly 
increased the oral bioavailability of topotecan in mice (Allen, 2002).   
The characterizations of recently developed compounds are summarized in 
table 5.3.  Minderman and coworkers have concentrated on multi-targeted MDR 
inhibitors.  Two in vitro characterizations of the compounds, VX-710 and BAY59-
8862, both targeting Pgp, BCRP and MRP1 were published in 2004 (Minderman, 
2004a; Minderman, 2004b).  VX-710 has already proven clinical safety and efficacy 
in Phase II clinical studies.  VX-710 was investigated in combination with paclitaxel in 
women with advanced multidrug resistant breast cancer (Toppmeyer, 2002) and in 
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combination with mitoxantrone and prednisone in men with hormone-refractory 
prostate cancer (Rago, 2003).   
 
Table 5.3   Novel MDR inhibitors targeting Pgp, BCRP and/or MRP1 in the literature 
    
Reference MDR inhibitor Target Cell Model 
In vitro/ 
In vivo 
In vitro Experiments     
Allen, 2002 
Netherlands 
Cancer Institute 
Ko143  
BCRP 
 
Several human + 
murine BCRP 
expressing cell 
lines 
In vitro/ in 
vivo   
Uptake MITX 
CS (MITX, TPC) 
Minderman, 
2004a 
Roswell Park 
Cancer 
Institute, NY 
VX-710  
(Biricodar) 
Pgp, 
BCRP, 
MRP1 
 
Pgp, BCRP and 
MRP over-
expressing human 
cell lines 
In vitro   
Uptake MITX, DNR 
CS (DOX, MITX, DNR, 
TPC) 
Minderman, 
2004b 
Roswell Park 
Cancer 
Institute, NY 
BAY59-8862 
(Ortataxel) 
Pgp, 
BCRP, 
MRP1 
 
Pgp, BCRP and 
MRP over-
expressing human 
cell lines 
In vitro   
Uptake MITX,DOX, DNR 
CS (DOX, MITX, DNR, 
TPC) 
Jekerle, 2006b 
University of 
Bonn/Toronto 
WK-X-34 
WK-X-50 
WK-X-84 
XR9577 
Pgp, 
BCRP, 
(MRPs) 
 
Pgp, BCRP and 
over-expressing 
human cell lines 
Selectively 
transfected cell 
lines with MRP1,2 
and 3  
In vitro   
Uptake R*, DNR 
Efflux MITX, DNR, 5-
CFDA 
CS (DNR, MITX) 
Abbreviations used in this table: 
R*: Radio-labeled substrate, CS: Chemosensitivity assay; 
DOX: doxorubicin; DNR: daunorubicin; MITX: mitoxantrone; PTX: paclitaxel; TPC: topotecan  
For in vivo characterization see table 7.1 
 
 
For over 15 years, research in the MDR field has focused on the development 
of selective Pgp inhibitors to target resistant tumor cells.  The recent concentration 
on multi-targeted MDR inhibitors, however, points at the potential that lies in a 
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“broad-spectrum approach”.  In line with these latest developments, the additional 
BCRP inhibitory properties of WK-X-34 and XR9577, make these two compounds 
particularly interesting.  Current knowledge in the field indicates that anti-MDR 
treatments benefit from BCRP inhibition due to the involvement of BCRP in many 
tumors and cancer stem cell subpopulations.  Therefore, WK-X-34 and XR9577 are 
two promising compounds that warrant further development.  XR9577 and WK-X-34 
appear to be of equal potency.  XR9577 has been formerly described by Roe and 
coworkers (Roe, 1999).  In contrast, WK-X-34 was developed and described solely 
by our research group.  Therefore, WK-X-34 was selected for further in vivo 
investigations. 
 
 
  
 
6 Results - in vivo 
 
 
Two separate sets of 99mTc-Sestamibi imaging experiments were performed in 
order to investigate the in vivo effects of WK-X-34 and MDR1 antisense ODN 
treatments in Pgp overexpressing and sensitive tumors.  The experimental designs 
of the “WK-X-34 imaging study” and the “WK-X-34 + antisense imaging study” are 
outlined in chapter 3.4.1. 
Imaging experiments were carried out about four weeks following tumor 
inoculation, when tumor xenografts reached a weight of approximately 0.5 g.  In 
picture 1 (Appendix) the development of the human ovarian cancer xenografts is 
presented over the span of four weeks.   
To begin with, the toxicity of the utilized WK-X-34 Cremophor EL formulation 
was investigated.   
 
6.1 Toxicity of the WK-X-34 formulation  
Based on in vitro results, the novel MDR inhibitor WK-X-34 was chosen for in 
vivo characterization as outlined in chapter 5.3.3.  The substituted 2-
benzamidobenzamide WK-X-34 (for structure see figure 3.1) exhibits very low water 
solubility; therefore in vivo formulations were developed using 10 % Cremophor EL 
ethanol as solvent.   
As Cremophor EL has been associated with some toxic in vivo effects (e.g. 
peripheral neuropathy) (Gelderblom, 2001), potential toxicity of the WK-X-34-
Cremophor EL formulation had been studied before 99mTc-Sestamibi imaging 
experiments were initiated.   
In vivo toxicity experiments were conducted in six-week old female CD1 mice.  
The animals were injected i.p. daily with a 100 µl dose of 20 or 50 mg/kg of WK-X-34 
Cremophor EL formulation for 14 days.  Controls received the vehicle only.  Mice 
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were examined every second day for 14 days for any signs of ill effects including 
weight loss, change in appetite or behavioral changes.   
Two days following the first dose of WK-X-34, mice appeared healthy, agile 
and no weight loss was detectable in all animals (see figure 6.1).  These 
experiments were carried on for 14 days.  Likewise, no differences in body weights 
were detected between all groups. 
 
 
 
 
 
 
 
 
 
 
Figure 6.1   Toxicity of WK-X-34/Cremophor EL formulation in CD1 mice 
Female CD1 mice were injected with either 20 or 50 mg/kg of WK-X-34 in Cremophor EL or vehicle control and 
potential weight loss was determined two days later.   
 
 
Potential hepatotoxicity of WK-X-34 in Cremophor EL was studied using the 
ALT hepatotoxicity test (see chapter 3.4.4).  A substantial loss of absorption was not 
detected and the slopes of all treated and control animals did not differ significantly 
from each other.  These findings indicate that WK-X-34 is unlikely to have any 
hepatotoxic effects in mice.   
WK-X-34 in the formulation with Cremophor EL ethanol (1:1) appeared to be 
fairly untoxic in mice.  As a precaution, the total amount of Cremophor EL was kept 
to a minimum of 10 % for all following experiments.   
 
 
0%
weight loss
2 x Controls
(CremophorEL/EtOH)
2 x Low Dose
20 mg/kg WK-X-34
(in CremophorEL/EtOH)
2 x High Dose
50 mg/kg WK-X-34
(in CremophorEL/EtOH)
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0.4%
weight gain
0.3%
weight gain
+0.6%
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0%
weight loss
2 days
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6.2 WK-X-34 imaging studies 
 
6.2.1 99mTc-Sestamibi imaging  
These studies were designed to investigate the in vivo performance of the 
selected MDR inhibitor WK-X-34.  Human ovarian cancer xenografts bearing a 
resistant A2780/Adr and a sensitive A2780/wt tumor on each back flank were 
developed in immunocomprimised mice.  99mTc-Sestamibi uptake was studied twice 
in the same animal in the absence and presence of WK-X-34.  Thus, effects of WK-
X-34 on the accumulation of 99mTc-Sestamibi in the resistant and sensitive tumor 
xenograft as well as potential inhibition of physiological Pgp in liver, kidney, brain, 
intestine and heart could be examined.  Gamma images obtained from 99mTc-
Sestamibi imaging experiments elegantly visualized the in vivo distribution of the Pgp 
substrate 99mTc-Sestamibi in the presence and absence of WK-X-34.  As each 
animal was imaged on two consecutive days without and with WK-X-34 
pretreatment, accumulation of 99mTc-Sestamibi could be compared in the same 
tumor of the same animal.   
Changes in the intensity of 99mTc-Sestamibi within the region of the A2780/Adr 
tumor upon WK-X-34 administration were detectable for all animals.  The 2 h images 
of a representative animal in the absence (baseline) and presence of 20 mg/kg WK-
X-34 are shown in figure 6.2.   
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Figure 6.2   99mTc-Sestamibi images of A2780/Adr and A2780/wt xenografts at 2 h   
Representative dorsal images of the same animal at baseline (left) and after administration of WK-X-34 (right) are 
depicted as taken 2 h after tail vein injection of 99mTc-Sestamibi in mice xenografts bearing an A2780/wt tumor on 
the left flank and an A2780/Adr tumor on the right flank.  The two images are normalized to the same color 
intensity 
 
 
In these images, A2780/Adr tumors are visible on the right flank and A2780/wt 
tumors are visible on the left flank, as indicated.  The tumor regions are enlarged in 
the box below and surrounded by a white ring.  On the right image (WK-X-34 
pretreatment), an increase in radio-intensity is detectable for the A2780/Adr tumor 
but not for the A2780/wt tumor.   
Furthermore, potential changes in the 99mTc-Sestamibi distribution throughout 
the body over the span of the imaging experiments were investigated.  In figure 6.3, 
the 15 min, 1 h, 2 h and 4 h gamma-images at baseline and upon WK-X-34 
pretreatment are presented for the same animal.   
 
 
 
Baseline at 2h                WK-X-34 pretreatment at 2h
Tumor
(A2780/wt)
Tumor
(A2780/Adr)
Tumor
(A2780/Adr)
Tumor
(A2780/wt)
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Figure 6.3    Time course of 99mTc-Sestamibi distribution in tumors and organs   
Representative dorsal 99mTc-Sestamibi images at baseline and after administration of WK-X-34 are depicted as 
taken 15 min, 1 h, 2 h and 4 h after tail vein injection of 99mTc-Sestamibi in BalbC nu/nu mice bearing an 
A2780/wt tumor on the left flank and an A2780/Adr tumor on the right flank (indicated by arrows).  All images are 
normalized to the same color intensity. 
 
 
Differences in the overall body distribution between baseline and WK-X-34 
treatments are easily detectable for all time points.  Radio-intensity was particularly 
increased in the region of the brain.  99mTc-Sestamibi appeared to accumulate in the 
brain, as higher levels were detectable at later time points (see figure 6.3: WK-X-34 
at 4 h).  An increase in the region of the A2780/Adr tumor on the right flank of the 
animal was furthermore visible on the 1 h, 2 h and 4 h images.  
 Regions of interest were drawn around the brain, heart, liver, intestine, right 
kidney, A2780/Adr tumor and A2780/wt tumor (see picture 5, appendix). The radio-
intensity (expressed in counts/pixel/second) in these regions was determined for 
each image and plotted against the imaging time point.  Representative radio-
intensity-time plots for the region of the whole body, brain and A2780/Adr tumor are 
shown in figure 6.4.  Whereas the radio-intensities in the region of the whole body 
Baseline 15 min             1 h                          2 h           4 h
WK-X-34 15 min              1 h                        2 h           4 h    
A2780/Adr tumorA2780/wt tumor
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were equal between baseline and WK-X-34 pretreatment, radio-intensity was 
increased in the regions of the brain and the A2780/Adr tumor upon WK-X-34 
pretreatment.  From radio-intensity-time plots the AUC values were calculated for 
each organ (for calculation see chapter 3.4.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.4   Radio-intensity-time plots for whole body, brain and A2780/Adr tumors    
The radio-intensity at baseline and upon WK-X-34 pretreatment in the region of the whole body, brain and 
A2780/Adr tumor is plotted against the time postinjection.  Representative plots from one animal are shown.  
Radio-intensity-time plots were generated for each gamma image and AUC values were calculated using the 
linear trapezoid method. 
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In figure 6.5, the AUCs of organs and tumors were compared between 
baseline and WK-X-34 treatment.  The results show changes in 99mTc-Sestamibi 
accumulation within the organ region (in % of baseline treatment) in the presence of 
WK-X-34.  Values above 100 % indicate increased accumulation of 99mTc-Sestamibi 
in the region.   
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.5   AUC analysis of 99mTc-Sestamibi distribution in tumors and organs   
99mTc-Sestamibi uptake into tumors and tissues on gamma images were analyzed by ROI analysis.  The AUC 
values for individual organs and tumors were calculated for imaging time points between 15 min and 4 h.  Results 
indicate the % change of uptake upon WK-X-34 treatments in comparison to control treatments.  Results are 
expressed as means of n=5 ± S.D. with p-levels of * ≤ 0.05 and ** ≤ 0.01, as determined by a paired two-tailed t-
test.   
 
 
Administration of WK-X-34 significantly increased the radio-intensity of 99mTc-
Sestamibi uptake into the Pgp-overexpressing (A2780/Adr) tumor to 136 % of control 
but did not significantly alter accumulation in the A2780/wt tumor.  Furthermore, 
significantly increased 99mTc-Sestamibi accumulation was detectable in the brain and 
intestine (148 % and 138 % of control) of the WK-X-34 treated mice.  This indicates 
a rapid and prolonged in vivo inhibition of Pgp in these tissues.  ROI analysis of 
99mTc-Sestamibi imaging of central organs such as the liver and the kidney showed 
considerable variability due to some overlaps in their imaging regions.  Therefore, 
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significant changes could not be detected.  WK-X-34 did not significantly affect whole 
body imaging values.   
 
6.2.2 99mTc-Sestamibi biodistribution  
To confirm results from 99mTc-Sestamibi imaging, biodistribution analyses 
were performed two hours postinjection of the radiopharmaceutical (see chapter 
3.4.9).  Table 6.1 summarizes the results from the biodistribution study.  Organ 
levels of 99mTc-Sestamibi are expressed as a % of the injected dose per gram of 
tissue (%ID/ g tissue).  Furthermore, results from tumors were normalized to the non-
Pgp expressing tissue muscle and are given as tissue/muscle ratios.  As compared 
to controls, ratios of 99mTc-Sestamibi concentrations in the A2780/Adr tumors to 
concentrations found in non-Pgp expressing muscle tissue were significantly 
increased by 9-fold in WK-X-34 pretreated mice (p<0.05).  In A2780/wt tumors, a 
much smaller elevation was seen however, the results were inconsistent and did not 
reach a level of significance.  Elevated levels in A2780/wt tumors, particularly at later 
time points, can be explained by an inhibition of Pgp-mediated routes of 99mTc-
Sestamibi excretion via the liver and the kidneys (Kabasakal, 2000).  99mTc-
Sestamibi is rapidly cleared from the blood into other organs.  Interestingly, relative 
blood levels in WK-X-34 treated animals are significantly lower compared to non-
treated animals.  Physiological Pgp is also inhibited in WK-X-34 treated animals.  
Hence, impaired 99mTc-Sestamibi efflux from tissues such as heart or brain back into 
the blood might account for lower blood levels.  Furthermore, significantly increased 
retention of radioactivity was detectable in the brain and liver.  In contrast to 99mTc-
Sestamibi imaging data, a significant increase was also detected for the region of the 
heart.   
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Table 6.1   Biodistribution of 99mTc-Sestamibi in control and WK-X-34 treated xenograft mice§  
 
 %ID/ g tissue ± S.D.  
Tissue Control WK-X-34 treatment % of control values 
 
Blood 0.18 ± 0.02 0.11* ± 0.02 61   ± 11  
Heart 5.90 ± 1.13 10.09* ± 1.55 171  ± 26 
Liver 5.83 ± 0.36 11.91* ± 2.44 204  ± 42 
Kidney 14.60 ± 1.24  15.07 ± 1.45 103  ± 10 
Intestine 6.50 ± 2.69  5.09 ± 1.47 78  ± 23 
Muscle 1.63 ± 0.13  2.58* ± 0.2 158  ± 13  
Brain 0.06 ± 0.00  0.10* ± 0.02 166 ± 33 
Adr Tumor 0.09 ± 0.12  0.95* ± 0.32 1055  ± 356 
Wt Tumor 0.13 ± 0.04 0.44 ± 0.28 338 ± 216 
 
Tissue/ muscle ratios 
 
Adr Tumor 0.05 ± 0.001 0.45* ± 0.20 900  ± 392    
Wt Tumor                  0.074 ± 0.05 0.284 ± 0.31 384  ± 419 
 
§ Values represent means ± S.D. for 5 xenograft mice per group with p-levels of * p < 0.05. 
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6.3 WK-X-34 + antisense imaging studies 
 
6.3.1 99mTc-Sestamibi imaging 
Mouse xenografts bearing two A2780/Adr tumors on each back flanks were 
injected with MDR1 antisense ODNs into one tumor for three days.  Animals were 
divided into a control and a WK-X-34 treatment group, and 99mTc-Sestamibi imaging 
was performed on day 4 following the antisense treatments.  The experimental setup 
of the “WK-X-34 + antisense imaging studies” is outlined in chapter 3.4.1.2.  Prior to 
the injection of the radiopharmaceutical 99mTc-Sestamibi, mice were pretreated either 
with 20 mg/kg of WK-X-34 or vehicle.   
Representative gamma images (Figure 6.6) show the in vivo distribution and 
uptake of 99mTc-Sestamibi 15 min and 1 h postinjection into both tumors.  The 
location of the control (blue) and antisense (orange) treated A2780/Adr tumor is 
indicated by arrows.  In controls, 99mTc-Sestamibi uptake was slightly increased in 
the antisense pretreated tumor as compared to the non treated tumor (see 1 h image 
of control animals).  Administration of WK-X-34 increased the amount of 99mTc-
Sestamibi into both tumors (see orange line).   
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Figure 6.6   99mTc-Sestamibi imaging of A2780/Adr xenografts 
Representative dorsal images of control (A) and WK-X-34 treated (B) mice were acquired 15 min and 1 h 
postinjection of 99mTc-Sestamibi.  Mice xenografts were bearing two A2780/Adr tumors on the right and left flank 
(see regions), of which one (orange) had been treated intra-tumorally with MDR1 antisense ODNs.  Images are 
normalized to the same color intensity. 
 
 
Again, ROI analyses were performed and these data are presented in figure 
6.7 for the 1 h imaging time point.  Data of four animals per group were analyzed.  
WK-X-34 WK-X-34
15 min                                       1 h 
Control 
15 min                                       1 h 
AS MDR1 tumor Control tumor
AS MDR1 tumorControl tumor
A.
B.
WK-X-34
 i                                         
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Increased 99mTechnetium accumulation of about 20 % and 90 % of control was 
determined within the region of the antisense treated and untreated tumor in WK-X-
34 treated mice, respectively.  Due to high variability between animals within the 
same treatment group, the data did not reach a level of significance. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7   ROI analyses of 99mTc-Sestamibi imaging in A2780/Adr xenografts 
99mTc-Sestamibi uptake into tumors was analyzed by ROI analysis.  The AUC values for both tumors were 
calculated for the 1 h imaging time point and normalized to whole body.  Results indicate the % change of uptake 
upon WK-X-34 and/or MDR1 AS treatments in comparison to control treatments.  Results are expressed as 
mean values of n=5 ± S.D.  Data were analyzed using a two-tailed unpaired t-test; a level of significance (α< 
0.05) was not reached. 
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6.3.2 99mTc-Sestamibi biodistribution  
Comparably to the WK-X-34 imaging study (see chapter 6.2), biodistribution 
analyses were performed and the results are presented in table 6.2.  Tumor levels of 
99mTc-Sestamibi were initially calculated as a % of injected dose per gram of tissue 
(%ID/ g tissue) and are normalized to the non-Pgp-expressing tissue “muscle”.  In 
the WK-X-34 pretreated mice, 99mTc-Sestamibi tissue/muscle ratios in untreated and 
antisense-pretreated tumors were significantly increased by 9- and 2-fold, 
respectively. 
 
 
Table 6.2   99mTc-Sestamibi biodistribution in A2780/Adr xenografts 
 
 Control WK-X-34 pretreatment 
Tissue/ muscle mean ± S.D.        mean ± S.D.  
 
Blood 0.32 ± 0.091 0.09 ± 0.091       
 
Control Tumor 0.05 ± 0.001 0.45* ± 0.196    (9-fold) 
MDR1 AS Tumor 0.18 ± 0.122 0.38* ± 0.065    (2-fold) 
 
Table 6.2 Accumulation of 99mTc-Sestamibi radioactivity in control and MDR1 AS treated tumors was determined 
from isolated tissues.  Results are expressed as a % dose/gram of tissue and normalized to muscle.  Data are 
expressed as means ± S.D. of 4 animals with p-levels determined by an unpaired two-tailed t-test of α ** < 0.01 
and * <0.05. 
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6.4 Tumor characterization  
 
6.4.1 Immunohistochemical analyses of tumor tissue 
Tumor growth was comparable in A2780/Adr and A2780/wt xenografts as 
observed by caliper measurements (for tumor development see picture 1 in 
appendix) and H&E histological analysis (Figure 6.8).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.8    H & E staining of tumor tissue   
Representative pictures of tumor tissue obtained from A2780/wt (A, B) and A2780/Adr (C, D) xenografts are 
shown.  Tissue sections were H & E stained and pictures were taken on a light microscope using a 40x/0.65 oil-
immersion objective. 
 
 
 In Figure 6.8, picture A and B show tissue sections from A2780/wt tumors and 
picture C and D are obtained from A2780/Adr tumor sections.  A blood vessel 
incorporated in the tumor tissue can be seen on picture A.  Infiltrated blood cells are 
visible on pictures C and D.  In figure C invasive growth of the tumor tissue into 
remaining muscle tissue can be observed.  To summarize, both tumors showed 
A.
B.
C.
D.
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invasive growth into muscle tissue with high vascularisation.  This observation is 
important as it confirms that detected changes in 99mTc-Sestamibi accumulation 
between resistant and sensitive tumors were not due to a difference in tissue 
formation. 
 
6.4.2 Immunofluorescence examinations of tumor tissue 
Additionally, Pgp expression was examined by immunofluorescence analysis 
using the FITC-labeled anti human Pgp monoclonal antibody according to methods 
specified in chapter 3.4.10.  Tissue sections from A2780/Adr and A2780/wt tumors 
as well as from antisense treated A2780/Adr tumors were analyzed.  Representative 
fluorescence microscopy pictures are shown in figure 6.9.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9.  Immunofluorescence analysis of tumor tissue  
Tissue slides of A2780/Adr xenografts treated intra-tumorally with MDR1 antisense ODNs were examined by 
immunofluorescence.  Representative tissue pictographs show tumor sections from unstained A2780/Adr 
controls (A) and stained sections from A2780/wt (B), MDR1 antisense ODNs treated A2780/Adr (C), and 
A2780/Adr control (D) (all pictures taken on an 40x/0.65 objective).   
 
 
A.
C. D.
B.
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Whereas no Pgp expression was detectable on tumor sections from A2780/wt 
tumors (picture 6.9-B), strong Pgp overexpression was visible in the A2780/Adr 
tumors (picture 6.9-D).  In MDR1 antisense pretreated tumors (picture 6.9-C) Pgp 
protein expression was detectable, but appeared to be lower in comparison to 
expression levels seen in non treated A2780/Adr tumors.  Background fluorescence 
in A2780/Adr tissue slides in the absence of the antibody (picture 6.9-A) was minimal 
and comparable to fluorescence detectable in antibody incubated slides of A2780/wt 
tumors (picture 6.9-B). 
 
6.4.3 MDR1 antisense treatment of tumors 
To confirm whether reductions in Pgp surface expression upon antisense 
treatments correlated with mRNA expression, levels of MDR1 were analyzed in 
A2780/Adr tumors.  RNA was isolated from tumor tissue and RT-PCR analysis was 
performed using primer and conditions as described in chapter 3.3.1.  As presented 
in figure 6.10, MDR1 levels were downregulated after intra-tumoral antisense 
treatments.  Expression of MDR1 mRNA was significantly reduced to about 10 % of 
controls in the antisense treated tumors 
 
 
 
 
 
 
 
 
 
 
Figure 6.10   RT-PCR analysis of tumor tissue  
RNA was isolated from tumor tissue and MDR1 expression analyzed by RT-PCR analysis.  Expression levels 
were normalized to 18S values and mean values ± S.D. from 4 tumors per group are presented (A).  
Representative RT-PCR gels with the PCR products from both tumors are depicted (B). 
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7 Discussion - in vivo  
 
 
In the following chapter, results from 99mTc-Sestamibi imaging and 
biodistribution experiments will be discussed.  These methods were used to 
characterize WK-X-34 in vivo.  In a second set of animal experiments, antisense 
treatments were compared to treatments with WK-X-34.  Some repetition of in vitro 
results will be necessary to correlate in vivo to in vitro results and to better discuss 
the in vivo findings in the context of this thesis.   
 
7.1 Characterization of WK-X-34  
 
Toxicities 
Doses of 20 mg/kg and 50 mg/kg of WK-X-34 in a Cremophor EL ethanol 
formulation were well tolerated both in healthy and tumor-bearing mice.  Likewise, 
other recently characterized Pgp inhibitors were nontoxic in vivo.  XR9576 (Mistry, 
2001) and OC144-093 (Newman, 2002) were found to be well tolerated in mice at 
doses of 2-8 mg/kg and 20 mg/kg, respectively.  As WK-X-34 was nontoxic in 
several cell lines (see table 4.2), it is likely that WK-X-34 might be well tolerated in a 
potential clinical application.   
 
Pgp inhibition in tumor xenografts 
The in vivo performance of WK-X-34 in sensitive and resistant human 
xenografts was investigated using the radiopharmaceutical 99mTc-Sestamibi 
(Piwnica-Worms, 1993; Del Vecchio, 2004 and Hendrikse, 1999).  This technique 
allows the non-invasive monitoring of Pgp activity and is approved by the FDA for the 
evaluation of novel Pgp inhibitors in clinical trials (see chapter 2.3.7).   
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Whereas the cellular uptake of 99mTc-Sestamibi is mainly due to passive 
diffusion, Pgp is known to play an important role in its cellular efflux.  Indeed, a 
strongly decreased accumulation of 99mTc-Sestamibi was seen in the Pgp-
overexpressing A2780/Adr cells as compared to the non-Pgp expressing A2780/wt 
cells.  Moreover, treatment of A2780/Adr cells with WK-X-34 increased 99mTc-
Sestamibi accumulation to levels seen in the A2780/wt cells (see figure 4.16).   
In vivo, WK-X-34 treatment was found to significantly increase 99mTc-
Sestamibi levels in A2780/Adr resistant but not in sensitive A2780/wt tumor 
xenografts.  This was detected through 99mTc-Sestamibi imaging and was further 
verified in 99mTc-Sestamibi biodistribution experiments.  The results indicate that WK-
X-34 is capable of reversing the multidrug resistant phenotype in vivo in solid tumors.   
WK-X-34–mediated changes in vivo on the tumor accumulation of 99mTc-
Sestamibi likely occur primarily through Pgp inhibition.  It has been reported that 
99mTc-Sestamibi can be transported by MRP1 and MRP2 in vitro (Chen, 2000).  The 
affinity of these two transporters to 99mTc-Sestamibi, however, is much lower than 
Pgp, and can not be detected in vivo (Sharma, 2003).  In vitro, WK-X-34 did not 
appear to inhibit MRP-mediated transport in selectively transfected cell lines (see 
chapter 4.3.4).  In vitro studies in MCF7/mx cells also demonstrated a lack of 
interaction between 99mTc-Sestamibi and BCRP (see figure 4.19).   
As in vitro studies have identified a dual interaction profile of WK-X-34 with 
Pgp and BCRP, it would be interesting to investigate in vivo effects of BCRP 
inhibition by WK-X-34.  At the time of the experiments, however, no suitable animal 
model was available for the study.  Two animal models of BCRP expressing tumors 
have only been developed very recently.  In 2004, Gefitinib, the epidermal growth 
factor tyrosine kinase inhibitor, was investigated in immunocomprimised mice 
inoculated with P388 cells that had been transfected with human BCRP (Yanase, 
2004).  In 2005, Garimella and coworkers reported a BCRP-overexpressing human 
ovarian xenograft model, which they used to study the BCRP inhibitor fumitremorgin 
C (Garimella, 2005).  Moreover, no comparable non-invasive imaging model for 
BCRP has been established to date.   
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Inhibition of physiological Pgp 
In the animals, human Pgp was solely expressed in the xenografts of 
A2780/Adr tumors.  However, mice furthermore express murine Pgp throughout the 
body particularly in their organs of excretion (i.e. liver, kidney) and barrier tissue (i.e. 
blood-brain-barrier).  Whereas humans only have one Pgp, which is encoded by 
MDR1, mice express two types of Pgp, encoded by mdr1a and mdr1b (Chen, 1986).  
Together mdr1a- and mdr1b-type Pgps fulfil the same function as the single human 
Pgp (Schinkel, 1997).  It was expected that WK-X-34 would interact with murine Pgp 
and impose changes in the accumulation of 99mTc-Sestamibi in organs and different 
tissues.  Indeed, 99mTc-Sestamibi imaging and biodistribution data revealed a 
significantly increased accumulation of 99mTc-Sestamibi in the brain, heart, liver and 
intestine of WK-X-34 treated animals.   
Increases in the organ accumulation of 99mTc-Sestamibi have been reported 
with other Pgp inhibitors (Rao, 1999; Planting, 2005).  Thus, there exists a potential 
for these agents to impact the distribution, clearance and organ toxicities of 
anticancer drugs.  Pharmacokinetic alterations of coadministered chemotherapeutic 
agents (e.g. daunorubicin) have been associated with third generation Pgp inhibitors 
(Dale, 1998; Lê, 2005).  Comparably, WK-X-34 caused increased 99mTc-Sestamibi 
levels in major organs and deep tissues.  These observations point to potential 
complications in the therapeutic use of third generation Pgp inhibitors.  A careful risk-
benefit evaluation as well as thorough toxicity monitoring should precede and 
accompany the therapeutic application of a Pgp inhibitor.   
Some pharmacokinetic properties of WK-X-34 could be deduced from the 
analysis of 99mTc-Sestamibi images.  Imaging data demonstrated a Pgp inhibition in 
WK-X-34 treated mice as soon as 75 min after administering WK-X-34 (1 h 
pretreatment with WK-X-34 + 15 min poatinjection of 99mTc-Sestamibi).  This 
suggests that WK-X-34 is rapidly absorbed from the intraperitoneal cavity into the 
blood with subsequent distribution to distant organs and tumors.  WK-X-34 continued 
to display effective in vivo inhibition of Pgp four hours after administration of 99mTc-
Sestamibi, indicating that the inhibitor was not being rapidly cleared from the system.  
This seems plausible, as pharmacokinetic investigations of another third generation 
Pgp inhibitor, XR9051 (Mistry, 1999) with a similar structure to WK-X-34 (compare 
structure of WK-X-34 in figure 3.1 to structure of XR9051 in figure 1.7) have 
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indicated rapid uptake with sufficiently long disposition in the system.  Mistry and 
coworkers found an apparent elimination half-life of XR9051 in plasma and liver of 
around 4 and 5 h, respectively.  In tumor xenografts, the maximum concentration of 
XR9051 was detected 1.5 h following administration of a 20 mg/kg dose i.v. with an 
apparent elimination half-life of around 8 h.   
 
Recent characterizations in the literature 
Most recently characterized third generation Pgp inhibitors included in vivo 
investigations in human or murine tumor xenograft models, which are summarized in 
table 7.1.   
The A2780/Adr xenograft model used in this thesis is a commonly applied 
tumor model, which was employed to test for MDR reversal of XR9051 and XR9576.  
Other tumor models include the murine leukemia model P388/Dox (Hyafil, 1993; 
Dantzig, 1996, Mistry, 1999 and Newman, 2000) and the human small cell lung 
cancer model SCLC-H69/LX4 (Mistry, 1999 and 2001).  Newman and coworkers 
generated a xenograft model with a selectively transfected human breast cancer cell 
line, MDA435/ LCC6MDR1 (Newman, 2000).  The great majority of xenograft models, 
however, were generated using multidrug resistant cell lines, which have been 
selected through cytotoxic treatments.  
The antitumor efficacy of commercially developed third generation Pgp 
inhibitors has been extensively studied in several different tumor models using 
common chemotherapeutic agents (e.g. paclitaxel, doxorubicin, etoposide).  Studies 
of pharmacokinetic parameters and potential alterations in the pharmacokinetic 
profile of co-administered chemotherapy were usually included.  In an academic 
setting or in the context of a PhD thesis, it is obvious that such a detailed 
characterization is not possible.   
Discussion – in vivo  
    
163
Table 7.1   Novel third generation Pgp inhibitors in the literature –in vivo characterization 
Reference MDR inhibitor Target Tumor Model 
In vivo Experiments 
Hyafil, 1993 
Laboratoire 
GLAXO 
GF120918 
Pgp,  
later 
BCRP1 
Mu leukemia and colon 
xenograft models (MDR 
P388/Dox; i.p.; C26MDR s.c.)  
DOX in xenograft 
DOX-PK in mice 
PK/Tox in mice 
Dantzig, 1996 
Lilly Research 
LY335979 Pgp2 
Mu leukemia (MDR 
P388/Dox; i.p.)  
Hu NSCLC xenografts i.p.  
DOX/ ETP in leukemia 
model 
TAX in xenograft;  PK  
Mistry, 1999 
Xenova Ltd 
XR9051 
Pgp 
 
Mu leukemia and colon model 
(MDR P388/ Dox; i.p.; MC26; 
s.c.)  
Hu ovarian and SCLC cancer 
xenograft (A2780/Adr + 
CH1/Dox; H69/LX4 s.c.)   
VCR, DOX in leukemia 
models and colon xenograft 
PTX, ETP, VCR, DOX in 
human xenografts  
PK in mice and xenografts 
Newman, 
2000 
Ontogen 
Corporation 
OC144-093 Pgp 
Mu leukemia (MDR 
P388/Dox; i.p.)  
Hu breast and colon xenografts 
(MDA435/ LCC6MDR1*  i.p; HCT-
15; s.c. ) 
DOX in xenograft 
PXT-PK in mice 
PK in dogs 
Mistry, 2001 
Xenova Ltd 
XR9576 
Pgp 
later 
BCRP3 
Mu colon carcinoma (MC26; 
s.c.) 
Hu ovarian and SCLC 
xenograft (A2780/Adr and 
A2780/wt s.c.; H69/LX4 s.c)   
 
PTX, ETP, VCR  in 
xenografts (A2780/Adr + 
H69/LX4) 
DOX in xenografts (MC26) 
PK of PTX in rats 
Jekerle, 
2006a 
University of 
Bonn/Toronto 
WK-X-34 
Pgp 
+ 
BCRP  
Hu ovarian cancer xenograft 
(A2780/Adr and A2780/wt; 
s.c.)   
Tox in mice 
MIBI* imaging and 
biodistribution in A2780/Adr 
& A2780/wt xenografts 
Allen, 2002 
Netherlands 
Cancer 
Institute 
Ko143  BCRP --------------------------------- 
Tox in mice 
Modification of oral BA of 
TPC in mice 
Abbreviations used in this table: 
BA: bioavailability; PK: Pharmacokinetic investigations; Tox: toxicity; SCLC: small cell lung cancer, Mu: Murine; 
Hu: Human 
DOX: doxorubicin; ETP: etoposide; PTX: paclitaxel; VCR: vincristine; MIBI*: 99mTc-Sestamibi; TPC: topotecan 
* human breast cancer cell line (MDA435/LCC6MDR1) is selectively transfected with human MDR1 
1  Malipaard, 2001; 3  Shepard, 2003; 3  Robey, 2004; for in vitro characterization see table 5.1 and 5.2  
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 Non-invasive 99mTc-Sestamibi imaging techniques, used for the initial in vivo 
characterization of WK-X-34, elegantly provided proof of in vivo efficacy.  
Comparable to other third generation Pgp inhibitors, WK-X-34 effectively reversed 
the MDR phenotype in human xenografts of ovarian cancer at a dose of 20 mg/kg.  
Moreover, some information on the distribution and pharmacological interactions of 
WK-X-34 with physiological Pgp in relevant tissues such as the blood –brain barrier 
or excreting organs was obtained.   
To investigate WK-X-34 for a potential application in humans, further 
preclinical studies, such as antitumor efficacy studies and pharmacokinetic 
investigations, are warranted.  Nevertheless, 99mTc-Sestamibi imaging techniques 
were particularly suitable for the initial in vivo testing of WK-X-34.   
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7.2 Antisense treatment in comparison to WK-X-34 
In a second set of in vivo experiments MDR1 antisense ODNs alone and in 
combination with WK-X-34 were used to reverse Pgp-mediated MDR in tumor 
xenograft models.  Likewise, 99mTc-Sestamibi imaging techniques were applied to 
assess Pgp inhibition in vivo.    
 
Downregulation of Pgp activity 
As mice were treated with both, the third generation Pgp inhibitor WK-X-34 
and MDR1 antisense ODNs, in vivo efficacy of both treatments could be compared.  
First, these treatments were evaluated in vitro using the chemotherapeutic drug 
daunorubicin.  Both, MDR1 antisense ODNs and WK-X-34 increased intracellular 
daunorubicin levels through functional Pgp inhibition (see figure 4.12 and 4.21).  In 
vivo, intratumoral treatments with MDR1 antisense ODNs resulted in transcriptional 
downregulation of MDR1 mRNA and Pgp expression in the A2780/Adr tumor (see 
figure 6.10).  MDR1 mRNA was downregulated to about 10 % of controls.  Likewise, 
Pgp surface expression was decreased as determined by immunofluorescence 
analysis techniques.  Yet reductions in protein levels appeared to be less 
pronounced.  This seems reasonable as results from in vitro antisense experiments 
showed a downregulation by only 50 % for the highest concentration of antisense 
ODNs (see figure 4.11).  Differences in the degree of downregulation between 
MDR1 mRNA and Pgp effects are likely to depend on their dissimilar half lives.  
Whereas MDR1 mRNA has a half life of 4 h, the half life of the protein Pgp is 14- 
16 h (Aleman, 2003).  As a result, transcriptional inhibition can first be detected on 
the mRNA level.  Translation of these effects into a reduction in Pgp surface 
expression thus occurs much slower and potentially not in a quantitative way. 
Changes in Pgp expression translated into an impaired Pgp-mediated MDR 
phenotype.  In tumor xenografts, functional Pgp inhibition was detected through 
altered 99mTc-Sestamibi accumulation both by imaging and biodistribution analysis 
with a significant degree of sensitivity.  An increased level of 99mTc-Sestamibi due to 
an impaired efflux activity of Pgp was detected in the antisense treated resistant 
tumor (see chapter 6.3.1 and 6.3.2).  Through additional functional Pgp inhibition by 
WK-X-34, intratumoral accumulation of 99mTc-Sestamibi was further increased and 
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reached a maximum level, which no longer differed between antisense untreated 
and pretreated tumors.  What can be concluded from this observation?   
Treatments with MDR1 antisense ODNs caused increased 99mTc-Sestamibi 
levels within the tumors; these differences, however, were nullified when WK-X-34 
was added (see figure 6.6 and table 6.2).  The results indicate that a single dose of 
the Pgp inhibitor WK-X-34 more effectively reverses Pgp-mediated MDR than a 
three-day treatment with MDR1 antisense ODNs.  Moreover, the combination of a 
Pgp inhibitor and antisense ODNs together does not offer an advantage over the 
single treatment with WK-X-34 alone.  Hence, a potential benefit of antisense ODNs 
treatment in the therapy of multidrug resistant cancer could not be concluded from 
these studies (Jekerle, 2006c).   
Nevertheless, results from in vivo antisense treatments demonstrated 
effectiveness of antisense ODNs in downregulating MDR1/Pgp in vivo.  For a 
potential clinical application, however, antisense treatments appear to be less 
powerful in comparison to small molecule MDR inhibitors such as WK-X-34.  
 
Antisense treatments in the literature 
In the antisense field, some studies have confirmed the effectiveness of 
antisense treatments in reversing the Pgp-mediated MDR phenotype in vivo.  
Ramachandran and coworkers (Ramachandran, 2003) were able to show that a 
combined four-day treatment of MDR1 antisense ODNs and doxorubicin significantly 
controlled tumor growth.  The effect was attributed to the addition of MDR1 antisense 
ODNs.  Unfortunately, such convincing examples are rare and can only be 
generated with a complicated experimental setup.  Ramachandran had to use a 
combination of two antisense sequences in order to observe efficacy in his in vivo 
experiment.   
In another study, Lopes de Menezes and coworkers (Lopes de Menezes, 
2003) used a combined treatment of antisense oligonucleotides directed against the 
antiapoptotic gene bcl-2 and PSC 833, a second generation Pgp inhibitor.  In vivo, 
the combination of bcl-2 antisense, PSC 833 and liposomal doxorubicin showed 
maximal growth suppression of multidrug resistant tumors in comparison to the 
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individual treatments.  While this study introduces an interesting therapeutic 
approach through targeting two different MDR mechanisms with a combination of a 
small molecule inhibitor and antisense treatment, the clinical relevance is 
questionable.  It remains to be seen, whether such complicated treatment strategies 
can be translated into the clinical practice.   
 
Limitations of antisense-based treatments  
Although convincing and rational in theory, therapeutic approaches targeting 
mRNA have been associated with many unexpected complications.  In vivo toxicity, 
stability and delivery-related problems are among the major obstacles in a 
successful clinical application of antisense ODNs.   
Even though some recent Phase I and II clinical trials of antisense-based 
drugs could demonstrate an acceptable level of safety of phosphorothioated ODNs 
(Galderisi, 1999), they have frequently been associated with toxicity complications 
(Kurreck, 2003).   
Delivery-related problems are more difficult to circumvent.  For good reasons, 
the body possesses a strong protection mechanism against infection from foreign 
nucleotides (Robinson, 2004).  Complicated delivery systems or backbone 
modifications had to be developed to enable antisense molecules to enter the 
system and persist in the circulation sufficiently long to guarantee a delivery to the 
site of action.  Indeed, after an i.v. or i.p. injection phosphorothioated antisense 
molecules were shown to remain in the blood circulation for up to 24 h before 
excretion via the urine (Galderisi, 1999).  Moreover, detectable levels of ODNs were 
found in most tissues up to 48 h postinjection with only 15-50 % of degradation in 
that period.  As most tumor tissue is poorly circulated by the blood (see chapter 
1.1.2), this brings about a reduced delivery into the tumor.  Even though in vivo 
experiments and initial trials can avoid this problem by direct injection into the target 
tumor, only a solution for such delivery-related problems can give rise to broad 
clinical application.   
So strikingly simple in theory, yet experts have reservations about the nature 
of the antisense mechanism (Robinson, 2004).  The only antisense-based drug with 
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FDA approval, Vitravene, is used to treat cytomegalovirus infections in the eyes of 
HIV patients.  Its antisense sequence actually targets viral DNA but not a human 
mRNA sequence.  Therefore, it remains unclear whether Vitravene actually works 
through the antisense mechanism.  To date, no antisense-based drug targeting a 
sequence within the human genome has demonstrated sufficient efficacy and safety 
to receive a marketing authorization.   
The above-mentioned aspects illustrate just how complicated in vivo 
applications of antisense molecules can be.  Some of these limitations were reflected 
in this thesis.  Substantial in vitro toxicities detected as significant downregulations in 
cell proliferation were observed upon antisense treatments.  In vivo, comparable 
toxicities were not seen in mice that were dosed intratumorally for three days with 
antisense ODNs.  Yet many reports have indicated in vivo toxicities associated with 
non-specific binding of antisense ODNs to several proteins (Levin, 1999).   
Delivery-related problems could mostly be avoided by the intratumoral route of 
administration.  In a clinical setting, however, intratumoral injections will not be 
feasible in the majority of cases.  Moreover, as antisense treatment via the most 
direct route of application over a treatment period of three consecutive days has not 
shown a satisfying degree of Pgp inhibition that was comparable to WK-X-34 alone, 
it remains highly questionable whether antisense treatment will be effective in a 
therapeutic application.  Even the combination of antisense ODNs and WK-X-34, 
which was originally thought to be effective due to a dual targeting of Pgp and MDR1 
mRNA, did not show a benefit over the single treatment with WK-X-34.  Overall, 
results from 99mTc-Sestamibi imaging studies demonstrated an inhibition of the Pgp-
mediated phenotype with a sufficient, yet much lower efficacy of antisense ODNs in 
comparison to WK-X-34.  The results appear to be in accordance with common 
experience and support the reservations outlined above.  In order to justify such 
complications associated with antisense-based therapy, their effectiveness needs to 
exceed other less complicated strategies.  Thus, the clinical usefulness of antisense-
based therapies in targeting multidrug resistant tumors remains questionable and will 
always be limited by the presence of potent and nontoxic small molecule inhibitors of 
Pgp.    
  
 
8 Conclusion  
 
 
In this thesis I have characterized novel multi-targeted MDR inhibitors and 
MDR1 antisense ODNs using common in vitro and in vivo experimental techniques.  
The evaluation of different treatment strategies alone and in combination addressed 
the hypothesis that the simultaneous targeting of different MDR mechanisms might 
be advantageous in mastering the complexity of multidrug resistant tumors (See 
rational; chapter 2.1).  
Whereas antisense ODNs were found to be less effective while associated 
with more complications, some Pgp inhibitors showed effective MDR reversing 
properties.  Among the tested compounds, the most effective, WK-X-34 and XR9577 
were found to be potent, specific and non-toxic inhibitors of both, Pgp- and BCRP-
mediated MDR in different cell lines.  These compounds clearly showed an 
advantage in potency and cellular tolerance over cyclosporin A, a broad spectrum 
MDR inhibitor with successful performance in clinical trials in AML patients.   
WK-X-34 was chosen for further in vivo characterization of toxicity, efficacy 
and pharmacokinetic alterations.  Using 99mTc-Sestamibi imaging techniques in 
human ovarian cancer xenografts, WK-X-34 was shown to effectively target MDR in 
vivo.  The MDR-reversing potency as well as typical interactions with other Pgp 
expressing tissues were comparable to those of other third generation Pgp inhibitors.  
A combined treatment of antisense ODNs and WK-X-34 was found to not be 
superior to the treatment with WK-X-34 alone. 
The selective interaction profile of WK-X-34 with Pgp and BCRP holds a great 
potential in a broader anti-MDR therapy, particularly with regard to solid tumors with 
Pgp and BCRP coexpression and highly protected cancer stem cell subpopulations.  
Therefore, extended preclinical development is anticipated and required to evaluate 
whether WK-X-34 might potentially be a promising candidate for the successful 
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therapeutic treatment of de novo or acquired Pgp- and BCRP-mediated MDR in 
human malignancies. 
 
Outlook 
Some recently developed potent MDR inhibitors of the third generation 
including WK-X-34 are effective in reversing the Pgp and BCRP-mediated MDR 
phenotype.  In multidrug resistant tumor cells, they can increase intracellular drug 
concentrations to levels found in sensitive tumor cells and sensitize the tumor to the 
chemotherapeutic treatment.  Unfortunately, there are many tumors, which lack 
expression of Pgp and BCRP, yet they do not respond to chemotherapy.  In these 
tumors, Pgp and BCRP targeting MDR inhibitors fail to reverse the MDR phenotype.  
Does it mean MDR inhibitors are not effective and the development of these 
compounds should not be pursued?   
As the pathology of a tumor cell is such a complex concert of numerous 
mechanisms, one therapy by itself has only limited potential.  Nevertheless, each 
therapeutic approach adds a weapon to the “arsenal” which is needed to fight the 
tumor cell.  With the development and characterization of the potent, selective and 
non-toxic MDR inhibitor, WK-X-34, we are on the way to create another tool to target 
a subpopulation of tumors, namely those tumor cells that are predominantly resistant 
through the overexpression of Pgp and BCRP.  If such a Pgp/BCRP inhibitor was 
only one “arrow” that could be added to the “arsenal”, it could be assembled together 
with other arrows and weapons.  The greater the selection of weapons, the more 
likely it will be for the therapist to find the right combination of weapons against the 
individual tumor.  Together with other existing and yet to be discovered therapies, 
MDR inhibitors are of value in the treatment of multidrug resistant cancer.   
 
  
 
9 Summary 
 
Purpose: The ATP-binding cassette (ABC) transporters P-glycoprotein (Pgp) and 
BCRP are implicated in the multidrug resistance (MDR) of many tumors.  Pgp-
mediated MDR can be functionally inhibited using small molecule inhibitors or 
transcriptionally downregulated by MDR1 antisense oligodeoxynucleotides (ODNs).  
Interestingly, simultaneous inhibition of several ABC transporters including Pgp and 
BCRP by cyclosporin A has been shown to circumvent MDR in clinical trials.  In this 
thesis, the novel multi-targeted tetrahydroisoquinolin-ethyl-phenyl-amine-based MDR 
inhibitors XR9577, WK-X-34, WK-X-50 and WK-X-84 were thoroughly in vitro and in 
vivo characterized for interaction with Pgp, BCRP and MRP-transporters and 
compared to treatments with MDR1 antisense ODNs.    
Methods: The novel MDR inhibitors and cyclosporin A were examined for cellular 
toxicity in several cell lines.  Inhibition of BCRP-mediated mitoxantrone efflux was 
studied in BCRP-overexpressing MCF7/mx cells.  Inhibition of Pgp function was 
assessed in 99mTc-Sestamibi and daunorubicin transport assays.  Reversal of Pgp- 
and BCRP-mediated resistance towards daunorubicin and mitoxantrone, 
respectively, were investigated in A2780/Adr and MCF7/mx cells.  Potential MRP-
interactions were evaluated in 5-CFDA efflux assays using selectively transfected 
MRP-1, -2 and -3 cell lines.   
Daunorubicin transport and Pgp surface expression in resistant A2780/Adr 
cells treated with MDR1 antisense ODNs were determined using flow cytometry, 
fluorescence microscopy and protein staining techniques. 
The in vivo performance and toxicity of WK-X-34 was evaluated by 99mTc-
Sestamibi imaging experiments using multidrug resistant human ovarian cancer 
(A2780/Adr) xenograft models.  To study antisense treatments in vivo, A2780/Adr 
xenograft models were dosed intratumorally with MDR1 antisense ODNs for three 
days followed by either WK-X-34 or vehicle treatment.  99mTc-Sestamibi distribution 
and accumulation were analyzed by imaging of the animals and gamma-counting of 
the isolated tissues.  Tumor xenografts were analyzed histologically and Pgp 
expression was monitored by immunohistochemistry and RT-PCR. 
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Results: WK-X-34 and XR9577 were the most potent MDR inhibitors and completely 
reversed 99mTc-Sestamibi and daunorubicin accumulation at concentrations of 10 
and 1 µM.  Daunorubicin chemosensitivity was increased by 7-8-fold after 10 µM 
XR9577 or WK-X-34 pretreatment.  All WK-X-compounds showed significant BCRP 
inhibition comparable to novobiocin in both mitoxantrone transport and 
chemosensitivity assays.  Compared to cyclosporin A, the in vitro toxicity was 
reduced for all WK-X-compounds.  Moreover, XR9577 or WK-X-34 showed 
increased specificity for Pgp and BCRP as only resistant cells were targeted and 
significant MRP interactions were not detected.  
In immunocomprimised mice dosed with WK-X-34 (20 mg/kg; i.p.), uptake of 
99mTc-Sestamibi was significantly increased in A2780/Adr xenograft tumors    
(AUCs0-4h 136%; p < 0.05) but not in sensitive A2780/wt tumors.  Moreover, 
increased levels of 99mTc-Sestamibi were detected in the brain, liver and intestine of 
WK-X-34 treated animals.   
MDR1 antisense treatments significantly increased daunorubicin levels in 
A2780/Adr cells.  In vivo, 99mTc-Sestamibi retention was significantly increased by 
over two fold in the antisense pretreated tumors.  Upon additional WK-X-34 
treatment, tissue/muscle ratios of 99mTc-Sestamibi were significantly increased by 9-
fold in the untreated but only by 2-fold in the antisense pretreated tumors and 
correlated with results from the 1-hour 99mTc-Sestamibi images.  99mTc-Sestamibi 
levels in the A2780/Adr tumors could not be further increased by a combined 
treatment with antisense ODNs and WK-X-34 as compared to WK-X-34 alone.  
MDR1 mRNA levels and Pgp expression were down-regulated in the antisense 
treated tumors. 
Conclusion: Among the novel MDR inhibitors, WK-X-34 and XR9577 were most 
effective in modulating Pgp and BCRP and demonstrated an increased in vitro 
tolerance and specificity over cyclosporin A.  In vivo, WK-X-34 potently inhibited the 
Pgp-mediated MDR phenotype in resistant human ovarian cancer xenograft models.  
In comparison to WK-X-34, MDR1 antisense ODNs were less effective while 
associated with more complications.  Based on these in vitro and in vivo 
characterizations, WK-X-34 may have potential utility in the treatment of multidrug 
resistant tumors 
.       
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Picture 1. Development of human ovarian cancer xenograft model 
5 x 106 A2780/Adr or A2780/wt cells in a 100 µl cell suspension (A) were injected s.c. into the back 
flank of immunocomprimised nude mice (B).  Tumor formation was visible after one week and tumor 
volume rapidly increased per week as depicted in C. 
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Picture 2. 99mTc-Sestamibi imaging studies 
Mice were injected with 5 MBq of 99mTc-Sestamibi into one of the lateral vein (A) anesthetised and 
placed on the imaging counter (B).  The injection spot on the tail was shielded with a led shield (C) 
Images were acquired using a small field-of-view gamma-camera ADAC TransCam equipped with a 
pinhole collimator (4 mm aperture) and processed using Pegasys X, Version 4.2 software (D). 
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Picture 3. 99mTc-Sestamibi biodistribution studies 
After 99mTc-Sestamibi imaging experiments were terminated, mice were sacrificed and tumors (A) as 
well as blood and remaining tissues (B) were isolated.  Tissues were weighted and placed into glass 
tubes (C) for gamma-counting using the Packard Cobra II Series Auto-Gamma ® Counting System 
(D). 
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Picture 4.  Residual 99mTc-Sestamibi activity 24 postinjection 
The same animal was imaged 15 min (A) and 24 h (B) following i.v. injection of 5 mBq 99mTc-
Sestamibi. Residual 99mTc-Sestamibi activity decreased to less than 2 % after 24 h. 
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Picture 5.  Regions of interest analysis 
Regions of interest were drawn around the whole body, central organs and tumors as depicted.  
Radio-intensity of 99mTc-Sestamibi uptake was determined for each organ and expressed in 
counts/pixel/second of acquisition time. 
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